• Abbas Z, Jafri W, Rasool S, Abid S, Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med. J. 48: 69-73 (2007). *

• Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol. Res. 38: 639-645 (2008). *

• Abu Al-Soud W, Stenram U, Ljungh A, Tranberg KG, Nilsson HO, Wadstrom T. DNA of Helicobacter spp. and common gut bacteria in primary liver carcinoma. Dig. Liver Dis. 40: 126-131 (2008).

• Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, Moriwaki H, Okano Y. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 35: 332-340 (2002). *

• Adachi T, Nakagawa H, Hagiya Y, Yasuoka T, Ishikawa T. Transport-metabolism interplay: LXR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharm. 6: 1678-1688 (2009). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 172: 899-905 (2005). *

• Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121 (2005). *

• Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 39: 1204-1212 (2004). *

• Adler M, De Gendt E, Vereerstraeten P, Degre D, Bourgeois N, Boon N, Gelin M, Ickx B, Donckier V. Value of the MELD score for the assessment of pre- and post-liver transplantation survival. Transplant. Proc. 37: 2863-2864 (2005). *

• Aebersold DM. Potential and future strategies for radiotherapy in hepatocellular carcinoma. Liver Int. 29: 145-146 (2009). *

• Aigelsreiter A, Janig E, Sostaric J, Pichler M, Unterthor D, Halasz J, Lackner C, Zatloukal K, Denk H. Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology 54: 561-570 (2009). *

• Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J. Hepatol. 52: 63-71 (2010).

• Ajdukiewicz AB, Kelleher PC, Krawitt EL, Walters CJ, Mason PB, Koff RS, Belanger L. Alpha-fetoprotein glycosylation is abnormal in some hepatocellular carcinoma, including white patients with a normal alpha-fetoprotein concentration. Cancer Lett. 74: 43-50 (1993).

• Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ. Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 136: 2365-2376.e7 (2009). *

• Akkiz H. Hepatocellular carcinoma pathogenesis: does PPAR alpha polymorphism have a role in hepatocarcinogenesis associated with HBV and HCV infections? Turk. J. Gastroenterol. 19: 231-233 (2008). *

• Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B. Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J. Viral Hepat. Dec 14 [Epub ahead of print] (2009).

• Akkiz H, Bayram S, Bekar A, Ozdil B, Akgollu E, Sumbul AT, Demiryurek H, Doran F. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiol. 33: 261-264 (2009).

• Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther. Clin. Risk Manag. 5: 617-626 (2009). *

• Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin. Proc. 82: 628-637 (2007). *

• Ali MY, Grimm CF, Ritter M, Mohr L, Allgaier HP, Weth R, Bocher WO, Endrulat K, Blum HE, Geissler M. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43: 817-822 (2005). *

• Alisa A, Boswell S, Pathan AA, Ayaru L, Williams R, Behboudi S. Human CD4+ T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4+ T cells. J. Immunol. 180: 5109-5117 (2008). *

• Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358: 221-230 (2008). *

• Almasio PL. HALT-C in the final analysis: a molehill out of a mountain. J. Hepatol. 50: 1280-1282 (2009).

• Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 128-133 (1994).

• Altimari A, Gruppioni E, Fiorentino M, Petraroli R, Pinna AD, Petropulacos K, Ridolfi L, Costa AN, Grigioni WF, Grigioni AD. Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation. Diagn. Mol. Pathol. 14: 34-38 (2005).

• Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann. Hepatol. 6: 170-173 (2007). *

• Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann. Hepatol. 7: 148-151 (2008). *

• Amitrano L, Guardascione MA, Bennato R, Manguso F, Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J. Hepatol. 42: 820-825 (2005). *

• Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology Dec 4 [Epub ahead of print] (2009). *

• Andriulli A, de Sio I, Solmi L, De Carlis L, Troisi R, Grasso A, Festa V, Caturelli E, Giacomoni A, Del Vecchio Blanco C, De Hemptinne B, Burroughs A, Perri F. Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation. Liver Transpl. 10: 1355-1363 (2004). *

• Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 26: S39-S47 (2008).

• Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SP. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 44: 992-1002 (2006). *

• Arch-Ferrer JE, Smith JK, Bynon S, Eckhoff DE, Sellers MT, Bland KI, Heslin MJ. Radio-frequency ablation in cirrhotic patients with hepatocellular carcinoma. Am. Surg. 69: 1067-1071 (2003).

• Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662-669 (2008). *

• Arii S. Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma. J. Hepatol. 41: 333-335 (2004). *

• Ashizawa T, Matsuno N, Yokoyama T, Kihara Y, Kuzuoka K, Taira S, Konno O, Jyojima Y, Akashi I, Nakamura Y, Hama K, Iwamoto H, Iwahori T, Nagao T, Kasahara M, Tanaka K. The role of plasmapheresis therapy for perioperative management in ABO-incompatible adult living donor liver transplantation. Transplant. Proc. 38: 3629-3632 (2006). *

• Aslinia F, Mindikoglu AL. Radiofrequency ablation in patients with hepatocellular carcinoma. Hepatology 50: 2053 (2009).

• Asselah T, Bieche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin. Liver Dis. 27: 13-27 (2007).

• Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J. Gastroenterol. 15: 3217-3227 (2009). *

• Athanassiadou P, Psyhoyiou H, Grapsa D, Gonidi M, Ketikoglou I, Patsouris E. Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. Acta Cytol. 51: 61-65 (2007).

• Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C, Terris B. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J. Pathol. 212: 345-352 (2007). *

• Avenaud P, Le Bail B, Mayo K, Marais A, Fawaz R, Bioulac-Sage P, Megraud F. Natural history of Helicobacter hepaticus infection in conventional A/J mice, with special reference to liver involvement. Infect. Immun. 71: 3667-3672 (2003). *

• Avila MA, Berasain C, Torres L, Martin-Duce A, Corrales FJ, Yang H, Prieto J, Lu SC, Caballeria J, Rodes J, Mato JM. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 33: 907-914 (2000). *

• Axelrod D, Koffron A, Kulik L, Al-Saden P, Mulcahy M, Baker T, Fryer J, Abecassis M. Living donor liver transplant for malignancy. Transplantation 79: 363-366 (2005).

• Aydogdu S, Arikan C, Kilic M, Ozgenc F, Akman S, Unal F, Yagci RV, Tokat Y. Outcome of pediatric liver transplant recipients in Turkey: single center experience. Pediatr. Transplant. 9: 723-728 (2005).

• Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958 (2008). *

• Bagnyukova TV, Tryndyak VP, Muskhelishvili L, Ross SA, Beland FA, Pogribny IP. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle 7: 3202-3210 (2008). *

• Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan CJ, Shi YH, Huang C, Wang Z, He YF, Fan J. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology 49: 460-470 (2009). *

• Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to Sorafenib. J. Biol. Chem. 284: 32015-32027 (2009). *

• Baig S, Alamgir M. The extrahepatic manifestations of hepatitis B virus. J. Coll. Physicians Surg. Pak. 18: 451-457 (2008).

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Banares R, Nunez O, Escudero M, Fernandez C, Vaquero J, Beceiro I, Echenagusia A, Clemente G, Santos L. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 41: 566-571 (2005). *

• Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40: 1078-1087 (2004). *

• Barajas M, Franchi F, Clavel C, Aranguren XL, Kramer MG, Abizanda G, Merino J, Moreno C, Garate L, Guitart A, Narvaiza I, Gutierrez-Perez M, Riezu-Boj JI, Berasain C, Prieto J, Prosper F. Multipotent adult progenitor cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochem. Biophys. Res. Commun. 364: 92-99 (2007). *

• Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc. Natl. Acad. Sci. U.S.A. 107: 2207-2212 (2010). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S133-S143 (2004). *

• Bartok I, Remenar, Toth J, Duschanek P, Kanyar B. Clinicopathological studies of liver cirrhosis and hepatocellular carcinoma in a general hospital. Hum. Pathol. 12: 794-803 (1981).

• Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J. Hepatol. 51: 810-820 (2009).

• Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect. Prev. 28: 385-391 (2004).

• Bartsch H, Nair J. Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res. 591: 34-44 (2005).

• Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment. Pharmacol. Ther. 15: 1427-1434 (2001). *

• Baudet JS, Medina A, Moreno A, Navazo L, Aviles J, Soriano A. Bronchobiliary fistula secondary to ruptured hepatocellular carcinoma into the bile duct. J. Hepatol. 41: 1066-1067 (2004). *

• Baumert TF. Novel vaccine strategies. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 58-59. October 20 - 21 (2003). *

• Baumgardner JN, Shankar K, Korourian S, Badger TM, Ronis MJ. Undernutrition enhances alcohol-induced hepatocyte proliferation in the liver of rats fed via total enteral nutrition. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G355-G364 (2007). *

• Baumhoer D, Lorf T, Gunawan B, Armbrust T, Fuzesi L, Ramadori G. Hepatic tumorigenesis in acute hepatic failure. Eur. J. Gastroenterol. Hepatol. 17: 1125-1130 (2005).

• Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 129: 899-906 (2008). *

• Beasley RP. Diabetes and hepatocellular carcinoma. Hepatology 44: 1408-1410 (2006). *

• Beaugrand M, N'kontchou G, Seror O, Ganne N, Trinchet JC. Local/regional and systemic treatments of hepatocellular carcinoma. Semin. Liver Dis. 25: 201-211 (2005).

• Beckebaum S, Cicinnati VR, Broelsch CE. Advances and limitations of liver transplantation in Germany. Verh. Dtsch. Ges. Pathol. 88: 45-50 (2004).

• Becker D. Enhanced imaging diagnosis of liver carcinomas. Technical progress is not a substitute for clinical knowledge. MMW Fortschr. Med. 142: 38-40 (2000).

• Befeler AS. New developments in hepatocellular carcinoma. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619 (2002). *

• Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 128: 1752-1764 (2005). *

• Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int. Dec 22 [Epub ahead of print] (2009). *

• Belghiti J. Transplantation for liver tumors. Semin. Oncol. 32: S29-S32 (2005).

• Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr. Pract. 13: 300-312 (2007).

• Belli G, Cioffi L, Fantini C, D'Agostino A, Russo G, Limongelli P, Belli A. Laparoscopic redo surgery for recurrent hepatocellular carcinoma in cirrhotic patients: feasibility, safety, and results. Surg. Endosc. 23: 1807-1811 (2009).

• Belli G, Limongelli P, Fantini C, D'Agostino A, Cioffi L, Belli A, Russo G. Laparoscopic and open treatment of hepatocellular carcinoma in patients with cirrhosis. Br. J. Surg. 96: 1041-1048 (2009).

• Benoit SL, Zbell AL, Maier RJ. Nickel enzyme maturation in Helicobacter hepaticus: roles of accessory proteins in hydrogenase and urease activities. Microbiology 153: 3748-3756 (2007). *

• Beppu T, Maruyama T, Ohashi K, Ohura S, Nakanishi R, Fukasawa M, Futagawa S. Results of non-decompression surgery for esophago-gastric varices - postoperative disappearance, recurrence, rebleeding rate of varices, and cumulative survival rate. Nippon Geka Gakkai Zasshi 93: 1159-1163 (1992).

• Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D, Gores GJ, Roskams T, Liedtke C, Trautwein C. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J. Exp. Med. 206: 1727-1737 (2009). *

• Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57: 655-663 (2008).

• Berber E, Rogers S, Siperstein A. Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer. A prospective study. Surg. Endosc. 19: 710-714 (2005). *

• Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellon JM, Gonzalez-Garcia J; The GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50: 407-413 (2009).

• Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311-316 (1998). *

• Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 13: 429-439 (2009).

• Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, Mentre F, Fantin B. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl. 11: 1093-1099 (2005). *

• Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 137: 1127-1137.e5 (2009). *

• Bianchi G, Marzocchi R, Agostini F, Marchesini G. Update on branched-chain amino acid supplementation in liver diseases. Curr. Opin. Gastroenterol. 21: 197-200 (2005).

• Bilaj F, Hyslop WB, Rivero H, Firat Z, Vaidean G, Shrestha R, Woosley JT, Semelka RC. MR imaging findings in autoimmune hepatitis: correlation with clinical staging. Radiology 236: 896-902 (2005). *

• Bilbao I, Dopazo C, Lazaro JL, Castells L, Escartin A, Lopez I, Sapisochin G, Balsells J, Margarit C. Our experience in liver transplantation in patients over 65 yr of age. Clin. Transplant. 22: 82-88 (2008). *

• Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, Zucman-Rossi J, Balabaud C, Saric J. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50: 481-489 (2009).

• Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, Zucman-Rossi J, Balabaud C. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int. 29: 459-465 (2009). *

• Bismuth H, Castaing D, Ericzon BG, Otte JB, Rolles K, Ringe B, Sloof M. Hepatic transplantation in Europe. First report of the European Liver Transplant Registry. Lancet 2: 674-676 (1987).

• Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 19: 311-322 (1999).

• Blachar A, Federle MP, Brancatelli G. Hepatic capsular retraction: spectrum of benign and malignant etiologies. Abdom. Imaging 27: 690-699 (2002). *

• Blachar A, Federle MP, Brancatelli G. Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology 220: 329-336 (2001). *

• Blachar A, Federle MP, Sosna J. Liver lesions with hepatic capsular retraction. Semin. Ultrasound CT MR 30: 426-435 (2009).

• Black D, Bird MA, Samson CM, Lyman S, Lange PA, Schrum LW, Qian T, Lemasters JJ, Brenner DA, Rippe RA, Behrns KE. Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J. Hepatol. 40: 942-951 (2004). *

• Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Broring DC, Pace A, Greten H, De Weerth A. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J. Hepatol. 41: 112-118 (2004). *

• Blanchet B, Hurtova M, Roudot-Thoraval F, Costentin CE, Barrault C, Jouault H, Medkour F, Laurent A, Duvoux C, Hulin A. Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma. Liver Int. 29: 1152-1157 (2009). *

• Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465-1477 (2006). *

• Blendis L. Percutaneous ethanol ablation of small hepatocellular carcinomas: twenty years on. Gastroenterology 130: 280-282 (2006). *

• Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J. Hepatol. 50: 592-603 (2009). *

• Blomme BA, Van Steenkiste C, Vanhuysse J, Colle I, Callewaert N, Van Vlierberghe H. The impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and men. Am. J. Physiol. Gastrointest. Liver Physiol. Jan 7 [Epub ahead of print] (2010). *

• Blum HE. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol. 11: 7391-7400 (2005). *

• Blum HE. Gene therapy for liver diseases: experimental strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 44-45 (2006). *

• Blum HE. Treatment of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19: 129-145 (2005).

• Boberg KM, Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59 (2004).

• Bohr UR, Annibale B, Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection - other Helicobacters. Helicobacter 12 Suppl. 1: 45-53 (2007). *

• Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J. Hepatol. 39: 1076-1084 (2003). *

• Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42: 27-34 (2005). *

• Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol. Med. 8: 318-325 (2002). *

• Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin. Liver Dis. 4: 409-429, vi-vii (2000).

• Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL. Experimental models for hepatitis C viral infection. Hepatology 50: 1646-1655 (2009).

• Borgonovo G, Razzetta F, Assalino M, Varaldo E, Puglisi M, Ceppa P. Rectal hepatoid carcinoma with liver metastases in a patient affected by ulcerative colitis. Hepatobiliary Pancreat. Dis. Int. 7: 539-543 (2008). *

• Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann. Hepatol. 8: 26-31 (2009).

• Bosch J. Invasive imaging. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 40. October 17 - 19 (2003). *

• Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48: 137-145 (2008). *

• Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int. 29 Suppl. 1: 148-158 (2009).

• Bowlus CL. Chapter 11. Tumor immunology: hepatocellular carcinoma, cholangiocarcinoma, and metastatic neoplasms. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 137-149 (2007). *

• Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52 (2007). *

• Bozkurt FM, Ergun EL. A typical (111)In-diaethylenotriamino pentaacetic acid-octreotide and (99m)Tc-(V)-dimercapto succinic acid uptake patterns, after radiation treatment. Hell. J. Nucl. Med. 11: 127-129 (2008).

• Braham A, Safer L, Bdioui F, Lejmi A, Brahmi I, Ben Chabenne N, Ben Mimoun H, Saffar H. Antiphospholipid antibodies in digestive diseases. Presse. Med. 30: 1890-1897 (2001).

• Braillon A. Surveillance programmes for hepatocellular carcinoma: evident-based medicine is not evidence-based medicine. Liver Int. 29: 141 (2009). *

• Braillon A. Hepatocellular carcinoma: sorafenib before liver transplantation? Hepatology Nov 13 [Epub ahead of print] (2009).

• Branco F, Bru C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann. Hepatol. 8: 220-227 (2009).

• Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127 (5 Suppl. 2): S56-S61 (2004). *

• Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50: 102-112 (2009).

• Breuhahn K, Baeuerle PA, Peters M, Prang N, Tox U, Kohne-Volland R, Dries V, Schirmacher P, Leo E. Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatol. Res. 34: 50-56 (2006).

• Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J. Immunol. 182: 5140-5151 (2009).

• Britto MR, Thomas LA, Balaratnam N, Griffiths AP, Duane PD. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand. J. Gastroenterol. 35: 889-893 (2000). *

• Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma - yes, of course! J. Hepatol. 43: 569-573 (2005). *

• Broome U, Bergquist A. Hepatocellular carcinoma, cholangiocarcinoma, colon and pancreas carcinoma in patients with primary sclerosing cholangitis. Epidemiology and risk factors. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 89-90. October 15-16 (2003). *

• Broome U, Eriksson LS. Assessment for liver transplantation in patients with primary sclerosing cholangitis. J. Hepatol. 20: 654-659 (1994).

• Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, Lindgren S, Fork FT, Jarnerot G, Olsson R. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J. Hepatol. 36: 586-589 (2002). *

• Brown KA. Liver transplantation. Curr. Opin. Gastroenterol. 21: 331-336 (2005).

• Bruix J. Hepatocellular carcinoma. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 31-33. October 17 - 19 (2003). *

• Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S179-S188 (2004). *

• Brunacci C, Piobbico D, Bartoli D, Castelli M, Pieroni S, Bellet MM, Viola-Magni M, Della Fazia MA, Servillo G. Identification and characterization of a novel peptide interacting with cAMP-responsive elements binding and cAMP-responsive elements modulator in mouse liver. Liver Int. 30: 388-395 (2010). *

• Brunati A, Feruzi Z, Sokal E, Smets F, Fervaille C, Gosseye S, Clapuyt P, de Ville de Goyet J, Reding R. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr. Transplant. 11: 117-119 (2007). *

• Brunetti E, Bruno R, Marangio A, Crippa FG, Filice C, Caturelli E. Is second biopsy helpful in the diagnosis of hepatocellular carcinoma with a first negative biopsy? Am. J. Gastroenterol. 95: 3688-3689 (2000). *

• Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24: 3-20 (2004).

• Brunt EM, Swanson PE. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. Am. J. Clin. Pathol. 97: S53-S61 (1992).

• Brunt EM, Walsh SN, Hayashi PH, Labundy J, Di Bisceglie AM. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int. 27: 662-671 (2007). *

• Bu P, Wan YJ. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer 7: 236 (2007). *

• Buamah PK. An apparent danazol-induced primary hepatocellular carcinoma: case report. J. Surg. Oncol. 28: 114-116 (1985).

• Buendia MA. Tumor suppressors in hepatocellular carcinoma: for many are called, but few are chosen. J. Hepatol. 46: 546-548 (2007). *

• Buendia MA. Liver cancer. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 20-21 (2006). *

• Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11: 191-207 (2007).

• Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 41: 685-686 (2004). *

• Burdelski M, Rogiers X. Liver transplantation in metabolic disorders. Acta Gastroenterol. Belg. 62: 300-305 (1999).

• Burgos San Juan L. Cholangiocarcinoma. Rev. Med. Chil. 136: 240-248 (2008).

• Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, O'Grady JG, Castaing D, Klempnauer J, Jamieson N, Neuhaus P, Lerut J, de Ville de Goyet J, Pollard S, Salizzoni M, Rogiers X, Muhlbacher F, Garcia Valdecasas JC, Broelsch C, Jaeck D, et al. 3-Month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 367: 225-232 (2006). *

• Burt AD. Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355 (2004). *

• Buschow C, Charo J, Anders K, Loddenkemper C, Jukica A, Alsamah W, Perez C, Willimsky G, Blankenstein T. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J. Immunol. Feb 8 [Epub ahead of print] (2010).

• Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127 (5 Suppl. 2): S189-S193 (2004). *

• Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S232-S241 (2004). *

• Byun JR, Cho SH, Yang DH, Kim YK, Ju JK, Choi SK, Chung IJ. Ileovesical fistula caused by hepatocellular carcinoma. Korean J. Intern. Med. 20: 76-79 (2005).

• Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology Dec 4 [Epub ahead of print] (2009). *

• Cabrera R, Nelson DR. Review article: management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31: 461-476 (2010). *

• Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment. Pharmacol. Ther. 26: 1-8 (2007). *

• Cahill BA, Braccia D. Current treatment for hepatocellular carcinoma. Clin. J. Oncol. Nurs. 8: 393-399 (2004).

• Cai MY, Xu YF, Qiu SJ, Ju MJ, Gao Q, Li YW, Zhang BH, Zhou J, Fan J. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin. Cancer Res. 15: 4686-4693 (2009). *

• Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J. Gastroenterol. 15: 300-309 (2009). *

• Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S97-S103 (2004). *

• Calmus Y. Graft-versus-host disease following living donor liver transplantation: high risk when the donor is HLA-homozygous. J. Hepatol. 41: 505-507 (2004). *

• Calmus Y. Liver transplantation for cancer. Rev. Prat. 58: 1745-1748 (2008).

• Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128 (2006). *

• Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, Simile MM, Bonelli P, Muroni MR, Seddaiu MA, Lim DS, Feo F, Pascale RM. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137: 1816-1826.e10 (2009). *

• Calvisi DF, Simile MM, Ladu S, Pellegrino R, De Murtas V, Pinna F, Tomasi ML, Frau M, Virdis P, De Miglio MR, Muroni MR, Pascale RM, Feo F. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int. J. Cancer 121: 2410-2420 (2007). *

• Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 29: 478-480 (2009). *

• Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 102: 3389-3394 (2005). *

• Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Rajender Reddy K. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin. Transplant. 21: 377-384 (2007). *

• Campos BD, Botha JF. Transplantation for hepatocellular carcinoma and cholangiocarcinoma. J. Natl. Compr. Canc. Netw. 7: 409-417 (2009).

• Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin. Pharmacother. 8: 1275-1282 (2007).

• Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 44: 446-457 (2006). *

• Cao K, Liu W, Nakamura H, Enomoto H, Yamamoto T, Saito M, Imanishi H, Shimomura S, Cao P, Nishiguchi S. Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatol. Res. 39: 1108-1117 (2009). *

• Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, Li W, Bi J. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol. Sin. 28: 879-887 (2007). *

• Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab. Invest. 87: 582-590 (2007). *

• Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F; the EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am. J. Gastroenterol. 102: 1661-1670 (2007). *

• Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125: 89-97 (2003). *

• Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65: 6245-6254 (2005). *

• Carbone J, Micheloud D, Salcedo M, Rincon D, Banares R, Clemente G, Jensen J, Sarmiento E, Rodriguez-Molina J, Fernandez-Cruz E. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Transpl. Infect. Dis. 10: 396-402 (2008).

• Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 127 (5 Suppl. 2): S218-S224 (2004). *

• Carr C, Desai J. OPCAB surgery in a cirrhotic hepatocellular carcinoma patient awaiting liver transplant. Ann. Thorac. Surg. 78: 1460-1462 (2004).

• Castera L. Liver stiffness and hepatocellular carcinoma: liaisons dangereuses? Hepatology 49: 1793-1794 (2009).

• Castera L, Boige V, Rocher L, Duclos-Vallee JC, Fabre M, Buffet C. Complete regression of hepatocellular carcinoma under tamoxifen. Am. J. Gastroenterol. 95: 827-829 (2000). *

• Castillo J, Goni S, Latasa MU, Perugorría MJ, Calvo A, Muntane J, Bioulac-Sage P, Balabaud C, Prieto J, Avila MA, Berasain C. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumours. Gastroenterology 137: 1805-1815.e4 (2009). *

• Castro-E-Silva O, Sankarankutty AK, Teixeira AC, Mente ED, Souza FF, Pacheco EG, Oliveira GR, Cagnolatti D, Correia RB, Campos W, Kemp R, Miranda A, Rondon LZ, Rizzo C, Mota GA, Martinelli AL, Ramalho FS, Ramalho LN, Zucoloto S. Liver transplantation at a university hospital, Faculty of the Medicine of Ribeirao Preto, University of Sao Paulo: results for the first 60 recipients. Transplant. Proc. 40: 785-788 (2008).

• Cathomas G, Renner EL. Liver transplantation and tumors: risk and chance. Schweiz. Med. Wochenschr. 130: 963-968 (2000).

• Caturelli E, Castellano L, Fusilli S, Palmentieri B, Niro GA, del Vecchio-Blanco C, Andriulli A, de Sio I. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology 226: 691-697 (2003). *

• Caturelli E, de Sio I. Biopsy diagnosis of hepatocellular carcinoma. Hepatology 47: 2145 (2008). *

• Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A, Fornari F, Del Vecchio Blanco C, De Sio I. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53: 1356-1362 (2004). *

• Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, Pares A. Incidence, risk factors and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centres. Hepatology 50: 1162-1168 (2009). *

• Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem. 18: 184-195 (2007). *

• Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, Monges G, Belghiti J, Sa Cunha A, Laurent-Puig P, Degott C, Zucman-Rossi J. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J. Hepatol. 41: 292-298 (2004). *

• Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int. J. Oncol. 35: 1409-1416 (2009).

• Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz. J. Med. Biol. Res. 42: 958-962 (2009). *

• Chakraborty JB, Mann DA. NF-kappaB signalling: embracing complexity to achieve translation. J. Hepatol. Nov 24 [Epub ahead of print] (2009).

• Chan AC, Lo CM, Ng KK, Chan SC, Fan ST. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int. 27: 81-85 (2007). *

• Chan EY, Larson AM, Gernsheimer TB, Kowdley KV, Carithers RL Jr, Reyes JD, Perkins JD. Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. Liver Transpl. 13: 516-522 (2007). *

• Chan JY, Li L, Miao J, Cai DQ, Lee KK, Chui YL. Differential expression of a novel gene BRE (TNFRSF1A modulator/BRCC45) in response to stress and biological signals. Mol. Biol. Rep. Sep 16 [Epub ahead of print] (2009). *

• Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, Ma HJ, Chou MC, Tsai HT, Yang SF. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin. Chem. Lab. Med. 47: 412-418 (2009). *

• Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J. Hepatol. 50: 323-333 (2009).

• Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng. Part A. 15: 559-567 (2009).

• Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann. Hepatol. 6: 208-213 (2007). *

• Chavez-Tapia NC, Mendez-Sanchez N, Uribe M. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Ann. Hepatol. 8 Suppl. 1: S34-S39 (2009). *

• Chazouilleres O. Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope? J. Hepatol. 40: 857-859 (2004). *

• Chen C, Zhang C, Zhuang G, Luo H, Su J, Yin P, Wang J. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest. 26: 965-974 (2008).

• Chen CJ, Yang HI, Iloeje UH; The REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49: S72-S84 (2009).

• Chen CY, Lin XZ, Wu HC, Shiesh SC. The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies. Clin. Biochem. 38: 520-525 (2005). *

• Chen GG, Ho RL, Wong J, Lee KF, Lai PB. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). Eur. J. Surg. Oncol. 33: 882-886 (2007).

• Chen GH, Yang Y, Lu MQ, Cai CJ, He XS, Zhu XF, Xu C, Li H, Huang JF. Liver transplantation for hepatocellular carcinoma: a report of 60 cases. Zhonghua Wai Ke Za Zhi 42: 413-416 (2004).

• Chen HJ, Xiao JR, Yuan W. Loss of p16(INK4), alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma. Med. Oncol. Oct 8 [Epub ahead of print] (2009). *

• Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ; for the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (the REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology Jan 26 [Epub ahead of print] (2010).

• Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 39: 177-186 (2009). *

• Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J. Hepatol. 52: 88-95 (2010).

• Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK, Fu L, Ma S, Zheng BJ, Guan XY. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology 50: 122-129 (2009).

• Chen L, Zeng Y, Yang H, Lee TD, French SW, Corrales FJ, Garcia-Trevijano ER, Avila MA, Mato JM, Lu SC. Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. FASEB J. 18: 914-916 (2004). *

• Chen S, Feng D. Novel parameter estimation methods for 11C-acetate dual-input liver model with dynamic PET. IEEE Trans. Biomed. Eng. 53: 967-973 (2006).

• Chen S, Ho C, Feng D, Chi Z. Tracer kinetic modeling of 11C-acetate applied in the liver with positron emission tomography. IEEE Trans. Med. Imaging 23: 426-432 (2004).

• Chen SC, Cummings OW, Hartley MP, Filomena CA, Cho WK. Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig. Dis. Sci. 51: 952-955 (2006). *

• Chen SC, Tsai HJ, Jan CM, Wang YH, Chen LT. Low dose of thalidomide can be effective in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1868-1869 (2006). *

• Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J. Gastroenterol. 11: 3297-3299 (2005). *

• Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst. Rev. 4: CD003181 (2007). *

• Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, He F. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet. Genomics 16: 219-227 (2006).

• Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Li N, Lu SC, Zhang JG, Zeng DB, Xie JG, Yang JY, Yan LN. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chin. Med. J. (Engl.) 120: 703-707 (2007).

• Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 51: 435-444 (2010).

• Chen YM, Chen LY, Wong FH, Lee CM, Chang TJ, Yang-Feng TL. Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics 66: 43-47 (2000). *

• Chen YM, Liao YJ, Liu SP, Tsai TF. Phenotypic differences between two Gnmt-/- mouse models for hepatocellular carcinoma. Hepatology 49: 2130-2131 (2009).

• Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY, Chen PH. Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int. J. Cancer 75: 787-793 (1998). *

• Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q, Wong OH, Lo CK, Ng IO, Chan LC, Lau GK, Lin CL, Huang F, Huang FP. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J. Immunol. 179: 6009-6015 (2007). *

• Cheng KS, Tang HL, Chou FT, Chou JW, Hsu CH, Yu CJ, Kao ST, Li TC. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Hepatogastroenterology 56: 1105-1110 (2009).

• Cheng XJ, Xu W, Zhang QY, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann. Oncol. 19: 527-532 (2008).

• Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol. Res. 32: 127-133 (2005).

• Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64: 3849-3854 (2004). *

• Cheung RS, Brooling JT, Johnson MM, Riehle KJ, Campbell JS, Fausto N. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells. Carcinogenesis 28: 2624-2631 (2007). *

• Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. J. Hepatol. Aug 3 [Epub ahead of print] (2009).

• Chiang KC, Persons KS, Istfan NW, Holick MF, Chen TC. Fish oil enhances the antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res. 29: 3591-3596 (2009).

• Chiang PC, Chien CL, Pan SL, Chen WP, Teng CM, Shen YC, Guh JH. Induction of endoplasmic reticulum stress and apoptosis by a marine prostanoid in human hepatocellular carcinoma. J. Hepatol. 43: 679-686 (2005). *

• Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251 (2006). *

• Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, Nakauchi H, Iwama A, Taniguchi H. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133: 937-950 (2007). *

• Chida Y, Sudo N, Kubo C. Does stress exacerbate liver diseases? J. Gastroenterol. Hepatol. 21: 202-208 (2006).

• Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 127 (5 Suppl. 2): S120-S125 (2004). *

• Chiu MM, Ko YJ, Tsou AP, Chau GY, Chau YP. Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol. Histopathol. 24: 1223-1232 (2009). *

• Cho EH, Suh KS, Yang SH, Lee HW, Cho JY, Cho YB, Yi NJ, Lee KU. Acute graft versus host disease following living donor liver transplantation: first Korean report. Hepatogastroenterology 54: 2120-2122 (2007).

• Cho YK. Comments on minimizing misdiagnosis of hepatocellular carcinoma from magnetic resonance imaging. Hepatology 50: 1316 (2009). *

• Cho YK, Kim JK. Sustained complete response and low complication rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis. Hepatology 47: 1791 (2008). *

• Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: 453-459 (2009). *

• Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 43: 1042-1052 (2006). *

• Choi JW, Park JY, Ahn SH, Yoon KT, Ko HK, Lee DY, Lee JT, Kim KS, Choi JS, Han KH, Chon CY, Kim DY. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am. J. Clin. Oncol. 32: 564-569 (2009).

• Choudhari SR, Khan MA, Harris G, Picker D, Jacob GS, Block T, Shailubhai K. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol. Cancer Ther. 6: 112-121 (2007).

• Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36: 1221-1226 (2002). *

• Christensen E. Portal hypertension and development of hepatocellular carcinoma: factors influencing significance in prognostic models. J. Hepatol. 50: 848-849 (2009). *

• Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 30: 166-174 (2010). *

• Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A, Ohta T, Asaka M, Hirohashi S. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J. Hepatol. 41: 629-636 (2004). *

• Chung C, Doll JA, Stellmach VM, Gonzales J, Surapureddi S, Cornwell M, Reddy JK, Crawford SE. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. Adv. Exp. Med. Biol. 617: 591-597 (2008).

• Chung H, Kudo M, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y. A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol. Res. 34: 124-129 (2006).

• Chung Moh M, Hoon Lee L, Shen S. Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J. Hepatol. 42: 833-841 (2005). *

• Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-Wilde H, Broelsch CE, Deleo AB, Gerken G, Beckebaum S. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int. J. Cancer 119: 2851-2860 (2006). *

• Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, Antonio Ciarleglio F, Bridda A, Francesco D'Amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J. Hepatol. 44: 723-731 (2006). *

• Clarke JD, Thuluvath PJ. Endoscopic frontiers in the field of hepatology. Minerva Gastroenterol. Dietol. 53: 101-109 (2007).

• Clavien PA. Fourth Forum on Liver Transplantation Hepatocellular Carcinoma: where are the controversies? J. Hepatol. 43: 556-557 (2005). *

• Clayton R, Bettschart V, Parks R, Garden O. Hepatocellular carcinoma secondary to cholecystectomy: a one in a million chance. HPB (Oxford) 4: 91-93 (2002). *

• Clerici C, Castellani D, Russo G, Fiorucci S, Sabatino G, Giuliano V, Gentili G, Morelli O, Raffo P, Baldoni M, Morelli A, Toma S. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Res. 24: 1255-1260 (2004).

• Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P. R. Health Sci. J. 27: 346-347 (2008).

• Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 101: 513-523 (2006). *

• Collier JD, Carpenter M, Burt AD, Bassendine MF. Expression of mutant p53 protein in hepatocellular carcinoma. Gut 35: 98-100 (1994). *

• Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 101: 17216-17221 (2004). *

• Colombo C. Liver disease in cystic fibrosis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 31-33 (2006). *

• Colombo M. Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer. Gastroenterology 136: 1832-1835 (2009). *

• Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int. 29 Suppl. 1: 143-147 (2009).

• Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin. Liver Dis. 25: 155-161 (2005).

• Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 60: 145-150 (2003). *

• Cook RJ, Horne DW, Wagner C. Effect of dietary methyl group deficiency on one-carbon metabolism in rats. J. Nutr. 119: 612-617 (1989). *

• Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem. Biophys. Res. Commun. 278: 250-257 (2000). *

• Coppola N, De Stefano G, Marrocco C, Scarano F, Scolastico C, Tarantino L, Rossi G, Battaglia M, Onofrio M, D'Aniello F, Pisapia R, Sagnelli C, Sagnelli E, Piccinino F, Giorgio A, Filippini P. Helicobacter spp. and liver diseases. Infez. Med. 11: 201-207 (2003).

• Coradini D, Speranza A. Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol. Sin. 26: 1025-1033 (2005).

• Cortez-Pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104 (2004).

• Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am. J. Surg. Pathol. 32: 433-444 (2008).

• Cotrim HP, Parana R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am. J. Gastroenterol. 95: 3018-3019 (2000). *

• Coulouarn C, Derambure C, Lefebvre G, Daveau R, Hiron M, Scotte M, Francois A, Daveau M, Salier JP. Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition. J. Hepatol. 42: 860-869 (2005). *

• Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059-2067 (2008). *

• Crippin JS. Motion - patients with primary sclerosing cholangitis should undergo early liver transplantation: arguments against the motion. Can. J. Gastroenterol. 16: 700-702 (2002). *

• Crippin JS. Treatment of hepatocellular carcinoma after transplantation and human rights. Hepatology 45: 263-265 (2007). *

• Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Noto LD, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D, Palmeri S. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann. N. Y. Acad. Sci. 1089: 98-103 (2006). *

• Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol. Res. 38: 762-769 (2008). *

• Croswell JM, Kramer BS. Clinical trial design and evidence-based outcomes in the study of liver diseases? J. Hepatol. 50: 817-826 (2009). *

• Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, Ravaioli M, La Barba G, Cavallari A, Bolondi L, Pinna AD. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J. Hepatol. 43: 310-316 (2005). *

• Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer 88: 1878-1882 (2003). *

• Cui Y, Konig J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83: 527-538 (2003).

• Cunnigham D, Mills PR, Quigley EM, Patrick RS, Watkinson G, MacKenzie JF, Russell RI. Hepatic granulomas: experience over a 10-year period in the West of Scotland. Q. J. Med. 51: 162-170 (1982).

• Curley SA. CHAPTER 99. Diagnosis and Management of Biliary Tract Cancer. (http://www.cancer.org/downloads/PUB/DOCS/SECTION29/99.pdf) SECTION 29. Neoplasms of the Alimentary Canal. pp. 1423-1430 (2003). *

• Curro G, Jiao L, Scisca C, Baccarani U, Mucciardi M, Habib N, Navarra G. Radiofrequency-assisted liver resection in cirrhotic patients with hepatocellular carcinoma. J. Surg. Oncol. 98: 407-410 (2008).

• Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 20: 231-240 (2004).

• Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).

• Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol. 3: 269-291 (2009).

• Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL. Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 93: 687-692 (1987).

• Czauderna P, Zbrzezniak G, Narozanski W, Korzon M, Wyszomirska M, Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr. Blood Cancer 46: 825-828 (2006).

• Dahms BB. Hepatoma in familial cholestatic cirrhosis of childhood: its occurrence in twin brothers. Arch. Pathol. Lab. Med. 103: 30-33 (1979).

• Dalgic A, Ozcay F, Arslan G, Emiroglu R, Sozen H, Moray G, Karakayali H, Bilgin N, Haberal M. Living-related liver transplantation in pediatric patients. Transplant. Proc. 37: 3133-3136 (2005).

• Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat. Res. 130: 1-38 (2006).

• Daniele B, Bencivenga A, Megna AS, Tinessa V. alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S108-S112 (2004). *

• Dardon A, Corona R, Mendez-Sanchez N. Hepatocellular carcinoma not associated with virus B and C and alcohol. Ann. Hepatol. 2: 46 (2003). *

• Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin. Gastroenterol. Hepatol. 4: 104-110 (2006). *

• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54: 533-539 (2005). *

• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127: 1372-1380 (2004). *

• Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc. Bayl. Univ. Med. Cent. 21: 266-280 (2008). *

• Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4: 1 (2009). *

• Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr. Treat. Options Gastroenterol. 9: 464-474 (2006). *

• de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48 Suppl. 1: S104-S112 (2008). *

• De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 20: 1225-1230 (1994).

• de The H. Altered retinoic acid receptors. FASEB J. 10: 955-960 (1996). *

• Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Boudjema K, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Dhumeaux D, Cherqui D, Duvoux C. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 11: 767-775 (2005). *

• Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J. Biol. Chem. 281: 39607-39619 (2006). *

• Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 49: S129-S137 (2009).

• Deguchi Y, Yoshimatsu K, Endo S. Natural killer-like T cell lymphoma of the small intestine: report of a case. Surg. Today 36: 474-477 (2006). *

• Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am. J. Transplant. 8: 1177-1185 (2008). *

• Del Poggio P, Maddeo A, Zabbialini G, Pitì A. Chemoembolization of hepatocellular carcinoma with drug eluting beads. J. Hepatol. 47: 157-158 (2007). *

• Delaunay JL, Durand-Schneider AM, Delautier D, Rada A, Gautherot J, Jacquemin E, Ait-Slimane T, Maurice M. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology 49: 1218-1227 (2009). *

• Delhem N, Carpentier A, Morales O, Miroux C, Groux H, Auriault C, Pancre V. Regulatory T-cells and hepatocellular carcinoma: implication of the regulatory T lymphocytes in the control of the immune response. Bull. Cancer 95: 1219-1225 (2008).

• Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kelekis D, Madariaga J, Dervenis C. Hepatic resection for hepatocellular carcinoma exceeding Milan criteria. Surg. Oncol. Jun 3 [Epub ahead of print] (2009).

• Dellon ES, Shaheen NJ. Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology 129: 1132-1134 (2005). *

• Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, Erlinger S, Valla DC. Factor V Leiden related Budd-Chiari syndrome. Gut 48: 264-268 (2001). *

• Delvecchio CJ, Capone JP. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol. 197: 121-130 (2008). *

• Demarchi B, Bresso F, Novero D, Palestro G, Sapone N, Pellicano R, Bonardi R, Smedile A, Rizzetto M, Astegiano M. Hepatocellular carcinoma complicating primary sclerosing cholangitis in Crohn's disease. A case report. Minerva Gastroenterol. Dietol. 53: 279-283 (2007).

• Der G, Love T, Schreck J, Horn M. Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16 (2005). *

• Desmet VJ. East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma. Hepatology 49: 355-357 (2009). *

• Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 20: 5-9 (2008).

• Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin. Proc. 77: 538-541 (2002). *

• Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig. Dis. Sci. 50: 1807-1812 (2005). *

• Dhupar R, de Vera ME, Marsh JW, Fontes PA, Steel JL, Zeh HJ, Gamblin TC. Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford) 11: 242-246 (2009). *

• Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S104-S107 (2004). *

• Di Bisceglie AM. Does bare-stent TIPS increase the risk of hepatocellular carcinoma in patients with cirrhosis? Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 256-257 (2005). *

• Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 49: S56-S60 (2009).

• Di Bisceglie AM. Screening for hepatocellular carcinoma: being old is not all bad. Am. J. Gastroenterol. 99: 1477-1478 (2004). *

• Di Stefano G, Derenzini M, Kratz F, Lanza M, Fiume L. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes. Liver Int. 24: 246-252 (2004). *

• Dieleman LA, Arends A, Tonkonogy SL, Goerres MS, Craft DW, Grenther W, Sellon RK, Balish E, Sartor RB. Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect. Immun. 68: 5107-5113 (2000). *

• Dietrich CF, Ignee A, Trojan J, Fellbaum C, Schuessler G. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 53: 401-405 (2004). *

• Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW, Sun SH. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49: 1492-1502 (2009).

• Ding W, Mouzaki M, You H, Laird JC, Mato J, Lu SC, Rountree CB. CD133(+) liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49: 1277-1286 (2009). *

• Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47: 575-579 (2000). *

• Diwan BA, Sipowicz M, Logsdon D, Gorelick P, Anver MR, Kasprzak KS, Anderson LM. Marked liver tumorigenesis by Helicobacter hepaticus requires perinatal exposure. Environ. Health Perspect. 116: 1352-1356 (2008). *

• Dombrowski F, Flaschka C, Klotz L, von Netzer B, Schulz C, Lehnert H, Evert M. Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats. Hepatology 43: 857-867 (2006). *

• Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 15: 2506-2611 (2009). *

• Donadon V, Balbi M, Zanette G. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and type 2 diabetes mellitus. Expert Rev. Gastroenterol. Hepatol. 3: 465-467 (2009). *

• Dong X, Zhou G, Zhai Y, Zhang H, Yang H, Zhi L, Zhang X, Chu J, He F. Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. Cancer Epidemiol. 33: 265-270 (2009).

• Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG. Hepatocellular carcinoma complicating cystic fibrosis related liver disease. J. Cyst. Fibros. 8: 288-290 (2009).

• Dore MP, Realdi G, Mura D, Graham DY, Sepulveda AR. Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig. Dis. Sci. 47: 1638-1643 (2002). *

• Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 52: 252-257 (2010). *

• Du J, Liang X, Liu Y, Qu Z, Gao L, Han L, Liu S, Cui M, Shi Y, Zhang Z, Yu L, Cao L, Ma C, Zhang L, Chen Y, Sun W. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ. 16: 219-229 (2009).

• Duberg AS, Hultcrantz R. Misleading figures on trends in mortality from hepatocellular carcinoma in Europe. Hepatology 49: 336 (2009). *

• Dubuquoy L, Louvet A, Hollebecque A, Mathurin P, Dharancy S. Peroxisome proliferator-activated receptors in HBV-related infection. PPAR Res. 2009: 145124 (2009). *

• Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46: 2050-2068 (2000). *

• Duong FH, Christen V, Lin S, Heim MH. Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. Hepatology Oct 22 [Epub ahead of print] (2009). *

• Durand F, Belghiti J. Liver transplantation in adults. Med. Sci. (Paris) 21: 89-94 (2005).

• Durazzo M, Premoli A, Bo S. Gastrointestinal problems in the elderly. Panminerva Med. 49: 151-158 (2007).

• Duvoux C. Epidemiology and diagnosis of hepatocellular carcinomas in cirrhosis. Ann. Chir. 52: 511-517 (1998).

• Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F, Saisho H. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J. Hepatol. 43: 458-464 (2005). *

• Eguchi S, Takatsuki M, Hidaka M, Tajima Y, Kanematsu T. Evolution of living donor liver transplantation over 10 years: experience of a single center. Surg. Today 38: 795-800 (2008).

• Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39: 970-977 (2004). *

• Eichenmuller M, Gruner I, Hagl B, Haberle B, Muller-Hocker J, von Schweinitz D, Kappler R. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 49: 482-490 (2009). *

• Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin. Ther. Targets 9: 83-99 (2005).

• Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873 (2006). *

• El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, El-Wahab MA, Tawhid ZE. HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol. Invest. 37: 661-674 (2008). *

• El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (5 Suppl. 2): S27-S34 (2004). *

• El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49: 116-123 (2009). *

• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576 (2007). *

• El-Seraq HB, Johnson ML, Hachem C, Morgan RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136: 1601-1608 (2009). *

• Elliott J. SOCS3 in liver regeneration and hepatocarcinoma. Mol. Interv. 8: 19-21 (2008). *

• Emlakcioglu E, Ozcakar L, Kaymak B, Bayraktar Y, Akinci A. Arthritis due to Wilson disease, penicillamine, psoriasis or hepatocellular carcinoma? Blurred focus, sharp boundaries. Acta Reumatol. Port. 34: 685-686 (2009).

• Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watashi K, Shimotohno K, Honjo T, Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26: 5587-5595 (2007). *

• Erdogan D, Busch OR, Gouma DJ, van Gulik TM. Morbidity and mortality after liver resection for benign and malignant hepatobiliary lesions. Liver Int. 29: 175-180 (2009). *

• Erickson BM, Thompson NL, Hixson DC. Tightly regulated induction of the adhesion molecule necl-5/CD155 during rat liver regeneration and acute liver injury. Hepatology 43: 325-334 (2006). *

• Eshima K, Fukaya S, Sugimoto A, Mori T, Yokoi H, Yamamoto Y, Sugiura S, Honda S, Masuko N, Murakami K, Yamasaki Y, Kagechika H. Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model. Tumour Biol. 30: 1-7 (2009).

• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237-267 (2009). *

• Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J. Immunother. 30: 425-437 (2007).

• Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; the HALT-C TrialGroup. Weight related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137: 549-557 (2009). *

• Everson GT. Increasing incidence and pretransplantation screening of hepatocellular carcinoma. Liver Transpl. 6 (6 Suppl. 2): S2-S10 (2000). *

• Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, Hassar M, Akil A, Pineau P, Benjelloun S. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect. Genet. Evol. 9: 877-881 (2009).

• Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, Hassar M, Pineau P, Benjelloun S. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol. Res. 37: 748-754 (2007). *

• Fabris C, Toniutto P, Falleti E, Fontanini E, Cussigh A, Bitetto D, Fornasiere E, Fumolo E, Avellini C, Minisini R, Pirisi M. MTHFR C677T polymorphism and risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin. Exp. Res. 33: 102-107 (2009). *

• Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44: 472-477 (2006). *

• Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, Minisini R, Pirisi M. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77: 304-313 (2009).

• Fan ST. Resecting hepatocellular carcinoma in cirrhotic liver. J. Gastroenterol. Hepatol. 19: S416-S418 (2004). *

• Fan ST. Reducing blood loss in liver surgery. J. Gastroenterol. Hepatol. 19: S414-S415 (2004). *

• Fan ST. Debate on live related liver transplant: pro. J. Gastroenterol. Hepatol. 19: S302-S303 (2004). *

• Fan ST, Lo CM, Chan KL, Lo R, Saing H, Wei W, Lai CL, Tsoi NS, Ng I, Chan JK, Chau MT, Tso WK, Wong J. Liver transplantation - perspective from Hong Kong. Hepatogastroenterology 43: 893-897 (1996).

• Fan ST, Lo CM, Man K. Liver transplantation report of 23 cases. Zhonghua Yi Xue Za Zhi 76: 267-270 (1996).

• Fan XG, Peng XN, Huang Y, Yakoob J, Wang ZM, Chen YP. Helicobacter species ribosomal DNA recovered from the liver tissue of Chinese patients with primary hepatocellular carcinoma. Clin. Infect. Dis. 35: 1555-1557 (2002). *

• Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-Glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 67: 4915-4923 (2007). *

• Fargion S, Mattioli M, Fracanzani AL, Fiorelli G. Iron and liver diseases. Can. J. Gastroenterol. 14 Suppl. D: 89D-92D (2000).

• Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F, for the Italian Liver Cancer (ITALICA) group. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol. 101: 524-532 (2006). *

• Farmer DG, Seu P, Swenson K, Economou J, Busuttil RW. Current and future treatment modalities for hepatocellular carcinoma. Clin. Liver Dis. 1: 361-396, ix (1997).

• Fartoux L, Serfaty L. Liver cirrhosis in adults: etiology and specific treatments. Rev. Prat. 55: 1539-1548 (2005).

• Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826 (2004). *

• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5 Suppl. 2): S35-S50 (2004). *

• Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langouet S. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J. Hepatol. 43: 288-293 (2005). *

• Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, Candelaresi C, Venter J, Di Sario A, Marzioni M, Bearzi I, Glaser S, Alvaro D, Marucci L, Francis H, Svegliati-Baroni G, Benedetti A. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 68: 6752-6761 (2008). *

• Feld J, Heathcote E. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128 (2003). *

• Feld JJ, Liang TJ. Hepatitis C - identifying patients with progressive liver injury. Hepatology 43: S194-S206 (2006). *

• Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 49: S96-S102 (2009).

• Feng F, Wang L, Albanese N, Holmes A, Xia P. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 149: 1505-1513 (2008). *

• Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, Yuan Y, Wang F, Wang XF, Xie D. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Ak/NF-kB signaling pathway. Hepatology 51: 535-544 (2010).

• Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J. Hepatol. 50: 604-620 (2009). *

• Fernandez-Irigoyen J, Santamaria M, Sanchez-Quiles V, Latasa MU, Santamaría E, Munoz J, Sanchez Del Pino MM, Valero ML, Prieto J, Avila MA, Corrales FJ. Redox regulation of methylthioadenosine phosphorylase in liver cells: molecular mechanism and functional implications. Biochem. J. 411: 457-465 (2008). *

• Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig. Liver Dis. 39 Suppl. 1: S13-S21 (2007).

• Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol. Diagn. 8: 207-212 (2004).

• Findor J, He XS, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun. Rev. 1: 220-225 (2002).

• Fiume L, Bolondi L, Busi C, Chieco P, Kratz F, Lanza M, Mattioli A, Di Stefano G. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J. Hepatol. 43: 645-652 (2005). *

• Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu. Rev. Physiol. 64: 663-680 (2002). *

• Floreani A. Liver disorders in the elderly. Best Pract. Res. Clin. Gastroenterol. 23: 909-917 (2009).

• Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology 29: 1425-1428 (1999). *

• Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98: 2757-2762 (2003). *

• Floreani A, Biagini MR, Chiaramonte M, Milani S, Surrenti C, Naccarato R. Incidence of hepatic and extra-hepatic malignancies in primary biliary cirrhosis (PBC). Ital. J. Gastroenterol. 25: 473-476 (1993).

• Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 8: 1165-1174 (2002). *

• Forde KA, Reddy KR. Hepatitis C virus infection and immunomodulatory therapies. Clin. Liver Dis. 13: 391-401 (2009).

• Forner A, Bruix J. To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer? Gastroenterology 137: 375-376 (2009). *

• Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J. Hepatol. Jan 6 [Epub ahead of print] (2010).

• Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 137: 26-29 (2009). *

• Forner A, Roayaie S. Clinical research in hepatocellular carcinoma: study design and endpoints. J. Hepatol. 50: 850-853 (2009).

• Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J. Expected developments in hepatology. Best Pract. Res. Clin. Gastroenterol. 16: 957-970 (2002). *

• Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation 87: 763-770 (2009).

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408 (2006). *

• Fox JG, Feng Y, Theve EJ, Fry RC, Fiala JL, Doernte AL, Williams M, Raczynski AR, McFaline JL, Essigmann JM, Schauer DB, Tannenbaum SR, Dedon PC, Weinman SA, Lemon SM, Rogers AB. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59: 88-97 (2010).

• Fox JG, Shen Z, Xu S, Feng Y, Dangler CA, Dewhirst FE, Paster BJ, Cullen JM. Helicobacter marmotae sp. nov. isolated from livers of woodchucks and intestines of cats. J. Clin. Microbiol. 40: 2513-2519 (2002). *

• Fracanzani AL, Borzio M, Roncalli M, Derenzini M, Trere D, Mattioli M, Taioli E, Fiorelli G, Fargion S. Can large cell change and high proliferative activity predict hepatocellular carcinoma in patients with hereditary hemochromatosis? Am. J. Gastroenterol. 95: 2940-2945 (2000). *

• Fracanzani AL, Burdick L, Borzio M, Roncalli M, Bonelli N, Borzio F, Maraschi A, Fiorelli G, Fargion S. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 34: 1109-1112 (2001). *

• Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 51: 501-510 (2010). *

• Francalanci P, Santorelli FM, Saccani S, Bonetti MF, Medicina D, Coni P, Faa G, Callea F. Z and Mmalton-1-antitrypsin deficiency-associated hepatocellular carcinoma: a genetic study. Liver Int. 29: 1593-1596 (2009). *

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49: 839-850 (2009).

• Friedewald SM, Molmenti EP, DeJong MR, Hamper UM. Vascular and nonvascular complications of liver transplants: sonographic evaluation and correlation with other imaging modalities and findings at surgery and pathology. Ultrasound Q. 19: 71-85 (2003).

• Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339 (2007). *

• Fu X, Tan L, Liu S, Li H, Chen L, Qin J, Wu M, Wang H. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics. J. Cancer Res. Clin. Oncol. 130: 514-520 (2004). *

• Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, Yatabe Y, Takeda S, Nakao A. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J. Hepatol. 41: 104-111 (2004). *

• Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43: 1267-1275 (2006). *

• Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta 221: 91-103 (1993).

• Fujita T. Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma. J. Hepatol. 50: 1051-1052 (2009).

• Fukuda H, Ebara M, Okabe S, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. J. Lab. Clin. Med. 143: 333-339 (2004). *

• Fuss M, Salter BJ, Herman TS, Thomas CR. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 127 (5 Suppl. 2): S206-S217 (2004). *

• Fuster J, Charco R, Llovet JM, Bruix J, Garcia-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl. Int. 18: 278-282 (2005). *

• Gaemers IC, Groen AK. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol. 17: 268-373 (2006).

• Gai XD, Li GL, Huang JZ, Xue HJ, Wang D. Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Ai Zheng 25: 954-959 (2006).

• Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, Bolondi L. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J. Hepatol. 41: 421-426 (2004). *

• Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51 (2004).

• Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, Lagiou P, Trichopoulos D. Does coffee protect against hepatocellular carcinoma? Br. J. Cancer 87: 956-959 (2002). *

• Ganslmayer M, Ocker M, Kraemer G, Zopf S, Hahn EG, Schuppan D, Herold C. The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma. J. Hepatol. 40: 952-956 (2004). *

• Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, Landi S, Zhou Y, Liu H. An insertion/deletion polymorphism at miRNA-122 binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30: 2064-2069 (2009). *

• Garcia A, Ihrig MM, Fry RC, Feng Y, Xu S, Boutin SR, Rogers AB, Muthupalani S, Samson LD, Fox JG. Genetic susceptibility to chronic hepatitis is inherited codominantly in Helicobacter hepaticus-infected AB6F1 and B6AF1 hybrid male mice, and progression to hepatocellular carcinoma is linked to hepatic expression of lipogenic genes and immune function. Infect. Immun. 76: 1866-1876 (2008). *

• Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol. 15: 280-288 (2009). *

• Garcia-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann. Hepatol. 8: 13-20 (2009). *

• Garcia-Leiva J, Gamboa-Dominguez A, Ceron-Lizarraga T, Morales-Espinosa D, Meza-Junco J, Arrieta O. Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. Ann. Hepatol. 5: 263-267 (2006). *

• Garcia-Tsao G, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am. J. Gastroenterol. 104: 1802-1829 (2009). *

• Garioud A, Seksik P, Chretien Y, Corphechot C, Poupon R, Poupon RE, Chazouilleres O. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur. J. Gastroenterol. Hepatol. Sep 22 [Epub ahead of print] (2009). *

• Gaynor JJ, Moon JI, Kato T, Nishida S, Selvaggi G, Levi DM, Island ER, Pyrsopoulos N, Weppler D, Ganz S, Ruiz P, Tzakis AG. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation 84: 155-165 (2007).

• Gehring AJ, Ho ZZ, Tan AT, Oo Aung M, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137: 682-690 (2009). *

• Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol. 9: 2681-2685 (2003). *

• Geissler M. DNA-based immunotherapy. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 43. October 20 - 21 (2003). *

• George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 49: 729-738 (2009).

• Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J. Hepatol. Jan 17 [Epub ahead of print] (2010).

• Germani G, Pleguezuelo M, Stigliano R, Burroughs AK. Risk of seeding is reduced by associating diagnostic biopsy with percutaneous ablation for hepatocellular carcinoma. Gut 58: 734-735 (2009).

• Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S194-S205 (2004). *

• Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S153-S158 (2004). *

• Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases - detection and therapeutic applications. Med. Sci. Monit. 11: RA337-RA345 (2005). *

• Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report. Rom. J. Gastroenterol. 13: 33-38 (2004).

• Giacomin A, Sergio A, Vanin V, Tartaro P, Paccagnella D, Mazzucco M, Farinati F. Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: a prospective randomized trial in the pre-sorafenib era. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig. Liver Dis. 38: 854-859 (2006).

• Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129: 1375-1383 (2005). *

• Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int. J. Biol. Markers 15: 226-230 (2000).

• Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, DI Nolfo MA, Del Poggio P, Benvegnu L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; FOR THE ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31: 493-501 (2010). *

• Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB, Bolondi L. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J. Hepatol. 50: 969-979 (2009).

• Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I, Corrocher R, Ganz T, Fattovich G. Reduced serum hepcidin levels in patients with chronic hepatitis C. J. Hepatol. 51: 845-852 (2009).

• Girlanda R, Rela M, Williams R, O'Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc. 37: 1708-1709 (2005). *

• Girometti R, Cereser L, Como G, Zuiani C, Bazzocchi M. Biliary complications after orthotopic liver transplantation: MRCP findings. Abdom. Imaging 33: 542-554 (2008). *

• Gluskin LE, Guariglia P, Payne JA, Banner BF, Economou P. Hepatocellular carcinoma in a patient with precirrhotic primary biliary cirrhosis. J. Clin. Gastroenterol. 7: 441-444 (1985).

• Goessling W. Deciphering hepatocellular carcinoma: from bench to bedside and back. Gastroenterology 137: 786-788 (2009). *

• Gollan JL. Morbus Wilson. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 91-92. October 17 - 19 (2003). *

• Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 15: 1301-1314 (2009). *

• Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14: 4300-4308 (2008). *

• Gondolesi G, Munoz L, Matsumoto C, Fishbein T, Sheiner P, Emre S, Miller C, Schwartz ME. Hepatocellular carcinoma: a prime indication for living donor liver transplantation. J. Gastrointest. Surg. 6: 102-107 (2002).

• Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, Emre S, Miller CM, Schwartz ME. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann. Surg. 239: 142-149 (2004). *

• Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie 79: 139-144 (1997).

• Gonzalez L, Blanc JF, Sa Cunha A, Rullier A, Saric J, Le Bail B, Balabaud C, Bioulac-Sage P. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin. Liver Dis. 24: 415-419 (2004).

• Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH, Sauerbruch T, Schmitz V. CD40 ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 48: 157-168 (2008). *

• Goodman J, Glasgow SC, Schnitzler M, Lowell JA, Shenoy S, Jendrisak MD, Desai N, Lisker-Melman M, Crippin J, Chapman WC. Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease. Arch. Surg. 140: 459-464 (2005). *

• Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR. Treatment endpoints for advanced cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 4-5 (2004). *

• Gouysse G, Frachon S, Hervieu V, Fiorentino M, D'Errico A, Dumortier J, Boillot O, Partensky C, Grigioni WF, Scoazec JY. Endothelial cell differentiation in hepatocellular adenomas: implications for histopathological diagnosis. J. Hepatol. 41: 259-266 (2004). *

• Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, Bauer M, Vonthein R, Gregor M, Lauer UM. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41: 879-886 (2005). *

• Gran JT, Gunnarsson R, Mork NJ. A man with erythodermia, muscle weakness and weight loss. Tidsskr. Nor. Laegeforen. 129: 2240-2241 (2009).

• Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma - a clinical viewpoint. J. Hepatol. 33: 667-672 (2000). *

• Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Muller T, Gressner AM. Elevated concentrations of 15-deoxy-delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs. Liver Int. 29: 730-735 (2009). *

• Greten TF, Manns MP, Reinisch I, Kaatsch P. Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut 54: 732 (2005). *

• Grewal HP, Shokouh-Amiri MH, Vera S, Stratta R, Bagous W, Gaber AO. Surgical technique for right lobe adult living donor liver transplantation without venovenous bypass or portocaval shunting and with duct-to-duct biliary reconstruction. Ann. Surg. 233: 502-508 (2001). *

• Grewal P, Martin P. Care of the cirrhotic patient. Clin. Liver Dis. 13: 331-340 (2009).

• Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418 (2005). *

• Grimaud JC, Bourliere M. Contraception and hepatogastroenterology. Fertil. Contracept. Sex 17: 407-413 (1989).

• Grover JK, Yadav S, Vats V, Joshi YK. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int. J. Colorectal Dis. 18: 279-291 (2003). *

• Gruttadauria S, Marsh JW, Cintorino D, Biondo D, Luca A, Arcadipane A, Vizzini G, Volpes R, Marcos A, Gridelli B. Adult to adult living-related liver transplant: report on an initial experience in Italy. Dig. Liver Dis. 39: 342-350 (2007).

• Gruttadauria S, Vasta F, Mandala L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant. Proc. 37: 2611-2613 (2005). *

• Gu W, Zhang YN, Li B, Han J, Cheng BB, Ling CQ. Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics. Zhong Xi Yi Jie He Xue Bao 4: 265-270 (2006).

• Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C. An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population. Hum. Genet. Oct 8 [Epub ahead of print] (2009).

• Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum. Immunol. 71: 83-87 (2010).

• Guckelberger O, Bechstein WO, Nussler NC, Radke C, Neuhaus P. Hepatocellular carcinoma in patients suffering from primary sclerosing cholangitis. J. Hepatol. 29: 513-514 (1998). *

• Guettier C. Which stem cells for adult liver? Ann. Pathol. 25: 33-44 (2005).

• Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin. Liver Dis. 12: 883-900 (2008).

• Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168: 66-73 (2007). *

• Gundling F, Schumm-Draeger PM, Schepp W. Hepatogenous diabetes - diagnostics and treatment. Z. Gastroenterol. 47: 436-445 (2009).

• Gundling F, Seidl H, Loffler N, Strassen I, Schepp W. Metabolic disturbances in liver cirrhosis (part 2), hepatogenous diabetes. Dtsch. Med. Wochenschr. 135: 22-24 (2010).

• Guo SY, Shen X, Yang J, Yuan J, Yang RL, Mao K, Zhao DH, Li CJ. TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner. Braz. J. Med. Biol. Res. 40: 621-631 (2007). *

• Guo WX, Pye QN, Williamson KS, Stewart CA, Hensley KL, Kotake Y, Floyd RA, Broyles RH. Reactive oxygen species in choline deficiency-induced apoptosis in rat hepatocytes. Free Radic. Biol. Med. 37: 1081-1089 (2004).

• Gupta K, Vasishta RK, Dutta U, Kochhar RK, Singh K. Embolization of cyanoacrylate glue in systemic circulation in a case of hepatocellular carcinoma: a case report. Diagn. Pathol. 4: 45 (2009). *

• Gurr W, Shaw M, Li Y, Sherwin R. RegII is a beta-cell protein and autoantigen in diabetes of NOD mice. Diabetes 56: 34-40 (2007). *

• Guyader D, Latournerie M. Incidental ultrasound finding of a 3cm liver nodule in a 45-year-old woman taking hormonal substitution after hysterectomy performed for cervix carcinoma. Gastroenterol. Clin. Biol. 33: F60-F67 (2009).

• Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis. J. Biol. Chem. 284: 9321-9330 (2009). *

• Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ alpha1-antitrypsin deficiency. Hepatology 43: 194 (2006). *

• Harada K, Yasoshima M, Ozaki S, Sanzen T, Nakanuma Y. PCR and in situ hybridization studies of telomerase subunits in human non-neoplastic livers. J. Pathol. 193: 210-217 (2001). *

• Haratake J, Horie A, Takeda S. Histochemical and ultrastructural study of copper-binding protein in hepatocellular carcinoma. Cancer 60: 1269-1274 (1987).

• Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J. Hepatol. 27: 512-516 (1997). *

• Harrison SA. Non-alcoholic steatohepatitis. Preface. Clin. Liver Dis. 13: xiii-xiv (2009). *

• Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44: 891-895 (2006). *

• Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49: 1563-1570 (2009).

• Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J. Hepatol. 50: 334-341 (2009).

• Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 1: 10-18 (2003). *

• Hattori E, Okumoto K, Adachi T, Takeda T, Ito J, Sugahara K, Watanabe H, Saito K, Saito T, Togashi H, Kawata S. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol. Res. 27: 309-314 (2003).

• Haurie V, Menard L, Nicou A, Touriol C, Metzler P, Fernandez J, Taras D, Lestienne P, Balabaud C, Bioulac-Sage P, Prats H, Zucman-Rossi J, Rosenbaum J. Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology 50: 1871-1883 (2009).

• Haussinger D, Schliess F. Glutamine metabolism and signaling in the liver. Front. Biosci. 12: 371-391 (2007).

• Hayashi E, Motomura Y, Shirakawa H, Yoshikawa T, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol. Rep. 22: 149-154 (2009).

• Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, Bak T, Kam I, Everson GT. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl. 10: 42-48 (2004). *

• Hayashi Y, Wang W, Ninomiya T, Nagano H, Ohta K, Itoh H. Liver enriched transcription factors and differentiation of hepatocellular carcinoma. Mol. Pathol. 52: 19-24 (1999). *

• Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26: 219-227 (2005). *

• He N, Park K, Zhang Y, Huang J, Lu S, Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 134: 793-802 (2008). *

• He YF, Liu YK, Lu HJ, Chen J, Yang PY. Comparative proteomic analysis of primary mouse liver c-Kit-(CD45/TER119)- stem/progenitor cells. J. Cell. Biochem. 102: 936-946 (2007). *

• Head HW, Dodd GD. Thermal ablation for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S167-S178 (2004). *

• Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S294-S302 (2004). *

• Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin. Gastroenterol. Hepatol. 1: 279-284 (2003). *

• Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, Pouderoux P, Bismuth M, Demattei C, Duny Y, Chaze I, Funakoshi N, Bureau JP, Daures JP, Blanc P. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 58: 833-838 (2009).

• Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J. Hepatol. 52: 220-227 (2010).

• Herr I, Groth A, Schemmer P, Buchler MW. Adult stem cells in progression and therapy of hepatocellular carcinoma. Int. J. Cancer 121: 1875-1882 (2007). *

• Herr I, Schemmer P, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 46: 266-274 (2007). *

• Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation? - no, never. J. Hepatol. 43: 573-577 (2005). *

• Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am. J. Med. Sci. 334: 228-230 (2007).

• Hidaka H, Kokubu S, Nakazawa T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K. Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol. Res. 39: 772-778 (2009). *

• Hidaka M, Eguchi S, Okudaira S, Takatsuki M, Tokai H, Soyama A, Nagayoshi S, Mochizuki S, Hamasaki K, Tajima Y, Kanematsu T. Multicentric occurrence and spread of hepatocellular carcinoma in whole explanted end-stage liver. Hepatol. Res. 39: 143-148 (2009). *

• Higai K, Miyazaki N, Azuma Y, Matsumoto K. Transcriptional regulation of the fucosyltransferase VI gene in hepatocellular carcinoma cells. Glycoconj. J. 25: 225-235 (2008). *

• Hino T, Kumashiro R, Ide T, Koga Y, Ishii K, Tanaka E, Morita Y, Hisamochi A, Murashima S, Tanaka K, Ogata K, Kuwahara R, Sata M. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int. J. Mol. Med. 11: 749-755 (2003).

• Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y. Interleukin-1beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J. Gastroenterol. 12: 776-779 (2006). *

• Hirooka M, Ishida K, Kisaka Y, Uehara T, Watanabe Y, Hiasa Y, Michitaka K, Onji M. Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma. Hepatol. Res. 38: 1172-1177 (2008). *

• Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Katafuchi Y, Kojiro M. Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J. Hepatol. 41: 782-789 (2004). *

• Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J. Hepatol. 50: 118-127 (2009). *

• Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47: 1524-1532 (2008). *

• Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, Poon RT. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44: 836-843 (2006). *

• Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HH, Guo HR. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 15: 657-663 (2004). *

• Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 80: 36-39 (2009).

• Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135: 234-243 (2008). *

• Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50: 799-807 (2009).

• Hoefs JC, Wang F, Kanel G. Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am. J. Gastroenterol. 92: 2054-2058 (1997).

• Hol L, van den Bos IC, Hussain SM, Zondervan PE, de Man RA. Hepatocellular carcinoma complicating biliary atresia after Kasai portoenterostomy. Eur. J. Gastroenterol. Hepatol. 20: 227-231 (2008).

• Holmstrom P, Gafvels M, Eriksson LC, Dzikaite V, Hultcrantz R, Eggertsen G, Stal P. Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Liver Int. 26: 976-985 (2006). *

• Homann N, Stickel F, Konig IR, Jacobs A, Junghanns K, Benesova M, Schuppan D, Himsel S, Zuber-Jerger I, Hellerbrand C, Ludwig D, Caselmann WH, Seitz HK. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int. J. Cancer 118: 1998-2002 (2006). *

• Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 44: 1122-1138 (2006). *

• Honda T, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Toyoda H, Ishiguro H, Ogawa S, Takeshima K, Kawachi T, Hibi T, Hayashi K, Katano Y, Fukuda Y, Goto H. Comparison of contrast-enhanced harmonic ultrasonography and power Doppler ultrasonography for depicting vascularity of hepatocellular carcinoma identified by angiography-assisted CT. Hepatol. Res. 27: 315-322 (2003).

• Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 127 (5 Suppl. 2): S319-S323 (2004). *

• Hookey LC, Le Moine O, Deviere J. Use of a temporary plastic stent to facilitate the placement of multiple self-expanding metal stents in malignant biliary hilar strictures. Gastrointest. Endosc. 62: 605-609 (2005).

• Hopf U. The elder patient with advanced liver disease. Schweiz. Rundsch. Med. Prax. 94: 743-750 (2005).

• Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 41: 1008-1016 (2004). *

• Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S. Gene map of the extended human MHC. Nat. Rev. Genet. 5: 889-899 (2004). *

• Horvath A, Folhoffer A, Lakatos PL, Halosz J, Illyes G, Schaff Z, Hantos MB, Tekes K, Szalay F. Rising plasma nociceptin level during development of HCC: a case report. World J. Gastroenterol. 10: 152-154 (2004). *

• Hoshida Y. Tumor-derived molecular information and outcome in hepatocellular carcinoma. J. Hepatol. 51: 595-596 (2009).

• Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J. Hepatol. 51: 842-844 (2009).

• Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359: 1995-2004 (2008). *

• Hoso M, Nakanuma Y. Argyrophilic nucleolar organizer regions in neoplastic and non-neoplastic hepatocytes bearing Mallory bodies. Liver 12: 112-115 (1992).

• Howroyd P, Swanson C, Dunn C, Cattley RC, Corton JC. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol. Pathol. 32: 591-599 (2004). *

• Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65: 242-249 (2003).

• Hsu CN, Lai JM, Liu CH, Tseng HH, Lin CY, Lin KT, Yeh HH, Sung TY, Hsu WL, Su LJ, Lee SA, Chen CH, Lee GC, Lee DT, Shiue YL, Yeh CW, Chang CH, Kao CY, Huang CY. Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics 8: 66 (2007). *

• Hsu CY, Huang YH, Su CW, Lin HC, Chiang JH, Lee PC, Lee FY, Huo TI, Lee SD. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int. 30: 77-84 (2010). *

• Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 99: 860-865 (2004). *

• Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, Xiang R, Ren H. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46: 1654-1662 (2009). *

• Hu RH, Ho MC, Wu YM, Yu SC, Lee PH. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin. Transplant. 19: 175-180 (2005). *

• Huang J, He X, Chen G, Zhu X, Lu M, Wang G, Fu Y, Yang Y, Guan X. Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China. Chin. Med. J. (Engl.) 115: 543-548 (2002).

• Huang J, Karakucuk V, Levitsky LL, Rhoads DB. Expression of HNF4alpha variants in pancreatic islets and Ins-1 beta cells. Diabetes Metab. Res. Rev. 24: 533-543 (2008).

• Huang J, Zhang X, Zhang M, Zhu JD, Zhang YL, Lin Y, Wang KS, Qi XF, Zhang Q, Liu GZ, Yu J, Cui Y, Yang PY, Wang ZQ, Han ZG. Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis 28: 1094-1103 (2007). *

• Huang MA, Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 18: 345-350 (2002).

• Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol. Carcinog. 48: 553-562 (2009). *

• Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, Zeng WT, Cao LQ, Tan HX, Su Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol. Res. 39: 786-794 (2009). *

• Huang Y, Fan XG, Wang ZM, Zhou JH, Tian XF, Li N. Identification of Helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J. Clin. Pathol. 57: 1273-1277 (2004). *

• Huang YC, Chen M, Shyr YM, Su CH, Chen CK, Li AF, Ho DM, Chen YM. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. J. Gastroenterol. Hepatol. 23: 1384-1389 (2008). *

• Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Chau GY, Chiang JH, Lui WY, Lee SD, Wu JC. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 24: 419-424 (2004). *

• Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, Lai MY, Chen PJ, Chen DS, Yang SS, Kao JH. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun. Aug 20 [Epub ahead of print] (2009).

• Hubner M, McCormack L, Clavien PA. Surgical therapy of liver tumors: resection vs. ablation. Schweiz. Rundsch. Med. Prax. 94: 1255-1259 (2005).

• Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 49: 450-465 (2006). *

• Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J. Hepatol. 43: 661-669 (2005). *

• Hui IC, Tung EK, Sze KM, Ching YP, Ng IO. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int. 30: 65-75 (2010). *

• Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, Wahren B, Broome U. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J. Hepatol. 30: 669-673 (1999). *

• Hung TM, Chang SC, Yu WH, Wang YW, Huang C, Lu SC, Lee PH, Chang MF. A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. Hepatology 50: 1184-1193 (2009). *

• Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, Loong CC, Chiang JH, Chiou YY, Lee SD. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int. 30: 198-207 (2010). *

• Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a modified cancer of the liver Italian program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am. J. Gastroenterol. 101: 975-982 (2006). *

• Huo TI, Lee SD. Role of the model for end-stage liver disease and serum alpha-fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver Int. 26: 1300-1301 (2006). *

• Huo TI, Lee SD. Management of inoperable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 19: S272-S278 (2004). *

• Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, Lee SD. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am. J. Gastroenterol. 102: 1920-1930 (2007). *

• Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 24: 210-215 (2004). *

• Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Huang YH, Lee PC, Chang FY, Lee SD. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl. 10: 1507-1513 (2004). *

• Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY, Lee SD. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am. J. Gastroenterol. 99: 1479-1487 (2004). *

• Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 234: 468-478 (2005). *

• Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J. Hepatol. 52: 79-87 (2010).

• Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl. 11: 1265-1272 (2005). *

• Hytiroglou P. Morphological changes of early human hepatocarcinogenesis. Semin. Liver Dis. 24: 65-75 (2004).

• Hytiroglou P, Theise ND. Telomerase activation in human hepatocarcinogenesis. Am. J. Gastroenterol. 101: 839-841 (2006). *

• Iacono OL, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, Mineo C, De Lisi S, Almasio PL , Craxi A. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am. J. Gastroenterol. 100: 2472-2477 (2005). *

• Ichikawa T, Uenishi T, Takemura S, Oba K, Ogawa M, Kodai S, Shinkawa H, Tanaka H, Yamamoto T, Tanaka S, Yamamoto S, Hai S, Shuto T, Hirohashi K, Kubo S. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. 16: 42-48 (2009). *

• Ichikawa T, Yanagi K, Motoyoshi Y, Hamasaki K, Nakao K, Toriyama K, Eguchi K. Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J. Gastroenterol. Hepatol. 21: 1865-1866 (2006). *

• Igarashi H, Aoyagi Y, Suda T, Mita Y, Kawai K. Studies on the correlation among the fucosylation index, concentration of alpha-fetoprotein and des-gamma-carboxy prothrombin as prognostic indicators in hepatocellular carcinoma. Hepatol. Res. 27: 280-288 (2003).

• Igetei R, Otegbayo JA, Ndububa DA, Lesi OA, Anumudu CI, Hainaut P, Gormally E. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann. Hepatol. 7: 339-344 (2008).

• Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H, Kaneko S. Ephrin-A1 expression contributes to the malignant characteristics of alpha-fetoprotein producing hepatocellular carcinoma. Gut 54: 843-851 (2005). *

• Iida T, Zendejas IR, Kayler LK, Magliocca JF, Kim RD, Hemming AW, Gonzalez-Peralta RP, Fujita S. Hepatocellular carcinoma in a 10-month-old biliary atresia child. Pediatr. Transplant. Nov 10 [Epub ahead of print] (2008).

• Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, Nakanuma Y, Futagawa S, Makuuchi M, Yamaoka Y. Report of the 15th follow-up survey of primary liver cancer. Hepatol. Res. 28: 21-29 (2004).

• Ikeda H, Nishi S, Sakai M. Transcription factor Nrf2/MafK regulates rat glutathione S-transferase P gene during hepatocarcinogenesis. Biochem. J. 380: 515-521 (2004). *

• Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Path. Int. 56: 40-45 (2006). *

• Ikeda S. Adult-onset citrullinemia. Brain Nerve 59: 59-66 (2007).

• Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN, Chen CJ. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int. Oct 16 [Epub ahead of print] (2009). *

• Imada J, Hoshino H, Nishimura D, Morita K, Yoshida N, Katada N, Sano H, Kato K, Mori N. Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 11: 546-550 (1996).

• Imai K, Sato M, Kojima N, Miura M, Sato T, Sugiyama T, Enomoto K, Senoo H. Storage of lipid droplets in and production of extracellular matrix by hepatic stellate cells (vitamin A-storing cells) in Long-Evans cinnamon-like colored (LEC) rats. Anat. Rec. 258: 338-348 (2000).

• Imai Y. Combination of transarterial chemoembolization and percutaneous local ablation therapy for hepatocellular carcinoma. Hepatol. Res. 40: 105-107 (2010). *

• Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Kudo S, Tanaka K. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis 30: 1729-1734 (2009). *

• Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T, Yoshida H, Kanai F, Hamamura K, Obi S, Yoshida H, Omata M. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am. J. Gastroenterol. 103: 3057-3062 (2008). *

• Inagaki Y, Yasui K, Endo M, Nakajima T, Zen K, Tsuji K, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Okanoue T. CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma. Cancer Genet. Cytogenet. 180: 30-36 (2008).

• Inoue M, Yoshimi I, Sobue T, Tsugane S; JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J. Natl. Cancer Inst. 97: 293-300 (2005). *

• International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49: 658-664 (2009). *

• Inui K, Takahashi Y, Komeichi H, Katsuta Y, Shimizu S, Mizuno K. Successful transcatheter chemoembolization for acute jaundice in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a case report. J. Nippon Med. Sch. 76: 217-220 (2009). *

• Ioannou GN. Percutaneous ablation for hepatocellular carcinoma. Hepatology 41: 942 (2005). *

• Ioannou GN, Kowdley KV. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? Clin. Gastroenterol. Hepatol. 1: 246-248 (2003). *

• Iqbal MJ, Wilkinson ML, Williams R. Sex steroid binding patterns in primary biliary cirrhosis complicated by hepatocellular carcinoma. Br. Med. J. (Clin. Res. Ed.) 289: 459-460 (1984). *

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Ishida K, Hirooka M, Hiraoka A, Kumagi T, Uehara T, Hiasa Y, Horiike N, Onji M. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil. Jpn. J. Clin. Oncol. 38: 596-603 (2008).

• Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J. Hepatol. 50: 562-571 (2009).

• Ishikawa A, Nishida H, Baba T, Mitamura K. Evaluation of balloon-occluded hepatic venography with carbon dioxide for portography and correlation between retrograde portogram and liver function in patients with liver cirrhosis. Hepatol. Res. 18: 239-251 (2000).

• Ishikawa H, Nakao K, Matsumoto K, Nishimura D, Ichikawa T, Hamasaki K, Eguchi K. Bone marrow engraftment in a rodent model of chemical carcinogenesis but no role in the histogenesis of hepatocellular carcinoma. Gut 53: 884-889 (2004). *

• Ishikawa T, Umesono K, Mangelsdorf DJ, Aburatani H, Stanger BZ, Shibasaki Y, Imawari M, Evans RM, Takaku F. A functional retinoic acid receptor encoded by the gene on human chromosome 12. Mol. Endocrinol. 4: 837-844 (1990). *

• Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43: 362-372 (2006). *

• Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134: 1908-1916 (2008). *

• Ishizawa T, Mise Y, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J. Hepatobiliary Pancreat. Surg. Nov 19 [Epub ahead of print] (2009). *

• Island ER, Pomposelli J, Pomfret EA, Gordon FD, Lewis WD, Jenkins RL. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch. Surg. 140: 353-358 (2005). *

• Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, Tsuchiya K, Hamano K, Asahina Y, Kurosaki M, Uchihara M, Miyake S. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol. Res. 29: 216-222 (2004).

• Ito K, Shiraki K, Sakai T, Yoshimura H, Nakano T. Portal hypertensive colopathy in patients with liver cirrhosis. World J. Gastroenterol. 11: 3127-3130 (2005). *

• Iwadate H, Ohira H, Suzuki T, Abe K, Yokokawa J, Takiguchi J, Rai T, Orikasa H, Irisawa A, Obara K, Kasukawa R, Sato Y. Hepatocellular carcinoma associated with Wilson's disease. Intern. Med. 43: 1042-1045 (2004). *

• Iwahori T, Matsuura T, Maehashi H, Sugo K, Saito M, Hosokawa M, Chiba K, Masaki T, Aizaki H, Ohkawa K, Suzuki T. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37: 665-673 (2003). *

• Iwazaki N, Kobayashi K, Morimoto K, Hirano M, Kawashima S, Furihata T, Chiba K. Involvement of hepatocyte nuclear factor 4alpha in transcriptional regulation of the human pregnane X receptor gene in the human liver. Drug Metab. Pharmacokinet. 23: 59-66 (2008). *

• Izumi Y, Hiramatsu N, Itose I, Inoue T, Sasagawa A, Egawa S, Nishida T, Kakiuchi Y, Toyama T, Nakanishi F, Ohkawa K, Mochizuki K, Kanto T, Tsujii M, Takehara T, Tsuji S, Kato M, Kasahara A, Hayashi N. Juvenile hepatocellular carcinoma with congestive liver cirrhosis. J. Gastroenterol. 40: 204-208 (2005). *

• Izuno K, Fujiyama S, Shibata J, Yoshida K, Sato T, Shimomura O, Takahashi M. Transrectal portal scintigraphy with I123 iodoamphetamine in liver diseases. Hepatogastroenterology 38 Suppl. 1: 8-11 (1991).

• Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F. Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases. Arch. Pathol. Lab. Med. 116: 643-648 (1992).

• Jakubovic BD, Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp. Mol. Pathol. 82: 184-189 (2007). *

• Janciauskiene S, Eriksson S, Callea F, Mallya M, Zhou A, Seyama K, Hata S, Lomas DA. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha(1)-antitrypsin. Hepatology 40: 1203-1210 (2004). *

• Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment. Pharmacol. Ther. 31: 415-423 (2010). *

• Jansen PL. Nonalcoholic steatohepatitis. Neth. J. Med. 62: 217-224 (2004). *

• Jansen PL. Non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1079-1085 (2004).

• Jansen PL. Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis. Ned. Tijdschr. Geneeskd. 149: 289-294 (2005).

• Jansen PL. Endogenous bile acids as carcinogens. J. Hepatol. 47: 434-435 (2007). *

• Jen-Eing J, Jung-Fa T, Lee-Yea C, Mei-Shang H, Zu-Yau L, Min-Yuh H, Shin-Chern C, Wan-Lung C, Liang-Yen W, Ming-Lung Y, Chia-Yen D, Jan-Gowth C. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 9: 987-992 (2007).

• Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a case-control study. Medicine (Baltimore) 87: 87-98 (2008).

• Jeng KS, Sheen IS, Tsai YC. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am. J. Gastroenterol. 99: 1503-1509 (2004). *

• Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). Hepatology 20: 1061-1077 (1994).

• Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361: 1437-1447 (2009). *

• Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HJ, Tang ZY, Croce CM, Wang XW. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480 (2009). *

• Ji L, Yu H. Relationship of single nucleotide polymorphism, environmental factors and the hereditary susceptibility of hepatocellular carcinoma. Wei Sheng Yan Jiu 38: 233-237 (2009).

• Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 13: 1133-1139 (2007). *

• Jiang MD, Peng ZP, Li SL, Wang ZG, Ran HT, Huo SH, Yin XL. Reversion of multidrug resistance of hepatocellular carcinoma by antisense oligonucleotides and ultrasonic microbubble intensifier transfection combined with ultrasound irradiation. Zhonghua Gan Zang Bing Za Zhi 14: 341-345 (2006).

• Jiang SY, Chou JM, Leu FJ, Hsu YY, Shih YL, Yu JC, Lee MS, Shyu RY. Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma. World J. Gastroenterol. 11: 948-953 (2005). *

• Jin F, Qu LS, Shen XZ. Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn. Pathol. 4: 39 (2009). *

• Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J. Hepatol. 43: 1013-1020 (2005). *

• Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer 104: 354-361 (2003). *

• Johal H, Scott G, Jones R, Camaris C, Riordan S, Rawlinson WD. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J. Hepatol. 50: 548-554 (2009).

• Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. J. Hepatol. 33: 1006-1008 (2000). *

• Johnson PJ, Krasner N, Portmann B, Eddleston AL, Williams R. Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut 19: 1022-1026 (1978). *

• Jolesz FA, Hynynen K, McDannold N, Freundlich D, Kopelman D. Noninvasive thermal ablation of hepatocellular carcinoma by using magnetic resonance imaging-guided focused ultrasound. Gastroenterology 127 (5 Suppl. 2): S242-S247 (2004). *

• Jones BA, Gores GJ. Hepatobiliary malignancy. Clin. Liver Dis. 2: 437-449, xi-xii (1998).

• Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26: 1138-1142 (1997). *

• Jou YS, Lee CS, Chang YH, Hsiao CF, Chen CF, Chao CC, Wu LS, Yeh SH, Chen DS, Chen PJ. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res. 64: 3030-3036 (2004). *

• Jung HY, Park SH, Yoo YD, Kim JS, Kim YH. CDK2/4 regulate retinoic acid-induced G1 arrest in hepatocellular carcinoma cells. Hepatol. Res. 31: 143-152 (2005).

• Jung JK, Park SH, Jang KL. Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by down-regulating retinoic acid receptor-{beta}2 expression via DNA methylation. J. Gen. Virol. Oct 14 [Epub ahead of print] (2009). *

• Jung KW, Eun Young Ha, Yu GI, Kim SJ, Chung WJ, Jang BK, Lee JJ, Shin DH, Hwang JS. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin. Chim. Acta 407: 16-19 (2009). *

• Jung Y, McCall SJ, Li YX, Diehl AM. Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology 45: 1091-1096 (2007). *

• Jungst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 39: 1663-1672 (2004). *

• Juran BD, Lazaridis KN. Applying genomics to the study of complex disease. Semin. Liver Dis. 27: 3-12 (2007). *

• Juran BD, Lazaridis KN. Genetics of hepatobiliary diseases. Clin. Gastroenterol. Hepatol. 4: 548-557 (2006).

• Kadokawa Y, Omagari K, Ohba K, Kitamura S, Ohara H, Takeshima F, Mizuta Y, Nanashima A, Yamaguchi H, Kohno S. Hepatocellular carcinoma in a male patient with early stage (stage I) primary biliary cirrhosis. Intern. Med. 44: 207-211 (2005). *

• Kakizoe T. Chemoprevention of cancer - focusing on clinical trials. Jpn. J. Clin. Oncol. 33: 421-442 (2003). *

• Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14: 22-28 (2008). *

• Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J. Gastroenterol. 43: 811-822 (2008). *

• Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat. Genet. 41: 591-595 (2009). *

• Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 45: 797-805 (2007). *

• Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H. Synergistic growth inhibition by acyclic retinoid and vitamin K(2) in human hepatocellular carcinoma cells. Cancer Sci. 98: 431-437 (2007). *

• Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int. J. Oncol. 35: 477-483 (2009).

• Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans M. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 111: 316-322 (2007). *

• Kang Kim M, Petrovic L, Maltz C. Metastatic hepatocellular carcinoma. J. Hepatol. 41: 684 (2004). *

• Kao JH, Chen DS. Local ablation vs. resection for the treatment of hepatocellular carcinoma. Hepatology 43: 373 (2006). *

• Kao YH, Chen CL, Jawan B, Chung YH, Sun CK, Kuo SM, Hu TH, Lin YC, Chan HH, Cheng KH, Wu DC, Goto S, Cheng YF, Chao D, Tai MH. Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J. Hepatol. 52: 96-105 (2010).

• Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismuller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma R, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology Nov 25 [Epub ahead of print] (2009). *

• Karpen SJ, Trauner M. The new therapeutic frontier - nuclear receptors and the liver. J. Hepatol. Dec 24 [Epub ahead of print] (2009). *

• Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol. Res. 39: 117-125 (2009). *

• Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 396-406 (2008). *

• Katamura Y, Aikata H, Kimura Y, Azakami T, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Chayama K. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient. Hepatol. Res. 39: 415-420 (2009).

• Kato H, Nakamura M, Muramatsu M, Orito E, Ueda R, Mizokami M. Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review. Hepatol. Res. 29: 180-190 (2004).

• Kato Y, Matsubara K, Akiyama Y, Hattori H, Hirata A, Suzuki F, Ohtaka H, Kato A, Sugiura Y, Kitajima M. Chemotherapy-induced sclerosing cholangitis as a rare indication for resection: report of a case. Surg Today 39: 905-908 (2009).

• Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M, Hosoda F, Ohki M, Imoto I, Inazawa J, Hirohashi S. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J. Hepatol. 43: 863-874 (2005). *

• Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Mitchell LA, Kohen R, Domany E, Galun E, Goldenberg D. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res. 66: 4001-4010 (2006). *

• Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int. Dec 22 [Epub ahead of print] (2009). *

• Kawamura H, Govindarajan S, Aswad F, Machida K, Lai MM, Sung VM, Dennert G. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice. Hepatology 44: 936-944 (2006). *

• Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol. Res. 39: 346-354 (2009). *

• Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387: 365-372 (2006).

• Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC, Kawakami Y, Takahashi S, Toyota N, Ito K, Hirokawa Y, Chayama K. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol. Res. 39: 134-142 (2009). *

• Kazemier G, Metselaar HJ, de Man RA, Tran TC, Groenland TH, Tilanus HW. Liver transplantation with a living donor: the first 3 cases in Rotterdam. Ned. Tijdschr. Geneeskd. 152: 817-821 (2008).

• Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49: 491-503 (2009). *

• Kee SJ, Kim TJ, Lee SJ, Cho YN, Park SC, Kim JS, Kim JC, Kang HS, Lee SS, Park YW. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. Rheumatol. Int. 29: 595-599 (2009). *

• Keeffe EB, Davis GL. Advances in liver disease: highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42 (2004). *

• Kelleher T, Staunton M, O'Mahony S, McCormick PA. Advanced hepatocellular carcinoma associated with cystic fibrosis. Eur. J. Gastroenterol. Hepatol. 17: 1123-1124 (2005).

• Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J. Gastroenterol. Hepatol. 20: 873-881 (2005). *

• Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, Chen JG, Qian GS, Kuang SY, Jackson PE, Gange SJ, Jacobson LP, Munoz A, Groopman JD. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127 (5 Suppl. 2): S310-S318 (2004). *

• Kettenbach J, Blum M, Kilanowicz E, Schwaighofer SM, Lammer J. Percutaneous radiofrequence-ablation of liver cell carcinoma: a current overview. Radiologe 44: 330-338 (2004).

• Khetchoumian K, Teletin M, Tisserand J, Herquel B, Ouararhni K, Losson R. Trim24 (Tif1alpha): an essential 'brake' for retinoic acid-induced transcription to prevent liver cancer. Cell Cycle 7: 3647-3652 (2008). *

• Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, Zucman-Rossi J, Cammas F, Lerouge T, Thibault C, Metzger D, Chambon P, Losson R. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet. 39: 1500-1506 (2007). *

• Khettry U, Azabdaftari G, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Gordon FD. Impact of model for end-stage liver disease (MELD) scoring system on pathological findings at and after liver transplantation. Liver Transpl. 12: 958-965 (2006). *

• Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J. Cell. Biochem. 100: 1301-1312 (2007). *

• Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN. Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology 50: 752-762 (2009).

• Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y, Han SB. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int. Immunopharmacol. 7: 1793-1801 (2007).

• Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28: 940-946 (2007). *

• Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization versus chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment. Pharmacol. Ther. 29: 1291-1298 (2009). *

• Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 39: 518-527 (2004). *

• Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXR alpha. Biochem. J. 416: 219-230 (2008). *

• Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann. Surg. Oncol. 16: 623-629 (2009). *

• Kim MJ, Kim JH, Lim JS, Oh YT, Chung JJ, Choi JS, Lee WJ, Kim KW. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20: 612-621 (2004).

• Kim ND, Im EO, Choi YH, Yoo YH. Synthetic bile acids: novel mediators of apoptosis. J. Biochem. Mol. Biol. 35: 134-141 (2002). *

• Kim S, Kotoula V, Hytiroglou P, Zardavas D, Zhang L. Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig. Liver Dis. 41: 591-598 (2009).

• Kim S, Moon SM, Kim YS, Kim JJ, Ryu HJ, Kim YJ, Choi JW, Park HS, Kim DG, Shin HD, Rutherford MS, Oh B, Lee JK. TNFR1 promoter -329G/T polymorphism results in allele-specific repression of TNFR1 expression. Biochem. Biophys. Res. Commun. 368: 395-401 (2008). *

• Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM, Lim YS, Lee HC, Lee YS, Suh DJ. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J. Hepatol. 15: 320-330 (2009).

• Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab. Invest. 84: 479-484 (2004). *

• Kim WR. Motion - the available treatments for hepatitis C are cost effective: arguments against the motion. Can. J. Gastroenterol. 16: 710-715 (2002). *

• Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waitlist registration for liver transplantation for viral hepatitis in the US. Gastroenterology 137: 1680-1686 (2009). *

• Kiran M, Chawla YK, Kaur J. Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol. 27: 687-694 (2008).

• Kiran M, Saxena R, Chawla YK, Kaur J. Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol. Cell. Biochem. 327: 7-13 (2009). *

• Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y, Inamori M, Kobayashi N, Kubota K, Sakaguchi T, Ueno N, Nakajima A. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol. Res. 39: 553-562 (2009). *

• Kisaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, Tanaka H, Michitaka K, Horiike N, Mochizuki T, Onji M. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int. 26: 1241-1247 (2006). *

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Kokudo N, Makuuchi M. Impact of incidentally found hepatocellular carcinoma on the outcome of living donor liver transplantation. Transpl. Int. 19: 720-725 (2006). *

• Kishimoto Y, Yamada S, Hirayama C. An association between alpha 1-antitrypsin phenotype and chronic liver disease. Hum. Genet. 84: 132-136 (1990).

• Kishnani PS, Chen YT. Important role of abnormal glycogen structure in the development of liver cirrhosis and progression to hepatocellular carcinoma in patients with glycogen storage disease type-III. J. Hepatol. 47: 300-301 (2007). *

• Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44: 983-991 (2006). *

• Kitiyakara T, Chapman RW. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad. Med. J. 84: 228-237 (2008).

• Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127 (5 Suppl. 2): S17-S26 (2004). *

• Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 10: 1301-1311 (2004). *

• Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikci B, Ozcay F, Laszlo A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Nemeth A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44: 478-486 (2006). *

• Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH, Gordon FD, Schilsky ML, Kowdley KV. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int. 27: 1394-1401 (2007). *

• Ko FC, Yeung YS, Wong CM, Chan LK, Poon RT, Oi-Lin Ng I, Yam JW. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int. 30: 139-148 (2010). *

• Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 82: 41-48 (2009). *

• Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13: 902-911 (2007). *

• Koelma IA, Nap M, Huitema S, Krom RA, Houthoff HJ. Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters. Arch. Pathol. Lab. Med. 110: 1035-1040 (1986).

• Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29: 688-696 (1999). *

• Kogo M, Kano A, Kiuchi Y, Mitamura K, Yoneyama K. Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma. Dig. Dis. Sci. 52: 2444-2451 (2007). *

• Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, Satomi S, Shimosegawa T. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J. Gastroenterol. 41: 1005-1010 (2006). *

• Kogure T, Ueno Y, Kimura O, Kondo Y, Inoue J, Fukushima K, Iwasaki T, Shimosegawa T. A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway. Hepatol. Res. 39: 479-489 (2009). *

• Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J. Gastroenterol. 44 Suppl. 19: 82-88 (2009). *

• Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150 (2005).

• Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol. Res. 34: 65-73 (2006).

• Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol. Res. 40: 69-82 (2010). *

• Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, Moriwaki H. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int. J. Oncol. 24: 797-805 (2004).

• Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin. Liver Dis. 19: 287-296 (1999).

• Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin. Liver Dis. 25: 133-142 (2005).

• Komi Y, Sogabe Y, Ishibashi N, Sato Y, Moriwaki H, Shimokado K, Kojima S. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab. Invest. Oct 19 [Epub ahead of print] (2009). *

• Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J. Hepatol. 45: 662-672 (2006). *

• Komori H, Nakatsura T, Beppu T, Nishimura Y, Baba H. Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma. Gan To Kagaku Ryoho 33: 1742-1744 (2006).

• Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am. J. Gastroenterol. 102: 1939-1946 (2007). *

• Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47: 1544-1556 (2008). *

• Kondo F, Koshima Y, Ebara M. Nodular lesions associated with abnormal liver circulation. Intervirology 47: 277-287 (2004).

• Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima N, Orito E, Osada H, Ueda R, Guo Y, Chen X, Issa JP, Sekido Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 37: 974-983 (2007). *

• Kongtawelert P, Tangkijvanich P, Ong-Chai S, Poovorawan Y. Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma. World J. Gastroenterol. 9: 2178-2181 (2003). *

• Konig R, Cai P, Guo X, Ansari GA. Transcriptomic analysis reveals early signs of liver toxicity in female MRL +/+ mice exposed to the acylating chemicals dichloroacetyl chloride and dichloroacetic anhydride. Chem. Res. Toxicol. 21: 572-582 (2008). *

• Konstantinov BA, Got'e SV, Tsirul'nikova OM, Filin AV, Kim EF. Transplantation of liver's right lobe from related donor. Khirurgiia (Mosk.) 8: 7-12 (2004).

• Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y, Hatakeyama K. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum. Pathol. 39: 1777-1783 (2008).

• Korner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC. Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J. Hepatol. 45: 825-835 (2006). *

• Kosuge M, Takizawa H, Maehashi H, Matsuura T, Matsufuji S. A comprehensive gene expression analysis of human hepatocellular carcinoma cell lines as components of a bioartificial liver using a radial flow bioreactor. Liver Int. 27: 101-108 (2007). *

• Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017 (2009). *

• Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am. J. Gastroenterol. 101: 1370-1378 (2006). *

• Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int. J. Cancer 120: 469-476 (2007). *

• Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S79-S86 (2004). *

• Koytak ES, Mizrak D, Bektas M, Verdi H, Arslan Ergul A, Idilman R, Cinar K, Yurdaydin C, Ersoz S, Karayalcin K, Uzunalimoglu O, Bozkaya H. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk. J. Gastroenterol. 19: 245-249 (2008). *

• Krasner N, Johnson PJ, Portmann B, Watkinson G, Macsween RN, Williams R. Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases. Gut 20: 255-258 (1979). *

• Krastev N, Grigorov N, Dinkov L, Genov Y, Mitova R, Donov M. The role of laparoscopy and laparoscopic ultrasonography in the diagnosis and differential diagnosis of nodular hepatocellular lesions. Khirurgiia (Sofiia) 53: 14-18 (1998).

• Kreft B, Pauleit D, Bachmann R, Conrad R, Kramer A, Schild HH. Incidence and significance of small focal liver lesions in MRI. Rofo. 173: 424-429 (2001).

• Kremer-Tal S, Narla G, Chen Y, Hod E, Difeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol. 46: 645-654 (2007). *

• Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40: 1047-1052 (2004). *

• Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, Teperman LW. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 219: 445-454 (2001). *

• Krom RA, Gips CH, Houthoff HJ, Newton D, van der Waaij D, Beelen J, Haagsma EB, Slooff MJ. Orthotopic liver transplantation in Groningen, The Netherlands (1979-1983). Hepatology 4: 61S-65S (1984).

• Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51: 154-164 (2010). *

• Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206: 1327-1337 (2009). *

• Kubo S, Matsukawa M. Tumor markers of hepatocellular carcinoma. Gan To Kagaku Ryoho 31: 2203-2206 (2004).

• Kubo S, Uenishi T, Yamamoto S, Hai S, Yamamoto T, Ogawa M, Takemura S, Shuto T, Tanaka H, Yamazaki O, Hirohashi K, Kinoshita H. Clinicopathologic characteristics of small intrahepatic cholangiocarcinomas of mass-forming type. Hepatol. Res. 29: 223-227 (2004).

• Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin. Liver Dis. 19: 297-309 (1999).

• Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: 1396-1405 (2004). *

• Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S277-S282 (2004). *

• Kulik LM, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Salem R. Use of yttrium-90 microspheres (TheraSphere(R)) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl. 11: 1127-1131 (2005). *

• Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23: 1053-1060 (1996). *

• Kullavanijaya P, Tangkijvanich P, Poovorawan Y. Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J. Trop. Med. Public Health 30: 96-105 (1999).

• Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol. Res. 40: 8-13 (2010). *

• Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol. Res. 40: 1-7 (2010). *

• Kumada T, Nakano S, Toyoda H, Hayashi K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamamoto A, Takeshima K, Hibi T, Yabashi T, Noda T, Sassa T, Furukawa M, Ogawa S. Assessment of tumor hemodynamics in small hepatocellular carcinoma: comparison of Doppler ultrasonography, angiography-assisted computed tomography, and pathological findings. Liver Int. 24: 425-431 (2004). *

• Kumagi T, Horiike N, Michitaka K, Hasebe A, Kawai K, Tokumoto Y, Nakanishi S, Furukawa S, Hiasa Y, Matsui H, Kurose K, Matsuura B, Onji M. Recent clinical features of Wilson's disease with hepatic presentation. J. Gastroenterol. 39: 1165-1169 (2004). *

• Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J. Viral Hepat. 14: 841-848 (2007).

• Kuo FY, Chen WJ, Lu SN, Wang JH, Eng HL. Fine needle aspiration cytodiagnosis of liver tumors. Acta Cytol. 48: 142-148 (2004).

• Kuo FY, Swanson PE, Yeh MM. Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am. J. Surg. Pathol. 33: 66-71 (2009).

• Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, Okita K, Oka M, Nakamura K. Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Electrophoresis 27: 2998 (2006).

• Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol. Res. 39: 432-438 (2009). *

• Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, Umeshita K, Sakon M, Ueno N, Oba S, Ishii S, Kato K, Monden M. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J. Hepatol. 41: 284-291 (2004). *

• Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Fukuda K, Tamakoshi A. Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Univariate analysis of JACC study data. Kurume Med. J. 51: 141-149 (2004).

• Kurtovic J, Riordan S. Clinical aspects of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 31-32. October 15-16 (2003). *

• Kurtovic J, Riordan SM, Williams R. Liver transplantation for hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19: 147-160 (2005).

• Kwack MH, Choi BY, Sung YK. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol. Cells 21: 224-228 (2006). *

• Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963 (2008). *

• Ladron de Guevara L, Rojas-Macuil P, Sanchez-Chavez X, Rossano-Garcia A, Gorraez-de-la-Mora MT, Cervantes-Sanchez G, Orozco-Vazquez J, Lemus-Velazquez M, Rosas-Zuniga L, Erazo-Valle A, Di-Silvio M. Hepatocellular carcinoma: epidemiological profile from a cohort of federal employees in Mexico. Ann. Hepatol. 8: 212-219 (2009).

• Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J. Gastroenterol. 13: 5299-5305 (2007). *

• Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, Shridhar V, Sanderson SO, Roberts LR. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J. Hepatol. 50: 1112-1121 (2009).

• Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295-1302 (2006). *

• Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, Yeh TS, Chen MF, Yeh CT. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol. Res. 39: 164-176 (2009). *

• Lal A, Okonkwo A, Schindler S, De Frias D, Nayar R. Role of biliary brush cytology in primary sclerosing cholangitis. Acta Cytol. 48: 9-12 (2004).

• Lalazar G, Preston S, Zigmond E, Ben Ya'acov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 6: 1249-1253 (2006).

• Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann. Hepatol. 8 Suppl. 1: S51-S59 (2009). *

• Lam VW, Poon RT. Role of branched-chain amino acids in management of cirrhosis and hepatocellular carcinoma. Hepatol. Res. 38 (s1: The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S107-S115 (2008). *

• Landau DA, Scerra S, Sene D, Resche-Rigon M, Saadoun D, Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J. Rheumatol. Jan 28 [Epub ahead of print] (2010).

• Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am. J. Gastroenterol. 99: 2158-2165 (2004). *

• Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J. Hepatol. 50: 89-99 (2009). *

• Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49: 523-532 (2009). *

• Langrehr JM, Blumhardt G, Bechstein WO, Keck H, Knoop M, Lohmann R, Lemmens HP, Lusebrink R, Schattenfroh N, Neuhaus P. Liver transplantation as a routine procedure? Indications and results in 270 patients. Fortschr. Med. 111: 139-144 (1993).

• Larrey D, Erlinger S. Drug-induced cholestasis. Baillieres Clin. Gastroenterol. 2: 423-452 (1988).

• Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 132: 1740-1745 (2007). *

• Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 66: 2673-2682 (2006). *

• Lau DT, Luxon BA, Xiao SY, Beard MR, Lemon SM. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology 42: 273-281 (2005). *

• Lauchart W, Strohmeyer G. Liver transplantation 1994. Schweiz. Rundsch. Med. Prax. 83: 1065-1068 (1994).

• Laumonier H, Blanc JF, Quesson B, Seror O, Laurent C, Bioulac-Sage P, Balabaud C, Trillaud H. Real-time monitoring of hepatocellular carcinoma radiofrequency ablation by quantitative temperature MRI. Semin. Liver Dis. 26: 391-397 (2006).

• Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J. Clin. Invest. 98: 1313-1323 (1996). *

• Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39: 1038-1047 (2004). *

• Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 41: 491-497 (2004). *

• Lee CF, Ling ZQ, Zhao T, Fang SH, Chang WC, Lee SC, Lee KR. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J. Gastroenterol. 15: 356-365 (2009). *

• Lee JC, Chen MJ, Chang CH, Tiai YF, Lin PW, Lai HS, Wang ST. Plasma amino acid levels in patients with colorectal cancers and liver cirrhosis with hepatocellular carcinoma. Hepatogastroenterology 50: 1269-1273 (2003).

• Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676 (2004). *

• Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127 (5 Suppl. 2): S51-S55 (2004). *

• Lee JS, Thorgeirsson SS. Genetic profiling of human hepatocellular carcinoma. Semin. Liver Dis. 25: 125-132 (2005).

• Lee JW, Jeong EG, Lee SH, Yoo NJ, Lee SH. Somatic mutations of BECN1, an autophagy-related gene, in human cancers. APMIS 115: 750-756 (2007). *

• Lee K, Yun ST, Kim YG, Yoon Y, Jo EC. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 43: 1063-1073 (2006). *

• Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, Chung D, Park G, Yu Y, Choi N, Kim K, Kim K, Hwang S. Liver transplantation for hepatocellular carcinoma: Korean experience. J. Hepatobiliary Pancreat. Surg. Sep 2 [Epub ahead of print] (2009). *

• Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Song KW, Chung DH. Toward 300 liver transplants a year. Surg. Today 39: 367-373 (2009). *

• Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, Choi DL, Joo SH, Jeon JY, Chu CW, Moon DB, Min PC, Koh KS, Han SH, Park SH, Choi GT, Hwang KS, Lee EJ, Chung YH, Lee YS, Lee HJ, Kim MH, Lee SK, Suh DJ, Kim JJ, Sung KB. Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J. Surg. 25: 277-284 (2002).

• Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 29: 955-965 (2009). *

• Lee WJ, Lim HK, Jang KM, Kim SH, Lee SJ, Lim JH, Choo IW. Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics 21: 97-116 (2001). *

• Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U. Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J. Trop. Med. Public Health 38: 881-885 (2007).

• Leen E, Kumar S, Khan SA, Low G, Ong KO, Tait P, Averkiou M. Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J. Gastroenterol. 15: 289-299 (2009). *

• Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: a review of current literature. World J. Gastroenterol. 14: 6915-6923 (2008). *

• Lefkowitch JH. Recent developments in liver pathology. Hum. Pathol. 40: 445-455 (2009).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 18: 290-298 (2002).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 20: 188-197 (2004).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 19: 185-193 (2003).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 22: 198-208 (2006).

• Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D, Lucas-Clerc C, Boudjema K, Guguen-Guillouzo C, Corlu A, Morel F. Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur. J. Cancer 45: 2882-2892 (2009). *

• Leidenius M, Hockersted K, Broome U, Ericzon BG, Friman S, Olausson M, Schrumpf E. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. J. Hepatol. 34: 792-798 (2001). *

• Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin. Liver Dis. 26: 373-384 (2006).

• Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. Imaging diagnosis. Semin. Liver Dis. 25: 162-170 (2005).

• Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom. Imaging 30: 401-408 (2005). *

• Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J. Hepatol. 43: 377-380 (2005). *

• Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 45: 435-441 (1999). *

• Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, Bolondi L. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am. J. Gastroenterol. Nov 24 [Epub ahead of print] (2009). *

• Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J. Gastroenterol. 15: 5592-5597 (2009). *

• Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, Terella A, Hertl M, Cosimi AB, Chung RT. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl. 10: 1343-1354 (2004). *

• Leuschner U. Primary biliary cirrhosis - presentation and diagnosis. Clin. Liver Dis. 7: 741-758 (2003).

• Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *

• Lewis JR, Te HS, Gehlbach B, Oto A, Chennat J, Mohanty SR. A case of biliopleural fistula in a patient with hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 6: 248-251 (2009). *

• Leyendecker JR, Dodd GD 3rd. Minimally invasive techniques for the treatment of liver tumors. Semin. Liver Dis. 21: 283-291 (2001).

• Li BD, Zhao QC, Zhu YT, Zhang FQ, Dou KF. Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi 44: 458-462 (2006).

• Li D, Zheng L, Jin L, Zhou Y, Li H, Fu J, Shi M, Du P, Wang L, Wu H, Chen GY, Zheng P, Liu Y, Wang FS, Wang S. CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology 50: 735-742 (2009).

• Li G, Chen X, Wang Q, Xu Z, Zhang W, Ye L. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27: 173-175 (2007).

• Li G, Dong S, Qu J, Sun Z, Huang Z, Ye L, Liang H, Ai X, Zhang W, Chen X. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver Int. Sep 23 [Epub ahead of print] (2009). *

• Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 128: 2029-2041 (2005). *

• Li HC, Stoicov C, Rogers AB, Houghton J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J. Gastroenterol. 12: 363-371 (2006). *

• Li J, Lin HJ, Jiang B, Bai Y, Zhang D, Zhang YL, Wang JD. Isolation and characterization of the first strain of Helicobacter hepaticus in China. Nan Fang Yi Ke Da Xue Xue Bao 28: 843-845 (2008).

• Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, Kapiotis S, Dudczak R, Kletter K. Comparison of (11)C-acetate positron emission tomography and (67)gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int. 26: 920-927 (2006). *

• Li Y, Xie Q, Lu F, Zhao J, Mao P, Li Z, Liu S, Zhuang H. Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int. 30: 112-118 (2010). *

• Li YL, Wu J, Wei D, Zhang DW, Feng H, Chen ZN, Bian H. Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Liver Int. 29: 593-602 (2009). *

• Liang TJ. Hepatitis B: the virus and disease. Hepatology 49: S13-S21 (2009).

• Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S62-S71 (2004). *

• Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant. Proc. 35: 2995-2997 (2003). *

• Liao YJ, Liu SP, Lee CM, Yen CH, Chuang PC, Chen CY, Tsai TF, Huang SF, Lee YH, Chen YM. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer 124: 816-826 (2009). *

• Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, Pirenne J, Nevens F, Roskams T. Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am. J. Gastroenterol. 101: 2341-2346 (2006). *

• Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol. 30: 1405-1411 (2006).

• Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, Trautwein C. Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology 129: 1602-1615 (2005). *

• Ligato S, Mandich D, Cartun RW. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod. Pathol. 21: 626-631 (2008).

• Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 43: 1074-1083 (2006). *

• Lim SC, Choi JE, Kang HS, Iy Han S. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int. J. Cancer Sep 2 [Epub ahead of print] (2009). *

• Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 12: 733-746, vii (2008).

• Limdi JK, Crampton JR. Hereditary haemochromatosis. QJM 97: 315-324 (2004). *

• Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, Liaw YF. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 61: 4238-4243 (2001). *

• Lin CH, Yu JC, Chen TW, Chan DC, Chen CJ, Hsieh CB. Sclerosing encapsulating peritonitis in a liver transplant patient: a case report. World J. Gastroenterol. 11: 5412-5413 (2005). *

• Lin F, Li YY, Xia JT, Wen MJ, Lai YY, Cai WS, Wu ZF, Fan SF. Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines. Zhonghua Gan Zang Bing Za Zhi 17: 422-425 (2009).

• Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma less than or equal to 4 cm. Gastroenterology 127: 1714-1723 (2004). *

• Lin YW, Lee HS, Chen CH, Huang GT, Lee PH, Sheu JC. Clonality analysis of multiple hepatocellular carcinomas by loss of heterozygosity pattern determined by chromosomes 16q and 13q. J. Gastroenterol. Hepatol. 20: 536-546 (2005). *

• Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J. Hepatol. 50: 518-527 (2009).

• Liu C, Cheng B. Association of polymorphisms of human leucocyte antigen-DQA1 and DQB1 alleles with chronic hepatitis B virus infection, liver cirrhosis and hepatocellular carcinoma in Chinese. Int. J. Immunogenet. 34: 373-378 (2007). *

• Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10: 728-733 (2004). *

• Liu HH, Chen KH, Shih YP, Lui WY, Wong FH, Chen YM. Characterization of reduced expression of glycine N-methyltransferase in cancerous hepatic tissues using two newly developed monoclonal antibodies. J. Biomed. Sci. 10: 87-97 (2003).

• Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453-1463 (2009).

• Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol. 104: 2617-2624 (2009). *

• Liu S, Yu M, He Y, Xiao L, Wang F, Song C, Sun S, Ling C, Xu Z. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 47: 1964-1973 (2008). *

• Liu W, Nakamura H, Tsujimura T, Cheng J, Yamamoto T, Iwamoto Y, Imanishi H, Shimomura S, Yamamoto T, Hirasawa T, Inagaki S, Nishiguchi S, Hada T. Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci. 97: 768-773 (2006). *

• Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136: 683-693 (2009). *

• Liu Z, Zhong L, Krishack PA, Robbins S, Cao JX, Zhao Y, Chung S, Cao D. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 437: 39-44 (2009). *

• Llado L, Figueras J, Memba R, Xiol X, Baliellas C, Vazquez S, Ramos E, Torras J, Rafecas A, Fabregat J, Lama C, Jaurrieta E. Is MELD really the definitive score for liver allocation? Liver Transpl. 8: 795-798 (2002). *

• Llanos L, Bellot P, Zapater P, Perez-Mateo M, Such J. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am. J. Gastroenterol. 104: 257-258 (2009). *

• Llatjos M, Muns R, Tallada N. Need for biopsy in hepatocellular carcinoma. J. Hepatol. 37: 874 (2002). *

• Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J. Hepatol. 38 Suppl. 1: S136-S149 (2003). *

• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19: 329-338 (1999).

• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48 Suppl. 1: S20-S37 (2008). *

• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327 (2008). *

• Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin. Liver Dis. 26: 248-253 (2006).

• Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25: 181-200 (2005).

• Llovet JM, Wurmbach E. Gene expression profiles in hepatocellular carcinoma: not yet there. J. Hepatol. 41: 336-339 (2004). *

• Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 10: 440-447 (2004). *

• Lobo-Yeo A, McSorley C, McFarlane BM, Mieli-Vergani G, Mowat AP, Vergani D. Detection of anti-liver cell membrane antibody using a human hepatocellular carcinoma cell line. Hepatology 9: 210-214 (1989).

• Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol. 12: 7239-7249 (2006). *

• Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S303-S309 (2004). *

• Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138: 493-502 (2010). *

• Long XD, Ma Y, Qu DY, Liu YG, Huang ZQ, Huang YZ, Lin ZH, Wei NB, Zhou SC. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann. Epidemiol. 18: 572-578 (2008).

• Long XD, Ma Y, Wei YP, Deng ZL. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol. Res. 36: 48-55 (2006).

• Long XD, Ma Y, Zhou YF, Yao JG, Ban FZ, Huang YZ, Huang BC. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer 9: 400 (2009). *

• Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, Wands JR. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 49: 1935-1943 (2009).

• Longerich T, Schirmacher P. A new link between cancer and inflammation? J. Hepatol. 51: 230-232 (2009).

• Lopez Dieguez Puerta M, Casal Esteban V, Barbado Hernandez FJ, Gil Guerrero L, Rodriguez Molinero MA, Larrauri J, Vazquez Rodriguez JJ. Nonalcoholic steatohepatitis, the enigma of bad progress. An. Med. Interna. 22: 85-87 (2005).

• Lopez LJ, Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 20: 248-253 (2004).

• Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 45: 605-628 (2005). *

• Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41: 1130-1137 (2005). *

• Lu SC, Mato JM. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J. Gastroenterol. Hepatol. 23 Suppl. 1: S73-S77 (2008). *

• Lu SC, Ramani K, Ou X, Lin M, Yu V, Ko K, Park R, Bottiglieri T, Tsukamoto H, Kanel G, French SW, Mato JM, Moats R, Grant E. S-Adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology 50: 462-471 (2009).

• Lu SY, Sui YF, Li ZS, Pan CE, Ye J, Zhang XM, Wang WY. The construction and expression of a hepatocellular carcinoma-specific superantigen SEA (D227A) expression vector. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19: 353-356 (2003).

• Luan F, Liu H, Gao L, Liu J, Sun ZS, Ju Y, Hou N, Guo C, Liang X, Zhang L, Sun W, Ma C. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 58: 1528-1537 (2009).

• Lucidarme D, Vandermolen P, Khattab H, Catala P, Le Capon JB, Creusy C, Filoche B. Hepatocellular carcinoma in asymptomatic primary biliary cirrhosis. Rev. Med. Interne. 17: 568-570 (1996).

• Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132 (2007). *

• Luedde T, Trautwein C. Intracellular survival pathways in the liver. Liver Int. 26: 1163-1174 (2006). *

• Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK, Fan ST. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int. 27: 879-890 (2007). *

• Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27: 6068-6074 (2008). *

• Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat. Rev. Gastroenterol. Hepatol. 6: 679-683 (2009).

• Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S, Michalopoulos GK. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44: 1012-1024 (2006). *

• Luyendyk JP, Shores KC, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 68: 220-225 (2002). *

• Ma H, Liu Y, Liu S, Xu R, Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 42: 1355-1363 (2005). *

• Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, Cao D. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J. Biol. Chem. 283: 3418-3423 (2008). *

• Ma L, Luo L, Qiao H, Dong X, Pan S, Jiang H, Krissansen GW, Sun X. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J. Hepatol. 46: 98-106 (2007). *

• Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556 (2007). *

• Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G515-G520 (2004). *

• Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann. Hepatol. 8 Suppl. 1: S67-S75 (2009). *

• Macheiner D, Heller G, Kappel S, Bichler C, Stattner S, Ziegler B, Kandioler D, Wrba F, Schulte-Hermann R, Zochbauer-Muller S, Grasl-Kraupp B. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J. Hepatol. 45: 81-89 (2006). *

• Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol. 80: 7199-7207 (2006). *

• Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM. Hepatitis C virus induces Toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J. Virol. 80: 866-874 (2006). *

• Machida T, Takahashi T, Itoh T, Hirayama M, Morita T, Horita S. Reactive lymphoid hyperplasia of the liver: a case report and review of literature. World J. Gastroenterol. 13: 5403-5407 (2007). *

• Madan K, Batra Y, Sreenivas V, Mizokami M, Tanaka Y, Chalamalasetty SB, Panda SK, Acharya SK. HBV genotypes in India: do they influence disease severity? Hepatol. Res. 39: 157-163 (2009). *

• Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 10: 449-455 (2004). *

• Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 35: 99-103 (1998).

• Maggs J, Cullen S. Management of autoimmune liver disease. Minerva Gastroenterol. Dietol. 55: 173-206 (2009).

• Maheshwari A, Thuluvath PJ. Cryptogenic cirrhosis and NAFLD: are they related? Am. J. Gastroenterol. 101: 664-668 (2006). *

• Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J. Hepatol. 47: 506-513 (2007). *

• Mailey B, Buchberg B, Prendergast C, Artinyan A, Khalili J, Sanchez-Luege N, Colquhoun SD, Kim J. A disease-based comparison of liver transplantation outcomes. Am. Surg. 75: 901-908 (2009).

• Majno P, Giostra E, Mentha G, For The Geneva Liver Cancer Study Group. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma? J. Hepatol. 43: 577-584 (2005). *

• Majno P, Giostra E, Morel P, Hadengue A, Mentha G; Geneva Liver Cancer Study Group. Management of hepatocellular carcinoma in the waiting list before liver transplantation. J. Hepatol. 42 Suppl.: S134-S143 (2005). *

• Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 10 Suppl. 2: S46-S52 (2004). *

• Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7: 800-806 (2009).

• Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, Schirmacher P, Breuhahn K. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50: 1130-1139 (2009).

• Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY. Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 25: 962-966 (2005). *

• Mann DA, Oakley F. NF-kappaB: a signal for cancer. J. Hepatol. 42: 610-611 (2005).

• Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology 47: 1150-1157 (2008). *

• Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin. Biol. Ther. 9: 1445-1451 (2009).

• Mao HJ, Li HN, Zhou XM, Zhao JL, Wan DF. Monitoring microarray-based gene expression profile changes in hepatocellular carcinoma. World J. Gastroenterol. 11: 2811-2816 (2005). *

• Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 11: 1242-1251 (2005). *

• Margreiter R. Current status of liver and bowel transplantation. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 83 (2005). *

• Marhenke S, Lamle J, Buitrago-Molina LE, Canon JM, Geffers R, Finegold M, Sporn M, Yamamoto M, Manns MP, Grompe M, Vogel A. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 48: 487-496 (2008). *

• Marotta F, Harada M, Goh K, Lorenzetti A, Gelosa F, Minelli E. Phytotherapeutic compound YHK exerts an inhibitory effect on early stage of experimentally-induced neoplastic liver lesions. Ann. Hepatol. 5: 268-272 (2006). *

• Marra F. NASH: are genes blowing the hits? J. Hepatol. 40: 853-856 (2004). *

• Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 50: 957-969 (2009).

• Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 22: 248-253 (2006).

• Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 21: 308-312 (2005).

• Marrero JA. Modern diagnosis of hepatocellular carcinoma: utilization of liver biopsy and genomic markers. J. Hepatol. 50: 659-661 (2009). *

• Marrero JA, Feng Z. Alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 138: 400-401 (2010). *

• Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma AFP, DCP, and AFP-L3 in hepatocellular carcinoma. Gastroenterology 137: 110-118 (2009). *

• Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716 (2005). *

• Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol. 42: 218-224 (2005). *

• Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36: 1349-1354 (2002). *

• Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S113-S119 (2004). *

• Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol. 43: 1007-1012 (2005). *

• Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 13: 233-247 (2009).

• Marsh JW, Dvorchik I. Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation? - yes. J. Hepatol. 43: 558-562 (2005). *

• Martin AP, Goldstein RM, Dempster J, Netto GJ, Katabi N, Derrick HC, Altrabulsi B, Jennings LW, Ueno T, Chinnakotla S, Dawson S 3rd, Randall HB, Levy MF, Onaca N, Sanchez EQ, Orr D, Klintmalm GB. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. Clin. Transplant. 20: 695-705 (2006). *

• Martin P. Key consultations in hepatology. Preface. Clin. Liver Dis. 13: xi-xii (2009). *

• Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma. Current management. Minerva Chir. 58: 469-478 (2003).

• Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16: 1292-1294 (2002). *

• Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, Martinez N, Varela M, Luka Z, Capdevila A, Rodriguez J, Aransay AM, Matthiesen R, Yang H, Calvisi DF, Esteller M, Fraga M, Lu SC, Wagner C, Mato JM. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47: 1191-1199 (2008). *

• Martinez-Chantar ML, Vazquez-Chantada M, Garnacho M, Latasa MU, Varela-Rey M, Dotor J, Santamaria M, Martinez-Cruz LA, Parada LA, Lu SC, Mato JM. S-Adenosylmethionine regulates cytoplasmic HuR via AMP-activated kinase. Gastroenterology 131: 223-232 (2006). *

• Martinez-Lopez N, Varela-Rey M, Ariz U, Embade N, Vazquez-Chantada M, Fernandez-Ramos D, Gomez-Santos L, Lu SC, Mato JM, Martinez-Chantar ML. S-Adenosylmethionine and proliferation: new pathways, new targets. Biochem. Soc. Trans. 36: 848-852 (2008). *

• Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Gloria H, Marinho R, Tavora I, Ramalho F, de Moura MC. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 26: 680-687 (2006). *

• Marui Y, McCall J, Gane E, Holden A, Duncan D, Yeong ML, Chow K, Munn S. Liver transplantation for hepatocellular carcinoma in New Zealand: a prospective intent-to-treat analysis. N. Z. Med. J. 118: U1532 (2005).

• Mas VR, Maluf DG, Stravitz R, Dumur CI, Clark B, Rodgers C, Ferreira-Gonzalez A, Fisher RA. Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression. Liver Transpl. 10: 607-620 (2004). *

• Masaki T. MicroRNA and hepatocellular carcinoma. Hepatol. Res. 39: 751-752 (2009). *

• Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49: 1954-1961 (2009). *

• Mathur S, Gane EJ, McCall JL, Plank LD. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J. Gastroenterol. Hepatol. 23: 239-243 (2008). *

• Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45: 1306-1312 (2007). *

• Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu. Rev. Nutr. 28: 273-293 (2008). *

• Matos JM, Witzmann FA, Cummings OW, Schmidt CM. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J. Surg. Res. 155: 237-243 (2009). *

• Matsumoto K, Huang J, Viswakarma N, Bai L, Jia Y, Zhu YT, Yang G, Borensztajn J, Rao MS, Zhu YJ, Reddy JK. Transcription coactivator PBP/MED1 deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse. Carcinogenesis Dec 14 [Epub ahead of print] (2009). *

• Matsumoto K, Suehiro M, Iio M, Kawabe T, Shiratori Y, Okano K, Sugimoto T. [13C]Methacetin breath test for evaluation of liver damage. Dig. Dis. Sci. 32: 344-348 (1987).

• Matsumoto K, Yu S, Jia Y, Ahmed MR, Viswakarma N, Sarkar J, Kashireddy PV, Rao MS, Karpus W, Gonzalez FJ, Reddy JK. Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development. J. Biol. Chem. 282: 17053-17060 (2007). *

• Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, Kojima S. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 61: 7675-7682 (2001). *

• Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24: 1353-1359 (2003). *

• Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol. Cell. Endocrinol. 121: 179-190 (1996).

• Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46: 48-57 (2007). *

• Mayoral R, Valverde AM, Llorente Izquierdo C, Gonzalez-Rodríguez A, Bosca L, Martin-Sanz P. Impairment of TGF-beta signaling in caveolin-1 deficient hepatocytes: role in liver regeneration. J. Biol. Chem. Dec 5 [Epub ahead of print] (2009). *

• Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51: 523-534 (2010).

• Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140-1151 (2009).

• McCarron KF, Prayson RA. The neuropathology of orthotopic liver transplantation: an autopsy series of 16 patients. Arch. Pathol. Lab. Med. 122: 726-731 (1998).

• McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 15: 1198-1203 (2006). *

• McIntyre N. Sheila: Professor Dame Sheila Sherlock (1918-2001). Hepatology 35: 507-509 (2002). *

• McKeon D, Day A, Parmar J, Alexander G, Bilton D. Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis. J. Cyst. Fibros. 3: 193-195 (2004).

• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 49: S45-S55 (2009).

• McPeake J, Williams R. Liver transplantation for hepatocellular carcinoma. Gut 36: 644-646 (1995). *

• Mee CJ, Farquhar MJ, Harris HJ, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor dependent manner. Gastroenterology Nov 25 [Epub ahead of print] (2009). *

• Meffert G, Gellerich FN, Margreiter R, Wyss M. Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC Gastroenterol. 5: 9 (2005). *

• Mehta NS, Benoit S, Mysore JV, Sousa RS, Maier RJ. Helicobacter hepaticus hydrogenase mutants are deficient in hydrogen-supported amino acid uptake and in causing liver lesions in A/J mice. Infect. Immun. 73: 5311-5318 (2005). *

• Melia WM, Johnson PJ, Neuberger J, Zaman S, Portmann BC, Williams R. Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation. Gastroenterology 87: 660-663 (1984).

• Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 58: 704-720 (2009).

• Mendez-Sanchez N, Vasquez-Fernandez F, Zamora-Valdes D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann. Hepatol. 7: 46-51 (2008). *

• Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann. Hepatol. 4: 52-55 (2005).

• Mendez-Sanchez N, Villa AR, Vazquez-Elizondo G, Ponciano-Rodriguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann. Hepatol. 7: 226-229 (2008). *

• Mendez-Sanchez N, Zamora-Valdes D, Vasquez-Fernandez F, Uribe M. Hepatocellular carcinoma in Hispanics. Ann. Hepatol. 6: 279-280 (2007). *

• Meng Y, Miyoshi I, Hirabayashi M, Su M, Mototani Y, Okamura T, Terada K, Ueda M, Enomoto K, Sugiyama T, Kasai N. Restoration of copper metabolism and rescue of hepatic abnormalities in LEC rats, an animal model of Wilson disease, by expression of human ATP7B gene. Biochim. Biophys. Acta 1690: 208-219 (2004). *

• Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN. Mimics of cholangiocarcinoma: spectrum of disease. Radiographics 28: 1115-1129 (2008). *

• Merle P, De la Monte S, Kim M, Herrmann M, Tanaka S, Von dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127: 1110-1122 (2004). *

• Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol. 43: 854-862 (2005). *

• Merli M, Nicolini G, Gentili F, Novelli G, Iappelli M, Casciaro G, Di Tondo U, Pecorella I, Marasco A, Muda AO, Nudo F, Mennini G, Corradini SG, Riggio O, Berloco P, Attili AF, Rossi M. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transplant. Proc. 37: 2535-2540 (2005). *

• Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 40 Suppl. 1: S30-S33 (2006).

• Metairie S, Lucidi V, Castaing D. Intra-hepatic cholangiocarcinoma. J. Chir. (Paris) 141: 315-321 (2004).

• Meza-Junco J, Chu QS, Christensen O, Rajagopalan P, Das S, Stefanyschyn R, Sawyer MB. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother. Pharmacol. 65: 1-4 (2009).

• Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, Cabrera-Aleksandrova T. Spontaneous partial regression of hepatocellular carcinoma in a cirrhotic patient. Ann. Hepatol. 6: 66-69 (2007). *

• Meza-Junco J, Montaño-Loza AJ, Martínez-Benitez B, Kimura-Hayama E. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. Ann. Hepatol. 6: 122-126 (2007). *

• Michaels A, Levy C. Endoscopic and surgical management of primary sclerosing cholangitis. Medscape J. Med. 10: 242 (2008). *

• Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; The Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. J. Gastroenterol. Sep 30 [Epub ahead of print] (2009). *

• Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int. J. Cancer 103: 455-465 (2003). *

• Midorikawa Y, Makuuchi M, Tang W, Aburatani H. Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J. Gastroenterol. 13: 1487-1492 (2007). *

• Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, Makuuchi M, Aburatani H. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 25: 5581-5590 (2006). *

• Midorikawa Y, Yamamoto S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H, Makuuchi M, Kokudo N, Sugimura H, Aburatani H. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology 49: 513-522 (2009). *

• Mieli-Vergani G, Vergani D. Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378 (2004). *

• Mieli-Vergani G, Vergani D. Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397 (2004). *

• Migita K, Maeda Y, Abiru S, Nakamura M, Komori A, Miyazoe S, Nakao K, Yatsuhashi H, Eguchi K, Ishibashi H. Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J. Hepatol. 46: 381-386 (2007). *

• Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP. Liver stem cells and hepatocellular carcinoma. Hepatology 49: 318-329 (2009). *

• Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr. Drug Discov. Technol. 4: 133-140 (2007).

• Miura H, Kawaguchi T, Takazoe M, Kitamura S, Yamada H. Hepatocellular carcinoma and Crohn's disease: a case report and review. Intern. Med. 48: 815-819 (2009). *

• Miyachi K, Hosaka H, Nakamura N, Miyakawa H, Mimori T, Shibata M, Matsushima S, Chinoh H, Horigome T, Hankins RW, Zhang M, Fritzler MJ. Anti-p97/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease? Scand. J. Immunol. 63: 376-382 (2006). *

• Miyagawa K, Sakakura C, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ito K, Yamagishi H, Ida H, Yazumi S, Chiba T, Ito Y, Hagiwara A. Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res. 26: 3633-3643 (2006).

• Miyakawa H, Fujikawa H, Kikuchi K, Kitazawa E, Kawashima Y. Irregular regeneration of hepatocytes and development of hepatocellular carcinoma in primary biliary cirrhosis. Am. J. Gastroenterol. 97: 488 (2002). *

• Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin. Exp. Res. 20: 91A-94A (1996).

• Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol. Int. Oct 22 [Epub ahead of print] (2009). *

• Miyake Y, Iwasaki Y, Terada R, Nagano T, Kobashi H, Sakaguchi K, Shiratori Y. A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis. Hepatol. Res. 38: 658-663 (2008). *

• Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment. Pharmacol. Ther. 24: 1197-1205 (2006). *

• Miyake Y, Sakaguchi K, Tanaka H, Nakamura S, Kobayashi Y, Fujioka S, Iwasaki Y, Shiratori Y. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern. Med. 44: 949-953 (2005). *

• Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med. Okayama 62: 217-226 (2008). *

• Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, Yoshie Y, Sanada T, Notsumata K, Tanaka N, Matsui O. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol. Res. 39: 374-381 (2009). *

• Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43: 1284-1294 (2006). *

• Mogl MT, Pascher A, Presser SJ, Schwabe M, Neuhaus P, Nuessler NC. An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma - a case report. World J. Gastroenterol. 13: 1998-2001 (2007). *

• Mohr L, Yeung A, Aloman C, Wittrup D, Wands JR. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S225-S231 (2004). *

• Mondragon-Sanchez R, Garduno-Lopez AL, Gomez-Gomez E, Frias-Mendivil M, Mondragon-Sanchez A, Bernal-Maldonado R. Intraoperative US-guided large volume ethanol injection for hepatocellular carcinoma greater than 4 cm. Ann. Hepatol. 4: 200-203 (2005). *

• Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am. J. Gastroenterol. 103: 1944-1951 (2008). *

• Montejo M, Valdivielso A, Suarez MJ, Testillano M, Bustamante J, Gastaca M, Campo M, Errazti G, Perdigo K, Aguirrebengoa K, Gonzalez de Zarate P, Ortiz de Urbina J. Infection after orthotopic liver transplantation: analysis of the first 120 consecutive cases. Rev. Clin. Esp. 200: 245-251 (2000).

• Moon DB, Lee SG. Adult-to-adult living donor liver transplantation at the Asan Medical Center. Yonsei Med. J. 45: 1162-1168 (2004). *

• Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J. Surg. Res. 147: 23-33 (2008). *

• Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 24: 457-464 (2004). *

• Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S87-S96 (2004). *

• Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T, Nakao A. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int. 25: 380-388 (2005). *

• Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int. J. Cancer 125: 388-397 (2009). *

• Morichika S, Arima T, Nagashima H. Clinical evaluation of autoantibodies to liver cell membrane specific antigen, liver specific lipoprotein, and Tamm-Horsfall glycoprotein in autoimmune chronic active hepatitis. Gastroenterol. Jpn. 22: 24-33 (1987).

• Moriguchi H. A novel method in order to evaluate the efficacies and the safeties of new drugs for hepatocellular carcinoma with loss of transforming growth factor-beta signaling. Hepatology 50: 2050-2051 (2009).

• Moriguchi H. The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy. Hepatology 50: 2046 (2009).

• Moriguchi H, Chung RT, Sato C. An identification of novel therapy for human hepatocellular carcinoma by using human induced pluripotent stem cells. Hepatology Nov 9 [Epub ahead of print] (2009).

• Moriguchi M, Takayama T, Nakamura M, Aramaki O, Higaki T, Nakayama H, Ohkubo T, Fujii M. Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, Koike K, Matsuura Y. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 104: 1661-1666 (2007). *

• Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27: 1074-1080 (2006). *

• Morishita A, Masaki T, Yoshiji H, Nakai S, Ogi T, Miyauchi Y, Yoshida S, Funaki T, Uchida N, Kita Y, Funakoshi F, Usuki H, Okada S, Izuishi K, Watanabe S, Kurokohchi K, Kuriyama S. Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma. Hepatology 40: 677-686 (2004). *

• Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver carcinogenesis with retinoids: basic and clinical aspects. Hepatol. Res. 37 Suppl. 2: S299-S302 (2007). *

• Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin. Liver Dis. 21: 195-212 (2001).

• Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 41: 204 (2005). *

• Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod. Pathol. 22: 182-190 (2009).

• Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann. Hepatol. 5: 16-24 (2006). *

• Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 50: 630-637 (2009).

• Mott JL, Gores GJ. Targeting IL-6 in cholangiocarcinoma therapy. Am. J. Gastroenterol. 102: 2171-2172 (2007). *

• Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 50: 1084-1092 (2009).

• Moustafa MA, Ogino D, Nishimura M, Ueda N, Naito S, Furukawa M, Uchida T, Ikai I, Sawada H, Fukumoto M. Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci. 95: 530-536 (2004). *

• Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 300: 2371-2378 (2008). *

• Mu LN, Cao W, Zhang ZF, Cai L, Jiang QW, You NC, Goldstein BY, Wei GR, Chen CW, Lu QY, Zhou XF, Ding BG, Chang J, Yu SZ. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control 18: 665-675 (2007). *

• Mucha SR, Rizzani A, Gerbes A, Camaj P, Thasler W, Bruns C, Eichhorst S, Gallmeier E, Kolligs F, Goke B, De Toni EN. JNK inhibition sensitizes hepatocellular carcinoma cells but not normal hepatocytes to TNF-related apoptosis inducing ligand. Gut 58: 688-698 (2009).

• Muhlbauer M, Ringel S, Hartmann A, Lallinger G, Weiss TS, Gabele E, Wunsch PH, Scholmerich J, Hellerbrand C. Lack of association between the functional CX3CR1 polymorphism V249I and hepatocellular carcinoma. Oncol. Rep. 13: 957-963 (2005).

• Murakami A, Tanaka Y, Ueda M, Nagano Y, Kunisaki R, Morimoto M, Enaka M, Tanabe M, Kawachi K, Sasaki T, Nozawa A. Hepatocellular carcinoma occurring in a young Crohn's disease patient. Pathol. Int. 59: 492-496 (2009). *

• Murakami T, Mochizuki K, Nakamura H. Imaging evaluation of the cirrhotic liver. Semin. Liver Dis. 21: 213-224 (2001).

• Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 50: 453-460 (2009).

• Murata Y, Abe M, Furukawa S, Kumagi T, Matsui H, Matsuura K, Matsuura B, Hiasa Y, Onji M. Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices. J. Gastroenterol. 41: 1220-1226 (2006). *

• Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin. Chim. Acta 218: 47-58 (1993).

• Mutoh S, Osabe M, Inoue K, Moore R, Pedersen L, Perera L, Rebolloso Y, Sueyoshi T, Negishi M. Dephosphorylation of threonine 38 is required for nuclear translocation and subsequent activation of human xenobiotic receptor CAR. J. Biol. Chem. 284: 34785-34792 (2009). *

• Myers RP, Quan H, Hubbard JN, Shaheen AA, Kaplan GG. Predicting in-hospital mortality in patients with cirrhosis: results differ across risk adjustment methods. Hepatology 49: 568-577 (2009). *

• N'kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M, Seror O. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50: 1475-1483 (2009).

• Na TY, Shin YK, Roh KJ, Kang SA, Hong I, Oh SJ, Seong JK, Park CK, Choi YL, Lee MO. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 49: 1122-1131 (2009).

• Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K. Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother. Pharmacol. 62: 271-276 (2008). *

• Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, Tajiri N, Yamasaki S, Koga H, Torimura T, Kumashiro R, Sata M. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am. J. Gastroenterol. 99: 2369-2375 (2004). *

• Nagao Y, French BA, Cai Y, French SW, Wan YJ. Inhibition of PPAR alpha/RXR alpha-mediated direct hyperplasia pathways during griseofulvin-induced hepatocarcinogenesis. J. Cell. Biochem. 69: 189-200 (1998). *

• Nagasawa M, Hara T, Kashino A, Akasaka Y, Ide T, Murakami K. Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem. Pharmacol. 78: 523-530 (2009). *

• Nagasue N, Ogawa Y, Yukaya H, Tamada R, Chang Y, Nakamura T. Emergency distal splenorenal shunt for medically uncontrollable variceal haemorrhage. Zentralbl. Chir. 113: 446-454 (1988).

• Nagata H, Hatano E, Tada M, Murata M, Kitamura K, Asechi H, Narita M, Yanagida A, Tamaki N, Yagi S, Ikai I, Matsuzaki K, Uemoto S. Inhibition of c-Jun NH(2)-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma. Hepatology 49: 1944-1953 (2009). *

• Nagayama Y, Hase W, Motoyoshi Y, Saitoh O, Sogawa R, Nakao K. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Oncol. Rep. 17: 1269-1273 (2007). *

• Nagoshi S. Sex- or gender-specific medicine in hepatology. Hepatol. Res. 38: 219-224 (2008). *

• Nagpal S, Na S, Rathnachalam R. Non-calcemic actions of vitamin D receptor ligands. Endocr. Rev. 26: 662-687 (2005). *

• Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, Charnaux N, Ganne-Carrie N, Grando-Lemaire V, N'kontchou G, Trinchet JC, Gattegno L, Pessayre D, Beaugrand M. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 50: 1484-1493 (2009).

• Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36: 150-155 (2002). *

• Nair V, Fischer SE, Adeyi OA. Non-viral-related pathologic findings in liver needle biopsy specimens from patients with chronic viral hepatitis. Am. J. Clin. Pathol. 133: 127-132 (2010). *

• Nakahira A, Kubo S, Yamamoto T, Ogawa M, Sakabe K, Tanaka S, Uenishi T, Shuto T, Tanaka H, Hirohashi K. Resection of hepatocellular carcinoma arising from primary biliary cirrhosis. J. Gastroenterol. 39: 302-303 (2004). *

• Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J. Hepatol. 52: 72-78 (2010).

• Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45: 118-127 (2007). *

• Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J. Hepatol. 46: 77-88 (2007). *

• Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An JL, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30: 41-49 (2008). *

• Nakanuma Y. Hepatocellular carcinoma in primary biliary cirrhosis at an early histologic stage: coincidental or causally related? Intern. Med. 44: 169-170 (2005). *

• Nakanuma Y, Hirata K. Unusual hepatocellular lesions in primary biliary cirrhosis resembling but unrelated to hepatocellular neoplasms. Virchows Arch. A. Pathol. Anat. Histopathol. 422: 17-23 (1993).

• Nakao K, Tsunoda A, Shimizu Y, Takenaka K, Morohara K, Suzuki N, Yamazaki K, Aoki T, Hoshino M, Kusano M, Kitadai E, Kurihara T, Takeuchi Y, Imawari M. Development of hepatocellular carcinoma following treatment with 6-mercaptopurine for ulcerative colitis: investigation of chromosomal aberration by comparative genomic hybridization. Int. J. Clin. Oncol. 10: 281-284 (2005).

• Nakashima O, Kurogi M, Yamaguchi R, Miyaaki H, Fujimoto M, Yano H, Kumabe T, Hayabuchi N, Hisatomi J, Sata M, Kojiro M. Unique hypervascular nodules in alcoholic liver cirrhosis: identical to focal nodular hyperplasia-like nodules? J. Hepatol. 41: 992-998 (2004). *

• Nakashima T, Sakamoto K, Okuda K. A minute hepatocellular carcinoma found in a liver with Clonorchis sinensis infection: report of two cases. Cancer 39: 1306-1311 (1977).

• Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19: 71-77 (2005).

• Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun. 306: 16-25 (2003). *

• Nart D, Ertan Y, Pala EE, Zeytunlu M, Kilic M, Yilmaz F. Intrahepatic cholangiocarcinoma arising in chronic viral hepatitis-associated cirrhosis: two transplant cases. Transplant. Proc. 40: 3813-3815 (2008). *

• Narumoto J. Studies on circulating soluble immune complexes of the liver disease. 7. Immune complexes in the clinical course and their ultracentrifugal analysis. Gastroenterol. Jpn. 16: 186-192 (1981).

• Narumoto J. Studies on circulating soluble immune complexes of the liver disease. 6. Comparative studies of 125I-pRF inhibition assay, 125I-Clq inhibition assay and 125I-Clq binding assay. Gastroenterol. Jpn. 16: 174-185 (1981).

• Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124 (2007). *

• Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 50: 1251-1262 (2009).

• Nemoto N, Suzuki S, Kikuchi H, Okabe H, Sassa S, Sakamoto S. Ethyl-eicosapentaenoic acid reduces liver lipids and lowers plasma levels of lipids in mice fed a high-fat diet. In Vivo 23: 685-689 (2009).

• Neo SY, Leow CK, Vega VB, Long PM, Islam AFM, Lai PBS, Liu ET, Ren EC. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39: 944-953 (2004). *

• Netto GJ, Altrabulsi B, Katabi N, Martin P, Burt K, Levy M, Sanchez E, Watkins DL, Jennings L, Klintmalm G, Goldstein R. Radio-frequency ablation of hepatocellular carcinoma before liver transplantation: a histologic and 'TUNEL' study. Liver Int. 26: 746-751 (2006). *

• Neuberger J. Transplantation for primary biliary cirrhosis. Semin. Liver Dis. 17: 137-146 (1997).

• Neuberger J. Liver transplantation for autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83 (2004). *

• Neuberger J. Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121 (2003).

• Neuberger J, Jothimani D. Long-term immunosuppression for prevention of nonviral disease recurrence. Transplant. Proc. 37: 1671-1674 (2005). *

• Neuhaus P. Organ shortage. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 112-113. October 17 - 19 (2003). *

• Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Isabel Fiel M, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 51: 725-733 (2009).

• Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, Plevris JN. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment. Pharmacol. Ther. 14: 1295-1301 (2000). *

• Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tuting T, Barchet W, Buttner R, Limmer A, Gutgemann I. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 49: 471-481 (2009). *

• Ng SS, Yu SC, Lai PB, Lau WY. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig. Dis. Sci. 53: 2813-2817 (2008). *

• Nguyen LN, Furuya MH, Wolfraim LA, Nguyen AP, Holdren MS, Campbell JS, Knight B, Yeoh GC, Fausto N, Parks WT. Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. Hepatology 45: 31-41 (2007). *

• Nguyen MH, Keeffe EB. General management. Best Pract. Res. Clin. Gastroenterol. 19: 161-174 (2005).

• Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 124: x-xiv (2005). *

• Niehof M, Borlak J. EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4alpha splice variants in hepatocellular carcinomas. Gastroenterology 134: 1191-1202 (2008). *

• Nii A, Shimada M, Ikegami T, Harino Y, Imura S, Morine Y, Kanemura H, Arakawa Y, Sugimoto K. Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatol. Res. 39: 274-281 (2009). *

• Nilsson HO, Mulchandani R, Tranberg KG, Wadstrom T. Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology 120: 323-324 (2001). *

• Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am. J. Gastroenterol. 101: 70-75 (2006). *

• Nishikawa T, Nakajima T, Katagishi T, Okada Y, Jo M, Kagawa K, Okanoue T, Itoh Y, Yoshikawa T. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int. 29: 846-856 (2009). *

• Nishimura Y, Nakatsura T, Senju S. Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi 31: 383-391 (2008).

• Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J. Hepatol. 49: 207-216 (2008).

• Nishiyama R, Kanai T, Abe J, Hara R, Watahiki Y, Sakaguchi T, Nakamura S. Hepatocellular carcinoma associated with autoimmune hepatitis. J. Hepatobiliary Pancreat. Surg. 11: 215-219 (2004). *

• Nissen NN, Cavazzoni E, Tran TT, Poordad FP. Emerging role of transplantation for primary liver cancers. Cancer J. 10: 88-96 (2004).

• Nocera A, Andorno E, Tagliamacco A, Morelli N, Bottino G, Ravazzoni F, Casaccia M, Barocci S, Alice S, Santori G, Ghirelli R, Valente U. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant. Proc. 40: 1950-1952 (2008). *

• Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S, Nakao A. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann. Surg. Oncol. Nov 7 [Epub ahead of print] (2009).

• Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br. J. Cancer 97: 1260-1265 (2007). *

• Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment. Pharmacol. Ther. 31: 407-414 (2010). *

• Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, Gasbarrini A. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am. J. Gastroenterol. 104: 1852-1854 (2009). *

• Nunez Martinez O, Clemente Ricote G, Garcia Monzon C. Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases. Med. Clin. (Barc.) 121: 743-748 (2003).

• Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48: 146-156 (2008). *

• O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838-847 (1991).

• O'Brien ML, Spear BT, Glauert HP. Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis. Crit. Rev. Toxicol. 35: 61-88 (2005).

• O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 134: 1764-1776 (2008). *

• Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective. Am. J. Gastroenterol. 100: 1853-1867 (2005). *

• Ogasawara S, Komuta M, Nakashima O, Akiba J, Tsuneoka M, Yano H. Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K, Takaesu G, Maehara Y, Iida M, Yoshimura A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131: 179-193 (2006). *

• Ogawa M, Yamamoto T, Kubo S, Uenishi T, Tanaka H, Shuto T, Tanaka S, Hirohashi K. Clinicopathologic analysis of risk factors for distant metastasis of hepatocellular carcinoma. Hepatol. Res. 29: 228-234 (2004).

• Oh JE, Kim MS, Ahn CH, Kim SS, Han JY, Lee SH, Yoo NJ. Mutational analysis of CASP10 gene in colon, breast, lung and hepatocellular carcinomas. Pathology 42: 73-76 (2010). *

• Ohata M, Toda G. Gamma-glutamyltranspeptidase (gamma-GT). Rinsho Byori 116: S62-S71 (2001).

• Ohkawara T, Nishihira J, Takeda H, Asaka M, Sugiyama T. Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J. Gastroenterol. 40: 117-122 (2005). *

• Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M. Visceral fat accumulation is an independent risk factor of hepatocellular carcinoma recurrence after curative treatment in NASH-suspected patients. Gut 58: 839-844 (2009).

• Okada S. Local ablation therapy for hepatocellular carcinoma. Semin. Liver Dis. 19: 323-328 (1999).

• Okada T, Mibayashi H, Hasatani K, Hayashi Y, Tsuji S, Kaneko Y, Yoshimitsu M, Tani T, Zen Y, Yamagishi M. Pseudolymphoma of the liver associated with primary biliary cirrhosis: a case report and review of literature. World J. Gastroenterol. 15: 4587-4592 (2009). *

• Okamoto H, Shidara K, Hoshi D, Kamatani N. Anti-arthritis effects of vitamin K(2) (menaquinone-4) - a new potential therapeutic strategy for rheumatoid arthritis. FEBS J. 274: 4588-4594 (2007). *

• Okino H, Satoh T, Watanabe J, Masumoto A, Takeda S. Hepatocellular carcinoma arising from autoimmune hepatitis: report of a case. Surg. Today 37: 716-718 (2007).

• Okoli AS, Fox EM, Raftery MJ, Mendz GL. Effects of Helicobacter hepaticus on the proteome of HEp-2 cells. Antonie Van Leeuwenhoek. 92: 289-300 (2007). *

• Okoli AS, Menard A, Mendz GL. Helicobacter spp. other than Helicobacter pylori. Helicobacter 14 Suppl. 1: 69-74 (2009). *

• Okubo H, Takei Y, Serizawa N, Enomoto N, Ikejima K, Sato N. Orthotopic hepatocellular carcinoma model with a controlled and reproducible tumorigenicity. J. Gastroenterol. Hepatol. 22: 423-428 (2007). *

• Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin. Liver Dis. 22: 15-26 (2002).

• Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, Moriwaki H. Retinoids in cancer chemoprevention. Curr. Cancer Drug Targets 4: 285-298 (2004).

• Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J. Hepatol. 51: 1030-1036 (2009).

• Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma. Am. J. Gastroenterol. 104: 2747-2753 (2009). *

• Oliva J, Bardag-Gorce F, French BA, Li J, French SW. The regulation of non-coding RNA expression in the liver of mice fed DDC. Exp. Mol. Pathol. 87: 12-19 (2009).

• Olsson R. Small duct primary sclerosing cholangitis: a separate disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 62. October 15-16 (2003). *

• Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (5 Suppl. 2): S159-S166 (2004). *

• Omata M, Yoshiyuki D, Daniele B, Plentz R, Rudolph KL, Manns M, Piratvisuth T, Chen DS, Tateishi R, Cutaputti A. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. J. Gastroenterol. Hepatol. 17: S40-S49 (2002). *

• Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin. Liver Dis. 9: 617-634 (2005).

• Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis.11: 1-16 (2007).

• Ono K, Kokubu S, Hidaka H, Watanabe M, Nakazawa T, Saigenji K. Risk factors of delay in restoration of hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma (HCC). Hepatol. Res. 31: 172-177 (2005).

• Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, Suzuki K, Matsuda Y, Taniguchi N. Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis. J. Lab. Clin. Med. 118: 476-483 (1991).

• Ooi K, Shiraki K, Morishita Y, Nobori T. High-molecular intestinal alkaline phosphatase in chronic liver diseases. J. Clin. Lab. Anal. 21: 133-139 (2007).

• Orban E, Szabo E, Lotz G, Kupcsulik P, Paska C, Schaff Z, Kiss A. Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol. Oncol. Res. 14: 299-306 (2008). *

• Orlando A, D'Antoni A, Camma C, Albanese M, Livraghi T, Torzilli G, Virdone R, Sciarrino E, Simonetti RG, Maringhini A, Pagliaro L, Cottone M. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am. J. Gastroenterol. 95: 2921-2927 (2000). *

• Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 104: 514-524 (2009).

• Oshima T, Kawasaki T, Ohashi R, Hasegawa G, Jiang S, Umezu H, Aoyagi Y, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M. Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol. Int. 57: 82-90 (2007). *

• Oya H, Sato Y, Yamamoto S, Takeishi T, Kobayashi T, Hatakeyama K. Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: a case report. Transplant. Proc. 36: 2297-2298 (2004). *

• Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 23: 885-892 (2002). *

• Ozaki I, Mizuta T, Zhao G, Zhang H, Yoshimura T, Kawazoe S, Eguchi Y, Yasutake T, Hisatomi A, Sakai T, Yamamoto K. Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol. Res. 27: 289-301 (2003).

• Ozcay F, Canan O, Bilezikci B, Torgay A, Karakayali H, Haberal M. Effect of living donor liver transplantation on outcome of children with inherited liver disease and hepatocellular carcinoma. Clin. Transplant. 20: 776-782 (2006). *

• Ozgenc F, Aydogdu S, Aksoylar S, Elmas N, Yuce G, Yagci RV, Tokat Y. Regenerative nodule mimicking hepatocellular carcinoma in a cirrhotic child due to hepatitis B: an imaging dilemma. Pediatr. Transplant. 8: 198-200 (2004). *

• Ozturk M. Differentiation and malignant transformation. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 25-27. October 20 - 21 (2003). *

• Packer A. Cancer genetics. Second-generation models. Nat. Rev. Genet. 5: 888 (2004). *

• Page JM, Harrison SA. NASH and HCC. Clin. Liver Dis. 13: 631-647 (2009).

• Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking upregulation in hepatocellular carcinoma, as non-coding RNA. Gastroenterology 132: 330-342 (2007). *

• Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: the crosstalk between the NF-kappaB and JNK pathways. Biol. Chem. 390: 965-976 (2009).

• Paradis V. Glycomics: a new taste of cirrhosis marker. J. Hepatol. 43: 913-914 (2005). *

• Paradis V, Bedossa P. In the new area of noninvasive markers of hepatocellular carcinoma. J. Hepatol. 46: 9-11 (2007). *

• Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41: 40-47 (2005). *

• Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 28: 953-988 (1998). *

• Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49: 851-859 (2009). *

• Pardo-Saganta A, Latasa MU, Castillo J, Alvarez-Asiain L, Perugorría MJ, Sarobe P, Rodriguez-Ortigosa CM, Prieto J, Berasain C, Santamaría M, Avila MA. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. J. Hepatol. 51: 1010-1020 (2009).

• Parent R, Kolippakkam D, Booth G, Beretta L. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res. 67: 4337-4345 (2007). *

• Pares A. Natural history of primary biliary cirrhosis. Gastroenterol. Hepatol. 31: 500-507 (2008).

• Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin. Liver Dis. 7: 779-794 (2003).

• Park HS, Jang KY, Kim YK, Cho BH, Moon WS. Histiocyte-rich reactive lymphoid hyperplasia of the liver: unusual morphologic features. J. Korean Med. Sci. 23: 156-160 (2008). *

• Park JS, Cheong JY, Kang JK, Cho JH, Yu S, Shin HD, Park BL, Cho SW. Association of interleukin-12 gene polymorphism with persistence of hepatitis B virus infection and hepatocellular carcinoma. Korean J. Gastroenterol. 50: 313-318 (2007).

• Park SC, Yoon JH, Kim W, Gwak GY, Kim KM, Lee SH, Lee SM, Lee HS. Eupatilin attenuates bile acid-induced hepatocyte apoptosis. J. Gastroenterol. 41: 772-778 (2006). *

• Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology 128: 2042-2053 (2005). *

• Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig. Dis. Sci. 45: 1944-1948 (2000). *

• Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity? J. Hepatol. 45: 734-743 (2006). *

• Parmiani G. Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J. Hepatol. 43: 369-370 (2005).

• Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 42: 1310-1319 (2005). *

• Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27: 193-198 (2002). *

• Pascale RM, Simile MM, Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res. 13: 1341-1356 (1993).

• Pascual S, Zapater P, Such J, Garcia-Herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-Mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int. 26: 673-679 (2006). *

• Pascussi JM, Robert A, Moreau A, Ramos J, Bioulac-Sage P, Navarro F, Blanc P, Assenat E, Maurel P, Vilarem MJ. Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology 45: 1146-1153 (2007). *

• Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J. Gastroenterol. 16: 281-288 (2010). *

• Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43: 425-434 (2006). *

• Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann A, Stickel F. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J. Hepatol. Jan 13 [Epub ahead of print] (2010).

• Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int. 30: 356-364 (2010). *

• Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, Panda SK, Acharya SK. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India. Indian J. Gastroenterol. 26: 274-278 (2007). *

• Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 11: 1086-1092 (2005). *

• Peck-Radosavljevic M. TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. Liver Int. 30: 3-4 (2010). *

• Pedrosa MC, Rohrer RM, Kaplan MM. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Clin. Transplant. 9: 322-325 (1995).

• Peffer RC, Moggs JG, Pastoor T, Currie RA, Wright J, Milburn G, Waechter F, Rusyn I. Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor. Toxicol. Sci. 99: 315-325 (2007). *

• Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F, Schirmacher P, Longerich T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Pelletier L, Rebouissou S, Paris A, Rathahao-Paris E, Perdu E, Bioulac-Sage P, Imbeaud S, Zucman-Rossi J. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 51: 557-566 (2010). *

• Pellicano R, Mazzaferro V, Grigioni WF, Cutufia MA, Fagoonee S, Silengo L, Rizzetto M, Ponzetto A. Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J. Gastroenterol. 10: 598-601 (2004). *

• Pellicano R, Menard A, Rizzetto M, Megraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect. Dis. 8: 254-260 (2008).

• Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, Zhang S, Gao ZF. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J. Gastroenterol. 11: 2704-2708 (2005). *

• Peng T, He S, Kruger M, Tang H, Wong-Staal F. Identification, validation and characterization of a novel cellular factor required for hepatitis C virus internal ribosome entry sitemediated translation. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 53. October 20 - 21 (2003). *

• Penuelas I, Mazzolini G, Boan JF, Sangro B, Marti-Climent J, Ruiz M, Ruiz J, Satyamurthy N, Qian C, Barrio JR, Phelps ME, Richter JA, Gambhir SS, Prieto J. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128: 1787-1795 (2005). *

• Perez A, Anzaldua M, McCormick J, Fishr-Hoh S. High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population. J. Gastroenterol. Hepatol. 19: 289-295 (2004). *

• Perez Saborido B, Meneu JC, Moreno E, Garcia I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am. J. Surg. 190: 383-387 (2005). *

• Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am. Fam. Physician 68: 1075-1082 (2003). *

• Perlmutter DH. Alpha-1-antitrypsin deficiency: diagnosis and treatment. Clin. Liver Dis. 8: 839-859, viii-ix (2004).

• Pessayre D, Fromenty B. NASH: a mitochondrial disease. J. Hepatol. 42: 928-940 (2005). *

• Peters M, Tinberg HM, Govindarajan S. Immunocytochemical identity of hepatocellular hyalin in alcoholic and non-alcoholic liver diseases. Liver 2: 361-368 (1982).

• Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, Gaudio E. MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications. Clin. Ter. 154: 325-335 (2003).

• Pewzner-Jung Y, Brenner O, Braun S, Laviad EL, Ben-Dor S, Feldmesser E, Horn-Saban S, Amann-Zalcenstein D, Raanan C, Berkutzki T, Erez-Roman R, Ben David O, Levy M, Holzman D, Park H, Nyska A, Merrill AH Jr, Futerman AH. A critical role for ceramide synthase 2 in liver homeostasis: II. Insights into molecular changes leading to hepatopathy. J. Biol. Chem. Jan 28 [Epub ahead of print] (2010). *

• Piantino P, Pecchio F, Gallo V, Giudice L, Bonardi O. Alpha fetoprotein in non-neoplastic liver diseases. Minerva Med. 72: 1125-1129 (1981).

• Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J. Neurol. Sci. Jan 5 [Epub ahead of print] (2010).

• Pichard V, Royer PJ, Richou C, Cauchin E, Goebes K, Gaignerie A, Masliah C, Gournay J, Gregoire M, Ferry N. Detection, isolation, and characterization of alpha-fetoprotein-specific T cell populations and clones using MHC class I multimer magnetic sorting. J. Immunother. 31: 246-253 (2008).

• Pierie JP, Muzikansky A, Tanabe KK, Ott MJ. The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma. Ann. Surg. Oncol. 12: 552-560 (2005). *

• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466 (2004). *

• Pineau P, Buendia MA. Studies of genetic defects in hepatocellular carcinoma: recent outcomes and new challenges. J. Hepatol. 33: 152-156 (2000). *

• Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin. Liver Dis. 19: 397-410 (1999).

• Piscaglia F, Sagrini E. Malignancies in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 20: 1-4 (2008).

• Pockros PJ. Novel therapies in hepatitis C virus. Preface. Clin. Liver Dis. 13: xiii (2009). *

• Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R, Muhlbacher F. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am. J. Transplant. 5: 788-794 (2005). *

• Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 11: 1117-1126 (2005). *

• Ponsioen CY, Kuiper H, Ten Kate FJ, van Milligen de Wit M, van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur. J. Gastroenterol. Hepatol. 11: 769-774 (1999).

• Ponzetto A, Pellicano R, Leone N, Cutufia MA, Turrini F, Grigioni WF, D'Errico A, Mortimer P, Rizzetto M, Silengo L. Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med. Hypotheses 54: 275-277 (2000).

• Poon RT. Prognostic impact of diabetes mellitus on patients with hepatocellular Am. J. Gastroenterol. 99: 1488-1489 (2004). *

• Poon TC, Wong N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 131: 1262-1270 (2006). *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Poupon R. Primary biliary cirrhosis. Schweiz. Med. Wochenschr. 121: 727-732 (1991).

• Powell CL, Kosyk O, Bradford BU, Parker JS, Lobenhofer EK, Denda A, Uematsu F, Nakae D, Rusyn I. Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury. Hepatology 42: 1137-1147 (2005). *

• Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J. Hepatol. 48: 380-381 (2008). *

• Prieto J. Cancer gene therapy: the experience from clinical trials. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 46-47 (2006). *

• Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SC, Banerjee R. S-Adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc. Natl. Acad. Sci. U.S.A. 103: 6489-6494 (2006). *

• Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, Mamani-Matsuda M, Jouanguy E, Gendrel D, Casanova JL. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180: 647-654 (2008). *

• Purnak T, Ozaslan E. Hypothyroidism and hepatocellular carcinoma: more questions than answers. Hepatology 50: 993-994 (2009).

• Qayyum A, Graser A, Westphalen A, Merriman RB, Ferrell LD, Yeh BM, Coakley FV. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR Am. J. Roentgenol. 183: 1573-1576 (2004). *

• Qesaraku B, Dudas J, Rave-Frank M, Hess CF, Ramadori G, Saile B, Christiansen H. Effect of tumour necrosis factor-alpha and irradiation alone or in combination on the viability of hepatocellular and biliary adenocarcinoma cell lines in vitro. Liver Int. 29: 910-921 (2009). *

• Qi P, Chen YM, Wang H, Fang M, Ji Q, Zhao YP, Sun XJ, Liu Y, Gao CF. -509C>T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol. Immunother. 58: 1433-1440 (2009). *

• Qi P, Wang H, Chen YM, Sun XJ, Liu Y, Gao CF. No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology 41: 555-560 (2009).

• Qian C, Drozdzik M, Caselmann WH, Prieto J. The potential of gene therapy in the treatment of hepatocellular carcinoma. J. Hepatol. 32: 344-351 (2000). *

• Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat. Dis. Int. 4: 173-177 (2005). *

• Qiu GH, Xie H, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M, Lai P, Ross JA, Hooi SC. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J. Hepatol. 46: 655-663 (2007). *

• Qiu W, Zhou G, Zhai Y, Zhang X, Xie W, Zhang H, Yang H, Zhi L, Yuan X, Zhang X, He F. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol. Biomarkers Prev. 17: 2514-2518 (2008). *

• Quiles-Perez R, Munoz-Gamez JA, Ruiz-Extremera A, O'Valle F, Sanjuan-Nunez L, Martin-Alvarez AB, Martin-Oliva D, Caballero T, Munoz de Rueda P, Leon J, Gonzalez R, Muntane J, Oliver FJ, Salmeron J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 51: 255-266 (2010).

• Ra SH, Kaplan JB, Lassman CR. Focal nodular hyperplasia after orthotopic liver transplantation. Liver Transpl. Oct 28 [Epub ahead of print] (2009).

• Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zornig M. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50: 1121-1129 (2009).

• Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous alpha 1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology 15: 407-410 (1992).

• Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342 (2004). *

• Rahman SM, Itakura H, Motoda A. Regenerative pattern of liver cells in primary biliary cirrhosis, alcoholic cirrhosis, posthepatitic cirrhosis (HBV-related) and hepatocellular carcinoma: comparative analysis by computerized morphometry. Pathol. Int. 46: 267-273 (1996).

• Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 50: 1142-1154 (2009).

• Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 103: 4-13 (2008). *

• Ramalho FS, Ramalho LN, Della Porta L, Zucoloto S. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1276-1280 (2006). *

• Ramia J, Garrote D, Mansilla A, Villar J, Gomez R, Ferron J. Hepatocellular carcinoma in non-cirrhotic liver and ulcerative colitis: incidental or casual relationship? Rev. Esp. Enferm. Dig. 96: 429-430 (2004).

• Rao PN, Crippin J, Levine E, Hunt J, Baliga S, Balart L, Anthony L, Mulekar M, Raj MH. Elevation of serum riboflavin carrier protein in hepatocellular carcinoma. Hepatol. Res. 35: 83-87 (2006).

• Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41: 1233-1240 (2005). *

• Rasmussen ME, Lauritsen LE, Andersen LP. Role of Helicobacter species in hepatobiliary diseases. Ugeskr. Laeger. 170: 2010-2015 (2008).

• Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 667-688 (2009).

• Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, D'Errico A, Ballardini G, Cavallari A, Grazi GL. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl. 10: 1195-1202 (2004). *

• Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, Trevisani F, Grigioni WF, Bolondi L, Pinna AD. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 78: 1780-1786 (2004).

• Ravaioli M, Luca Grazi G, Cescon M, Trevisani F, Piscaglia F, Ercolani G, Pinna AD. Down-staging of hepatocellular carcinoma prior to liver transplantation: the power of selection. Hepatology 49: 1056 (2009).

• Ray S, Boldogh I, Brasier AR. STAT3 NH(2)-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology 129: 1616-1632 (2005). *

• Reddy JK, Sambasiva Rao M. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G852-G858 (2006). *

• Reddy SK, Austin SL, Spencer-Manzon M, Koeberl DD, Clary BM, Desai DM, Smith AD, Kishnani PS. Liver transplantation for glycogen storage disease type Ia. J. Hepatol. 51: 483-490 (2009).

• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229 (2005). *

• Reig M, Bruix J. Sorafenib for hepatocellular carcinoma: global validation. Gastroenterology 137: 1171-1173 (2009). *

• Renz JF, Kin C, Kinkhabwala M, Jan D, Varadarajan R, Goldstein M, Brown R Jr, Emond JC. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann. Surg. 242: 556-565 (2005). *

• Reschke M, Ferby I, Stepniak E, Seitzer N, Horst D, Wagner EF, Ullrich A. Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. Hepatology Nov 13 [Epub ahead of print] (2009). *

• Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49: 1185-1193 (2009). *

• Riegler JL. Preneoplastic conditions of the liver. Semin. Gastrointest. Dis. 7: 74-87 (1996).

• Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Mullhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 49: 1602-1609 (2009).

• Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50: 791-798 (2009).

• Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am. J. Gastroenterol. 100: 1311-1316 (2005). *

• Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; the Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J. Hepatol. 50: 923-928 (2009).

• Ritter M, Ali MY, Grimm CF, Weth R, Mohr L, Bocher WO, Endrulat K, Wedemeyer H, Blum HE, Geissler M. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J. Hepatol. 41: 999-1007 (2004). *

• Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 137: 850-855 (2009). *

• Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified? Clin. Liver Dis. 9: 315-328 (2005).

• Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 10: 534-540 (2004). *

• Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 25: 212-225 (2005).

• Rodriguez-Luna H, Vargas HE, Byrne T, Rakela J. Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence. Transplantation 79: 1737-1740 (2005).

• Rogers AB, Fox JG. Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G361-G366 (2004). *

• Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, Boussahmain C, Cormier KS, Fox JG. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res. 67: 11536-11546 (2007). *

• Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection, a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 136: 1629-1638 (2009). *

• Rosen HR. Liver disease associated with alpha1-antitrypsin deficiency. Clin. Liver Dis. 2: 175-185 (1998).

• Rosenthal P. Digestive disease week 2000. American association for the study of liver diseases. IDrugs 3: 868-871 (2000).

• Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822 (2006). *

• Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin. Liver Dis. 23: 385-396 (2003).

• Rountree CB, Senadheera S, Mato JM, Crooks GM, Lu SC. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 47: 1288-1297 (2008). *

• Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, Konig J, Schilling M. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand. J. Immunol. 63: 468-477 (2006). *

• Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, Konig J, Rau B, Schilling M. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J. Gastroenterol. 12: 6627-6633 (2006). *

• Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 42: 514-521 (2005). *

• Rudnick DA, Shikapwashya O, Blomenkamp K, Teckman JH. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 44: 976-982 (2006). *

• Rudolph KL. Telomeres and telomerase in liver regeneration and cancer. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 19. October 20 - 21 (2003). *

• Ruelas-Villavicencio AL, Vargas-Vorackova F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? Ann. Hepatol. 3: 152-159 (2004). *

• Ruers TJ, de Jong KP, Ijzermans JN. Radiofrequency for the treatment of liver tumours. Dig. Surg. 22: 245-253 (2005).

• Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 13: 287-290 (2001).

• Russo MW, Brown RS Jr. Ethical issues in living donor liver transplantation. Curr. Gastroenterol. Rep. 5: 26-30 (2003).

• Rusyn I, Peters JM, Cunningham ML. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit. Rev. Toxicol. 36: 459-479 (2006). *

• Ryder S. Predicting survival in early hepatocellular carcinoma. Gut 54: 328-329 (2005). *

• Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52 Suppl. 3: iii1-iii8 (2003). *

• Saffroy R, Pham P, Chiappini F, Goupil MG, Castera L, Azoulay D, Barrier A, Samuel D, Debuire B, Lemoine A. The MTHFR 677C>T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis 25: 1443-1448 (2004). *

• Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 73: 616-622 (2002).

• Sagnelli E, Coppola N. Hepatitis viruses and development of hepatocellular carcinoma. Infez. Med. 5: 73-86 (1997).

• Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007. Curr. Opin. Gastroenterol. 23: 292-298 (2007).

• Said A, Lucey MR. Liver transplantation: an update. Curr. Opin. Gastroenterol. 22: 272-278 (2006).

• Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int. 29: 1162-1170 (2009). *

• Saito T, Gale M Jr. RIG-I mediated hepatic innate immune signaling that controls HCV infection. Uirusu. 58: 105-115 (2008).

• Saji N, Taniguchi K, Tadano M, Shimizu H, Kawarai T, Kita Y. A case of brainstem encephalitis following multiple cranial neuropathy in a hepatocellular carcinoma patient - association with cytomegalovirus and varicella-zoster virus infection. Brain Nerve 59: 1273-1279 (2007).

• Sakakima Y, Hayashi S, Yagi Y, Hayakawa A, Tachibana K, Nakao A. Gene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agents. Cancer Gene Ther. 12: 884-889 (2005).

• Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Tanaka K. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett. 271: 98-104 (2008).

• Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Tanaka K. hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among Japanese. J. Epidemiol. 16: 233-239 (2006). *

• Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin. Liver Dis. 25: 171-180 (2005).

• Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, Pons F, Rimola A, Garcia-Valdecasas JC, Bru C, Bruix J. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 10: 1294-1300 (2004). *

• Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, Bru C, Bruix J. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352-1360 (2004). *

• Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P, Pfahl M. Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol. Endocrinol. 7: 1347-1356 (1993). *

• Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138: 52-64 (2010). *

• Samarasena J, Borgaonkar M. Development of hepatocellular carcinoma in a patient with Crohn's disease treated with azathioprine. Dig. Dis. Sci. 52: 2748-2750 (2007). *

• Sanchez CR, Murray S, Montali RJ. Use of desferoxamine and S-adenosylmethionine to treat hemochromatosis in a red ruffed lemur (Varecia variegata ruber). Comp. Med. 54: 100-103 (2004).

• Sanchez W. Expanding transplant criteria for hepatocellular carcinoma: small steps down a long road. Hepatology 49: 724-725 (2009).

• Sancho-Bru P, Juez E, Moreno M, Khurdayan V, Morales-Ruiz M, Colmenero J, Arroyo V, Brenner DA, Gines P, Bataller R. Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver Int. 30: 31-41 (2010). *

• Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology 46: 1304-1305 (2007). *

• Sandroussi C, Crawford M, Lockwood DS, Tang P, Gallagher JP, Pleass H, Strasser SI, Shackel NA, McCaughan GW, Verran DJ. Donor and recipient selection leads to good patient and graft outcomes for right lobe split transplantation versus whole graft liver transplantation in adult recipients. Liver Transpl. 15: 1586-1593 (2009).

• Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126: 1005-1014 (2004). *

• Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della Corte C, Ronchi G, Rumi MG, Biondetti P, Colombo M. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut Dec 1 [Epub ahead of print] (2009).

• Sangro B. Refined tools for the treatment of hepatocellular carcinoma. J. Hepatol. 42: 629-631 (2005). *

• Sangro B, Mazzollini G, Prieto J. Future therapies for hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17: 515-521 (2005).

• Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc. Natl. Acad. Sci. U.S.A. 100: 3065-3070 (2003). *

• Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younossi ZM. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig. Dis. Sci. 49: 850-853 (2004). *

• Sarin SK, Kumar M, Garg S, Hissar S, Pandey C, Sharma BC. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1478-1482 (2006). *

• Sarobe P, Feijoo E, Alfaro C, Mazzolini G, Melero I. MAGE antigens: therapeutic targets in hepatocellular carcinoma? J. Hepatol. 40: 155-158 (2004). *

• Sasahira N, Tada M, Yoshida H, Tateishi R, Shiina S, Hirano K, Isayama H, Toda N, Komatsu Y, Kawabe T, Omata M. Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation. Gut 54: 698-702 (2005). *

• Sasaki M, Hodo Y, Nakanuma Y. Hepatocellular carcinoma arising in primary biliary cirrhosis presenting with nodular regenerative hyperplasia: report of an autopsy case. J. Gastroenterol. Hepatol. 21: 1866-1868 (2006). *

• Sato K, Takagi H, Fukusato T, Kanda D, Mori M. Hepatocellular carcinoma in primary biliary cirrhosis: case reports and review of the literature. Histopathology 40: 490-492 (2002). *

• Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 447: 996-999 (2005). *

• Sato M, Watanabe Y, Tokui K, Kawachi K, Sugata S, Ikezoe J. CT-guided treatment of ultrasonically invisible hepatocellular carcinoma. Am. J. Gastroenterol. 95: 2102-2106 (2000). *

• Sato R, Maesawa C, Fujisawa K, Wada K, Oikawa K, Takikawa Y, Suzuki K, Oikawa H, Ishikawa K, Masuda T. Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. Gut 53: 1001-1009 (2004). *

• Sato T, Yamazaki K, Toyota J, Karino Y, Ohmura T, Akaike J. Endoscopic ultrasonographic evaluation of hemodynamics related to variceal relapse in esophageal variceal patients. Hepatol. Res. 39: 126-133 (2009). *

• Sato Y, Yamamoto S, Oya H, Nakatsuka H, Kobayashi T, Takeishi T, Hirano K, Hara Y, Watanabe T, Waguri N, Suda T, Ichida T, Aoyagi Y, Hatakeyama K. Preoperative human-telomerase reverse transcriptase mRNA in peripheral blood and tumor recurrence in living-related liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 52: 1325-1328 (2005).

• Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40: 276-283 (2004). *

• Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67: 2497-2507 (2007). *

• Scanga A, Kowdley K. Sorafenib: a glimmer of hope for unresectable hepatocellular carcinoma? Hepatology 49: 332-334 (2009). *

• Scatton O, Chiappini F, Liu XH, Riou P, Marconi A, Debuire B, Azoulay D, Lemoine A. Generation and modulation of hepatocellular carcinoma circulating cells: a new experimental model. J. Surg. Res. 150: 183-189 (2008).

• Schaffer RL 3rd, Kulkarni S, Harper A, Millis JM, Cronin DC 2nd. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience. Liver Transpl. 9: 1211-1215 (2003). *

• Schaffner F. The history of liver disease at The Mount Sinai Hospital. Mt. Sinai J. Med. 67: 76-83 (2000). *

• Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int. 26: 904-911 (2006). *

• Scheers I, Bachy V, Stephenne X, Sokal EM. Risk of hepatocellular carcinoma in liver mitochondrial respiratory chain disorders. J. Pediatr. 146: 414-417 (2005). *

• Schmitt M, Horbach A, Kubitz R, Frilling A, Haussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J. Hepatol. 41: 274-283 (2004). *

• Schmitz V, Raskopf E, Gonzalez-Carmona MA, Vogt A, Rabe C, Leifeld L, Kornek M, Sauerbruch T, Caselmann WH. Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. Gut 56: 271-278 (2007). *

• Schmitz V, Wang L, Barajas M, Gomar C, Prieto J, Qian C. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 53: 561-567 (2004). *

• Scholmerich J, Schacherer D. Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 53: 1224-1226 (2004). *

• Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu M, Wiedenmann B, Berg T, Schott E. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am. J. Gastroenterol. 102: 2471-2481 (2007). *

• Schrem H, Till N, Becker T, Bektas H, Manns MP, Strassburg CP, Klempnauer J. Long-term results after liver transplantation. Chirurg. 79: 121-129 (2008).

• Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 93: 4001-4005 (1996). *

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104 (1999). *

• Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S268-S276 (2004). *

• Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl. 11: 494-496 (2005). *

• Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J. Hepatol. 43: 584-589 (2005). *

• Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S1-S4 (2004). *

• Segat L, Fabris A, Padovan L, Milanese M, Pirulli D, Lupo F, Salizzoni M, Amoroso A, Crovella S. MBL2 and MASP2 gene polymorphisms in patients with hepatocellular carcinoma. J. Viral Hepat. 15: 387-391 (2008).

• Segat L, Milanese M, Crovella S. Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology 132: 2618-2619 (2007). *

• Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-Ishi M, Kodera Y, Maeda T, Takano S, Togawa A, Yoshitomi H, Otsuka M, Yamamoto M, Nakano M, Miyazaki M, Nomura F. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 48: 519-530 (2008). *

• Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol. Chem. 387: 349-360 (2006). *

• Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int. J. Cancer Aug 26 [Epub ahead of print] (2009). *

• Seki E, Brenner DA. The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor? J. Hepatol. 47: 307-309 (2007). *

• Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 136: 2304-2315.e4 (2009). *

• Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41: 864-880 (2004). *

• Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J. Gastroenterol. Hepatol. 23: 1410-1414 (2008). *

• Sevenet F, Capron JP. Asymptomatic forms of primary biliary cirrhosis seen in 10 years in Picardie. Presse. Med. 15: 1957-1960 (1986).

• Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117 (2004). *

• Shackel NA, McCaughan GW, Warner FJ. Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin-6 signaling. Hepatology 47: 2134-2136 (2008). *

• Shah TU, Semelka RC, Pamuklar E, Firat Z, Gerber RD, Shrestha R, Russo MW. The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am. J. Gastroenterol. 101: 533-540 (2006). *

• Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. PPARalpha regulates an miRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell. Biol. 27: 4238-4247 (2007). *

• Shao CK, Zhou J, Feng ZY, Chen GH. A clinicopathological analysis of liver retransplantation in 22 cases. Zhonghua Gan Zang Bing Za Zhi 15: 370-373 (2007).

• Shao RX, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, Kawabe T, Omata M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 128: 86-95 (2005). *

• Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 10: 36-41 (2004). *

• Shen DY, Fang ZX, You P, Liu PG, Wang F, Huang CL, Yao XB, Chen ZX, Zhang ZY. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int. 30: 119-125 (2010). *

• Shen Y, Xia M, Zhang J, Xu L, Yang J, Chen A, Miao F, Ferrone S, Xie W. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol. Immunol. 46: 2045-2053 (2009). *

• Shen YQ, Zhang JQ, Xia M, Miao FQ, Shan XN, Xie W. Low-molecular-weight protein (LMP)2/LMP7 abnormality underlies the downregulation of human leukocyte antigen class I antigen in a hepatocellular carcinoma cell line. J. Gastroenterol. Hepatol. 22: 1155-1161 (2007). *

• Sheng XL, Zhang H. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells. World J. Gastroenterol. 13: 5944-5950 (2007). *

• Sherman M. Screening for hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19: 101-118 (2005).

• Sherman M. Hepatocellular carcinoma. Clin. Liver Dis. 9: xi-xii (2005). *

• Sherman M. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment. J. Hepatol. 50: 854-856 (2009). *

• Sherman M. What is the long-term efficacy of percutaneous ethanol injection for small hepatocellular carcinoma? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 78-79 (2006). *

• Sherman M. Hepatocellular carcinoma: beyond screening. J. Hepatol. 39: 269-271 (2003). *

• Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25: 143-154 (2005).

• Sherman M. Vinyl chloride and the liver. J. Hepatol. 51: 1074-1081 (2009). *

• Sherman M. Hepatitis C and hepatocellular carcinoma: grist for the mill. Gastroenterology 136: 39-42 (2009). *

• Sherman M. Pathogenesis and screening for hepatocellular carcinoma. Clin. Liver Dis. 8: 419-443, viii (2004).

• Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: conference proceedings. Hepatology 40: 1465-1473 (2004). *

• Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, Rosen M, Soulen M, Shaked A, Reddy KR, Olthoff KM. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 10: 911-918 (2004). *

• Shi YH, Ding WX, Zhou J, He JY, Xu Y, Gambotto AA, Rabinowich H, Fan J, Yin XM. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48: 497-507 (2008). *

• Shibuya A. Hepatocellular carcinoma accompanied with primary biliary cirrhosis. Nippon Rinsho 59 Suppl. 6: 465-468 (2001).

• Shibuya A, Tanaka K, Miyakawa H, Shibata M, Takatori M, Sekiyama K, Hashimoto N, Amaki S, Komatsu T, Morizane T. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35: 1172-1178 (2002). *

• Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2A maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 137: 1986-1994 (2009). *

• Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130 (2005). *

• Shimada M, Fujii M, Morine Y, Imura S, Ikemoto T, Ishibashi H. Living-donor liver transplantation: present status and future perspective. J. Med. Invest. 52: 22-32 (2005). *

• Shimada M, Hasegawa H, Gion T, Utsunomiya T, Shirabe K, Takenaka K, Otsuka T, Maehara Y, Sugimachi K. The role of telomerase activity in hepatocellular carcinoma. Am. J. Gastroenterol. 95: 748-752 (2000). *

• Shimizu A, Koyama M, Okuda Y, Takase K, Nakano T, Tameda Y. Hepatocellular carcinoma in primary biliary cirrhosis: a case report and review of the Japanese literature. Hepatogastroenterology 45: 2352-2355 (1998).

• Shimizu M, Iijima H, Horibe T, Yamada M, Suzuki S, Yanagisawa K, Seki T, Moriyasu F. Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol. Res. 29: 235-242 (2004).

• Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci. 100: 369-374 (2009). *

• Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203 (2005). *

• Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 21: 106-112 (1995).

• Shiraki M, Terakura Y, Iwasa J, Shimizu M, Miwa Y, Murakami N, Nagaki M, Moriwaki H. Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Nutrition Aug 18 [Epub ahead of print] (2009). *

• Si S, Sun Y, Li Z, Ge W, Zhang X, Hu P, Huang Y, Chen G, Song H, Huang Y, Ma B, Li X, Sui Y. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma. Gene Ther. 13: 1603-1610 (2006). *

• Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin. Liver Dis. 21: 71-80 (2001).

• Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 44: 151-157 (2006). *

• Sigruener A, Buechler C, Orso E, Hartmann A, Wild PJ, Terracciano L, Roncalli M, Bornstein SR, Schmitz G. Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm. Metab. Res. 39: 781-789 (2007).

• Sikorska K, Stalke P, Lakomy EA, Michalska Z, Witczak-Malinowska K, Stolarczyk J. Disturbances of iron metabolism in chronic liver diseases. Med. Sci. Monit. 9 Suppl. 3: 64-67 (2003).

• Silvain C, Zeevi A, Saidman S, Duquesnoy RJ, Van Thiel DH. Phenotypic and functional characteristics of colonic lymphocytes isolated from patients with primary sclerosing cholangitis and inflammatory bowel disease. Hepatogastroenterology 42: 250-258 (1995).

• Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 48: 1149-1156 (2008). *

• Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Simonin Y, Disson O, Lerat H, Antoine E, Biname F, Rosenberg AR, Desagher S, Lassus P, Bioulac-Sage P, Hibner U. Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. Hepatology 50: 1370-1379 (2009).

• Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Aliment. Pharmacol. Ther. 30: 37-47 (2009). *

• Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl. 11: 700-704 (2005). *

• Singson RC, Fraiman M, Geller SA. Hepatocellular carcinoma with fibrolamellar pattern in a patient with autoimmune cholangitis. Mt. Sinai J. Med. 66: 109-112 (1999). *

• Skagen C, Lucey M, Said A. Liver transplantation: an update 2009. Curr. Opin. Gastroenterol. 25: 202-208 (2009).

• Slater K, Bak TE, Kam I, Wachs ME. Living donor liver transplant for fibrolamellar hepatocellular carcinoma using a deceased donor graft to reconstruct inferior vena cava. Liver Transpl. 10: 555-556 (2004). *

• Snook JA, Kelly P, Chapman RW, Jewell DP. Fibrolamellar hepatocellular carcinoma complicating ulcerative colitis with primary sclerosing cholangitis. Gut 30: 243-245 (1989). *

• Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, DI Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. Jan 12 [Epub ahead of print] (2010). *

• Sohn BH, Park IY, Lee JJ, Yang SJ, Jang YJ, Park KC, Kim DJ, Lee DC, Sohn HA, Kim TW, Yoo HS, Choi JY, Bae YS, Yeom YI. Functional switching of TGFbeta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology Dec 25 [Epub ahead of print] (2009). *

• Sola S, Amaral JD, Aranha MM, Steer CJ, Rodrigues CM. Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors. Curr. Med. Chem. 13: 3039-3051 (2006).

• Solazzo M, Fantappie O, Lasagna N, Sassoli C, Nosi D, Mazzanti R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp. Cell Res. 312: 4070-4078 (2006). *

• Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, Clavien PA. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology Nov 20 [Epub ahead of print] (2009). *

• Song EY, Kim KS, Kim KA, Kim YD, Kwon DH, Byun SM, Kim HJ, Chung TW, Choe YK, Chung TW, Kim CH. Determination of UDP-N-acetylglucosamine:beta-D-mannoside-1,4-N-acetylglucosaminyltransferase-III in patients sera with chronic hepatitis and liver cirrhosis using a monoclonal antibody. Glycoconj. J. 19: 415-421 (2002). *

• Song HJ, Kim YS, Han CH, Jang JY, Kim JH, Cheon YK, Kim YS, Moon JH, Cho YD, Shim CS, Kwon KH, Kim BS. A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor. Korean J. Hepatol. 12: 449-454 (2006).

• Song TJ, Wai Kit Ip E, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 127 (5 Suppl. 2): S248-S260 (2004). *

• Song ZZ. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47: 2145-2146 (2008). *

• Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J. Hepatol. 50: 351-357 (2009).

• Sotiropoulos GC, Kaiser GM, Lang H, Molmenti EP, Beckebaum S, Fouzas I, Sgourakis G, Radtke A, Bockhorn M, Nadalin S, Treckmann J, Niebel W, Baba HA, Broelsch CE, Paul A. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant. Proc. 40: 3194-3195 (2008). *

• Sotiropoulos GC, Malago M, Molmenti EP, Losch C, Lang H, Frilling A, Broelsch CE, Neuhauser M. Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Transpl. Int. 20: 141-146 (2007). *

• Soung YH, Jeong EG, Ahn CH, Kim SS, Song SY, Yoo NJ, Lee SH. Mutational analysis of caspase 1, 4, and 5 genes in common human cancers. Hum. Pathol. 39: 895-900 (2008).

• Spadaro A, Ajello A, Morace C, Zirilli A, D'arrigo G, Luigiano C, Martino F, Bene A, Migliorato D, Turiano S, Ferrau O, Freni MA. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J. Gastroenterol. 11: 1987-1990 (2005). *

• Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin. Liver Dis. 26: 385-390 (2006).

• Spengler U. Hepatic microcirculation - a critical but neglected factor for the outcome of viral hepatitis. J. Hepatol. 50: 631-633 (2009). *

• Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pacific J. Cancer Prev. 5: 118-125 (2004). *

• Stauber RE, Wagner D, Stadlbauer V, Palma S, Gurakuqi G, Kniepeiss D, Iberer F, Smolle KH, Haas J, Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int. 29: 1516-1520 (2009). *

• Steele IL, Levy C, Lindor KD. Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20 (2007). *

• Stefani AL, Barzon L, Castagliuolo I, Guido M, Pacenti M, Parolin C, Farinati F, Palu G. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 42: 728-735 (2005). *

• Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv. Ther. 26: 893-907 (2009). *

• Steinmuller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 17 Suppl. 2: 138-144 (2003).

• Stephen FO, Rossaro L. 12th update in gastroenterology and hepatology for the primary care practitioner. Expert Rev. Gastroenterol. Hepatol. 2: 635-637 (2008).

• Sterzenbach T, Bartonickova L, Behrens W, Brenneke B, Schulze J, Kops F, Chin EY, Katzowitsch E, Schauer DB, Fox JG, Suerbaum S, Josenhans C. Role of the Helicobacter hepaticus flagellar sigma factor FliA in gene regulation and murine colonization. J. Bacteriol. 190: 6398-6408 (2008). *

• Stewart CJ, Mills PR, Carter R, O'Donohue J, Fullarton G, Imrie CW, Murray WR. Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J. Clin. Pathol. 54: 449-455 (2001). *

• Stieger B. Recent insights into the function and regulation of the bile salt export pump (ABCB11). Curr. Opin. Lipidol. 20: 176-181 (2009).

• Stintzing S, Neureiter D, Hahn EG, Wiest GH. A 53 year old woman presenting with proteinases inhibitor deficiency and liver cirrhosis without any sign of emphysema. Dtsch. Med. Wochenschr. 130: 2823-2825 (2005).

• Strassburg CP. Molecular characterization of autoantigens in liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 30. September 12 - 13 (2003). *

• Strassburg CP. The role of microsomal antigens in autoimmune hepatitis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 35 (2004). *

• Strassburg CP, Alex B, Zindy F, Gerken G, Luttig B, Meyer zum Buschenfelde KH, Brechot C, Manns MP. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J. Hepatol. 25: 859-866 (1996).

• Strassburg CP, Lankisch TO, Manns MP, Ehmer U. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch. Toxicol. 82: 415-433 (2008). *

• Strassburg CP, Manns MP. Chapter 8. Prevalence and significance of autoantibodies in acute and chronic liver diseases and hepatocellular carcinoma. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 95-110 (2007). *

• Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerova D, Rayner A, Dutton L, Meier Y, Antoniou A, Stieger B, Arnell H, Ozcay F, Al-Hussaini HF, Bassas AF, Verkade HJ, Fischler B, Nemeth A, Kotalova R, Shneider BL, Cielecka-Kuszyk J, McClean P, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134: 1203-1214 (2008). *

• Stroescu C, Herlea V, Dragnea A, Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J. Gastrointestin. Liver Dis. 15: 9-14 (2006). *

• Strunk HM. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma. Hepatology 50: 652-653 (2009).

• Studach LL, Rakotomalala L, Wang WH, Hullinger RL, Cairo S, Buendia MA, Andrisani OM. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Hepatology 50: 414-423 (2009).

• Su CW, Wu JC, Chiou YY, Tsay SH, Huo TI, Huang YH, Hung HH, Lin HC, Lee SD. Successful radiofrequency ablation therapy for hepatocellular carcinoma in a male patient with early stage primary biliary cirrhosis and positive serum hepatitis B core antibody. J. Chin. Med. Assoc. 71: 40-44 (2008).

• Suga T. Hepatocarcinogenesis by peroxisome proliferators. J. Toxicol. Sci. 29: 1-12 (2004). *

• Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T. The expressions of cytochrome P450, UDP-glucuronosyltranferase and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice. Drug Metab. Dispos. Dec 14 [Epub ahead of print] (2009). *

• Sugeno H, Takebayashi Y, Higashimoto M, Ogura Y, Shibukawa G, Kanzaki A, Terada K, Sugiyama T, Watanabe K, Katoh R, Nitta Y, Fukushima T, Koyama Y, Inoue N, Sekikawa K, Ogawa K, Sato Y, Takenoshita S. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma. Anticancer Res. 24: 1045-1048 (2004).

• Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: the convergence of epidemiology and treatment effectiveness. J. Hepatol. 50: 655-658 (2009).

• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol. Res. 39: 213-222 (2009).

• Sun J, Xu HM, Zhou HJ, Dong QZ, Zhao Y, Fu LY, Hei ZY, Ye QH, Ren N, Jia HL, Qin LX. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. Jul 11 [Epub ahead of print] (2009).

• Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51: 545-556 (2010).

• Sun X, Rokuhara A, Tanaka E, Gad A, Mutou H, Matsumoto A, Yoshizawa K, Kiyosawa K. Nucleotide mutations associated with hepatitis B e antigen negativity. J. Med. Virol. 76: 170-175 (2005). *

• Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol. 22: 1387-1398 (2007). *

• Sunagawa H, Takayama H, Yamashiro T, Sasaki H, Sashida Y, Matsuura K, Kayou M. Hepatocellular carcinoma in a patient with primary biliary cirrhosis and seronegativity for markers of hepatitis B virus and hepatitis C virus: report of a case. Surg. Today 33: 219-223 (2003). *

• Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, Tsai KS, Yu MW. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 137: 1687-1697 (2009). *

• Suriawinata A, Fiel MI. Liver pathology in obesity. Semin. Liver Dis. 24: 363-370 (2004).

• Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin. Liver Dis. 24: 77-88 (2004).

• Sutcliffe R, Maguire D, Murphy P, Portmann B, Rela M, O'Sullivan G, Mufti G, Heaton N. Detection and clinical significance of bone marrow micrometastases in patients undergoing liver transplantation for hepatocellular carcinoma. Transplantation 80: 88-94 (2005).

• Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Hopfner M, Krahn A, Heine B, Stein H, Somasundaram R, Schuppan D, Zeitz M, Scherubl H. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J. Hepatol. 41: 799-807 (2004). *

• Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor J. Hepatol. 43: 808-816 (2005). *

• Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 5: 259-264 (2007).

• Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int. 28: 1052-1064 (2008). *

• Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 565-580 (2009).

• Szalay F, Hantos MB, Horvath A, Lakatos PL, Folhoffer A, Dunkel K, Hegedus D, Tekes K. Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma. World J. Gastroenterol. 10: 42-45 (2004). *

• Tabibian JH, Landaverde C, Winn J, Geller SA, Nissen NN. Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis. Ann. Hepatol. 8: 64-67 (2009).

• Tabone M, Vigano L, Laudi C, Ferrero A, Pellerito R, Capussotti L. Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: which is the best treatment schedule? Hepatology 41: 1433 (2005). *

• Taddei T, Mistry P, Schilsky ML. Inherited metabolic disease of the liver. Curr. Opin. Gastroenterol. 24: 278-286 (2008).

• Tagger A, Ribero ML, Larghi A, Donato F, Zuin M, Chiesa R, Benetti G, Ramella G, Borzio M, Podda M. Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. Am. J. Gastroenterol. 94: 484-488 (1999). *

• Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 49: 1859-1867 (2009).

• Takahashi A, Saito H, Takahashi Y, Sato A, Takagi T, Irisawa A, Sakuma F, Kuroda M, Tsuchiya T, Ohira H. Cyst-like extension of hepatic subcapsular bleeding caused by ruptured hepatocellular carcinoma into the bursa omentalis. Hepatol. Res. 39: 1010-1014 (2009). *

• Takai H, Kato A, Kato C, Watanabe T, Matsubara K, Suzuki M, Kataoka H. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int. 29: 1056-1064 (2009). *

• Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol. Res. 39: 223-230 (2009). *

• Takami T, Terai S, Yokoyama Y, Tanimoto H, Tajima K, Uchida K, Yamasaki T, Sakaida I, Nishina H, Thorgeirsson SS, Okita K. Human homologue of maid is a useful marker protein in hepatocarcinogenesis. Gastroenterology 128: 1369-1380 (2005). *

• Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and PPAR alpha-null mice. J. Occup. Health 50: 169-180 (2008). *

• Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Yamashita T, Takamura H, Ohta T, Zen Y, Kaneko S. dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma. Liver Int. Nov 30 [Epub ahead of print] (2009).

• Takayama S, Takahashi H, Matsuo Y, Okada Y, Takeyama H. Effect of Helicobacter bilis infection on human bile duct cancer cells. Dig. Dis. Sci. Sep 3 [Epub ahead of print] (2009).

• Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469 (2006). *

• Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med. Okayama 56: 317-320 (2002). *

• Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Maehara Y. Living donor liver transplantation for the patient with hepatocellular carcinoma. Gan To Kagaku Ryoho 31: 2118-2121 (2004).

• Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr. Drug Targets 9: 1013-1024 (2008).

• Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S126-S132 (2004). *

• Tameda M, Shiraki K, Ooi K, Takase K, Kosaka Y, Nobori T, Tameda Y. Aspartate aminotransferase-immunoglobulin complexes in patients with chronic liver disease. World J. Gastroenterol. 11: 1529-1531 (2005). *

• Tan MG, Ooi LL, Aw SE, Hui KM. Cloning and identification of HDMCP, a novel liver-specific uncoupling protein that is downregulated in human hepatocellular carcinoma. J. Biol. Chem. 279: 45235-45244 (2004). *

• Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, Lee SD. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: n-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 43: 690-697 (2006). *

• Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep. 18: 1225-1230 (2007). *

• Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299: 53-60 (2008). *

• Tanaka N, Aoyama T. Possible mechanisms of hepatitis C virus-related hepatocarcinogenesis. Nippon Rinsho 62: 2137-2144 (2004).

• Tanaka S, Yamamoto T, Tanaka H, Kodai S, Ogawa M, Ichikawa T, Hai S, Sakabe K, Uenishi T, Shuto T, Kubo S. Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: immunohistochemical evidence. Hepatol. Res. 32: 52-57 (2005).

• Tanaka Y, Naitoh M, Yoshiura K, Ookubo K, Uegaki S, Matsumoto K, Sawabe M, Esaki Y, Kino K, Tsuru M, Fukazawa T, Takubo K. Hepatocellular carcinoma arising in an elderly male with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 12: 239-241 (2000).

• Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 29: 502-510 (2009). *

• Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y, Guan XY. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Tang KS, Lee CM, Teng HC, Huang MJ, Huang CS. UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis. Biochem. Biophys. Res. Commun. 366: 643-648 (2008). *

• Tanggo Y, Fujiyama S, Kin F, Tashiro A, Shiraoku H, Akahoshi M, Sato Y, Hashiguchi O, Sagara K. Clinical usefulness of serum cholylglycine determination in various liver diseases. Gastroenterol. Jpn. 17: 447-452 (1982).

• Tanwar S, Khan SA, Grover VP, Gwilt C, Smith B, Brown A. Liver transplantation for hepatocellular carcinoma. World J. Gastroenterol. 15: 5511-5516 (2009). *

• Taouli B, Losada M, Holland A, Krinsky G. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S144-S152 (2004). *

• Tapuria N, Sinha CK, Michael NG, Fisher PW. Haematogenous metastasis to ascending colon in a patient with hepatocellular carcinoma and autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol. 19: 607-609 (2007).

• Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44: 1518-1527 (2006). *

• Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54: 419-425 (2005). *

• Tatrai P, Dudas J, Batmunkh E, Mathe M, Zalatnai A, Schaff Z, Ramadori G, Kovalszky I. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab. Invest. 86: 1149-1160 (2006). *

• Taylor NS, Xu S, Nambiar P, Dewhirst FE, Fox JG. Enterohepatic Helicobacter species are prevalent in mice from commercial and academic institutions in Asia, Europe, and North America. J. Clin. Microbiol. 45: 2166-2172 (2007). *

• Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48: 816-820 (2001). *

• Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127 (5 Suppl. 2): S283-S293 (2004). *

• Teoh N, Pyakurel P, Dan YY, Swisshelm K, Hou J, Mitchell C, Fausto N, Gu Y, Farrell G. Induction of p53 renders ATM deficient mice refractory to hepatocarcinogenesis. Gastroenterology Nov 14 [Epub ahead of print] (2009). *

• ter Borg PJC, van Buuren HR, van Berge Henegouwen GR. Extra-hepatic disorders in patients with primary biliary cirrhosis (PBC) Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 36. October 15-16 (2003). *

• Terada T, Terasaki S, Nakanuma Y. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer 72: 1551-1556 (1993).

• Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol. Res. 38 (s1: The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S72-S75 (2008). *

• Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13: 2271-2282 (2007). *

• Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J. Gastroenterol. 15: 578-582 (2009). *

• Theise ND, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. Hepatology 16: 949-955 (1992).

• Thenappan A, Li Y, Kitisin K, Rashid A, Shetty K, Johnson L, Mishra L. Role of transforming growth factor beta signaling and expansion of progenitor cells in regenerating liver. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Theve EJ, Feng Y, Taghizadeh K, Cormier KS, Bell DR, Fox JG, Rogers AB. Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus. Infect. Immun. 76: 4071-4078 (2008). *

• Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49: S138-S145 (2009).

• Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801 (2009). *

• Thompson R. Genetics of hereditary cholestatic and metabolic liver diseases. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 41 (2006). *

• Thorgeirsson SS. Genomic decoding of hepatocellular carcinoma. Gastroenterology 131: 1344-1346 (2006). *

• Thorgeirsson SS. Outfoxing liver cancer with p19(ARF) tumor suppressor? Hepatology 40: 1010-1012 (2004). *

• Thorgeirsson SS. Microarrays for liver diseases. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 15 (2006). *

• Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology 43: S145-S150 (2006). *

• Thudi KR, Kreikemeier JT, Phillips NJ, Salvalaggio PR, Kennedy DJ, Hayashi PH. Cat scratch disease causing hepatic masses after liver transplant. Liver Int. 27: 145-148 (2007). *

• Thuluvath PJ. Should we change the selection criteria for liver transplantation in patients with hepatocellular carcinoma? 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, Manns MP, Kubicka S. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther. 7: 1315-1323 (2000).

• Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 148-155 (2005). *

• Tirotta D, Durante V. An unusual complication of hepatocellular carcinoma: the pleurobiliary fistula. Recenti Prog. Med. 100: 84-86 (2009).

• Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. 14: 1741-1748 (2008). *

• Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology Jan 23 [Epub ahead of print] (2010). *

• Togni R, Bagla N, Muiesan P, Miquel R, O'Grady J, Heaton N, Knisely AS, Portmann B, Quaglia A. Microsatellite instability in hepatocellular carcinoma in non-cirrhotic liver in patients older than 60 years. Hepatol. Res. 39: 266-273 (2009). *

• Tokushige K. Diagnosis and therapy in NASH. Rinsho Byori 57: 848-853 (2009).

• Tokushige K, Hashimoto E, Noto H, Yatsuji S, Tobari M, Torii N, Taniai M, Shiratori K, Murayama H. Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis. Hepatol. Res. 39: 939-943 (2009). *

• Tolia V, Nilsson HO, Boyer K, Wuerth A, Al-Soud WA, Rabah R, Wadstrom T. Detection of Helicobacter ganmani-like 16S rDNA in pediatric liver tissue. Helicobacter 9: 460-468 (2004). *

• Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther. Clin. Risk Manag. 3: 1153-1163 (2007). *

• Tomasi ML, Iglesias-Ara A, Yang H, Ramani K, Feo F, Pascale MR, Luz Martínez-Chantar M, Mato JM, Lu SC. S-Adenosylmethionine regulates apurinic/apyrimidinic endonuclease 1 stability: implication in hepatocarcinogenesis. Gastroenterology 136: 1025-1036 (2009). *

• Torimura T, Ueno T, Kin M, Taniguchi E, Nakamura T, Inoue K, Sakata R, Hashimoto O, Sakamoto M, Ohira H, Kumashiro R, Sata M, Yano H, Kojiro M, Veitonmaki N, Cao Y. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology 130: 1301-1310 (2006). *

• Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698 (2008). *

• Tortorella C, Sacco R, Orlando P, Salerno MT, Schiraldi O, Antonaci S. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. Immunopharmacol. Immunotoxicol. 22: 19-33 (2000).

• Torzilli G. Surgical technique: new advancements for expanding indications and safety: the Western experience. J. Hepatobiliary Pancreat. Surg. Nov 7 [Epub ahead of print] (2009). *

• Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 49: 832-838 (2009). *

• Tovar V, Villanueva A, Llovet JM. Cell biology and genetics in liver cancer. Gastroenterol. Hepatol. 30: 360-369 (2007).

• Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 4: 111-117 (2006). *

• Tran TT. Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trauner M, Fickert P, Moustafa T, Guelly C, Fuchsbichler A, Denk H, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from nor-ursodeoxycholic acid. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 77-78 (2006). *

• Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F; Mauro Bernardi for the Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am. J. Gastroenterol. 99: 1470-1476 (2004). *

• Trevisani F, Magini G, Santi V, Morselli-Labate AM, Chiara Cantarini M, Anna Di Nolfo M, Del Poggio P, Benvegnu L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; for the Italian Liver Cancer (ITA LI.CA) Group. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am. J. Gastroenterol. 102: 1022-1031 (2007). *

• Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM. Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig. Dis. Sci. Jan 27 [Epub ahead of print] (2010). *

• Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582 (2009).

• Tsai WL, Cheng JS, Lai KH, Lin CP, Lo GH, Hsu PI, Yu HC, Lin CK, Chan HH, Chen WC, Chen TA, Li WL, Liang HL. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study. Aliment. Pharmacol. Ther. 28: 304-311 (2008). *

• Tseng CS , Tang KS, Lo HW, Ker CG, Teng HC, Huang CS. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am. J. Gastroenterol. 100: 1758-1763 (2005). *

• Tseng TL, Shih YP, Huang YC, Wang CK, Chen PH, Chang JG, Yeh KT, Chen YM, Buetow KH. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res. 63: 647-654 (2003). *

• Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto M, Aoyagi Y. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 24: 432-436 (2004). *

• Tsuchiya A, Kamimura H, Takamura M, Yamagiwa S, Matsuda Y, Sato Y, Nomoto M, Ichida T, Aoyagi Y. Clinicopathological analysis of CD133(+) and NCAM(+) human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol. Res. 39: 1080-1090 (2009). *

• Tsuchiya H, Akechi Y, Ikeda R, Nishio R, Sakabe T, Terabayashi K, Matsumi Y, Ashla AA, Hoshikawa Y, Kurimasa A, Suzuki T, Ishibashi N, Yanagida S, Ganz T, Shiota G. Suppressive effects of retinoids on iron-induced oxidative stress in the liver. Gastroenterology 136: 341-350.e8 (2009). *

• Tsunematsu S, Saito H, Tada S, Ebinuma H, Tsuchiya M, Kumagai N, Morizane T, Nomura T, Ishii H. Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. J. Gastroenterol. Hepatol. 12: 319-324 (1997).

• Tsuneoka Y, Fukushima K, Matsuo Y, Ichikawa Y, Watanabe Y. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci. 59: 1711-1715 (1996). *

• Tu QV, Okoli AS, Kovach Z, Mendz GL. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol. 4: 1283-1301 (2009).

• Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am. J. Gastroenterol. Jan 5 [Epub ahead of print] (2010). *

• Turissini SB, Kaplan MM. Hepatocellular carcinoma in primary biliary cirrhosis. Am. J. Gastroenterol. 92: 676-678 (1997).

• Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl. Acad. Sci. U.S.A. 104: 14771-14776 (2007). *

• Uchida Y, Watanabe M. Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis. Gastroenterol. Jpn. 28: 666-672 (1993).

• Uchimura S, Iizuka N, Tamesa T, Miyamoto T, Hamamoto Y, Oka M. Resampling based on geographic patterns of hepatitis virus infection reveals a common gene signature for early intrahepatic recurrence of hepatocellular carcinoma. Anticancer Res. 27: 3323-3330 (2007).

• Uehara T, Hirooka M, Kisaka Y, Abe M, Hiasa Y, Onji M. Usefulness of the hyperechoic rim for assessing the therapeutic efficacy of radiofrequency ablation in hepatocellular carcinoma patients. Hepatol. Res. 39: 954-962 (2009). *

• Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J. Surg. Oncol. 98: 358-362 (2008).

• Umar RK, Rinella ME. An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98 (2006). *

• Underner M, Hadjadj S, Beauchant M, Bridoux F, Debiais F, Meurice JC. Effects of smoking on the thyroid gland, digestive system, kidney and bone. Rev. Mal. Respir. 25: 1261-1278 (2008).

• Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45: 246-253 (2006). *

• Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41: 722-730 (2005). *

• Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112 (2009).

• Urbani L, Mazzoni A, Catalano G, De Simone P, Vanacore R, Pardi C, Bortoli M, Biancofiore G, Campani D, Perrone V, Mosca F, Scatena F, Filipponi F. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant. Proc. 36: 3068-3070 (2004). *

• Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol. Res. 32: 235-242 (2005).

• Valgimigli M, Valgimigli L, Trere D, Gaiani S, Pedulli GF, Gramantieri L, Bolondi L. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic. Res. 36: 939-948 (2002).

• Valla DC. Primary Budd-Chiari syndrome. J. Hepatol. 50: 195-203 (2009). *

• Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand. J. Gastroenterol. 32: 77-83 (1997).

• van der Putten AB, Bijleveld CM, Slooff MJ, Wesenhagen H, Gips CH. Selection criteria and decisions in 375 patients with liver disease, considered for liver transplantation during 1977-1985. Liver 7: 84-90 (1987).

• van Hengel J, D'Hooge P, Hooghe B, Wu X, Libbrecht L, De Vos R, Quondamatteo F, Klempt M, Brakebusch C, van Roy F. Continuous cell injury promotes hepatic tumorigenesis in Cdc42-deficient mouse liver. Gastroenterology 134: 781-792 (2008). *

• van Leeuwen DJ, Reeders JW. Primary sclerosing cholangitis and cholangiocarcinoma as a diagnostic and therapeutic dilemma. Ann. Oncol. 10 Suppl. 4: 89-93 (1999).

• Van Thiel DH, Colantoni A, De Maria N. Liver transplantation for hepatocellular carcinoma? Hepatogastroenterology 45: 1944-1949 (1998).

• Van Thiel DH, Yong S, Li SD, Kennedy M, Brems J. The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods. Liver Transpl. 10: 631-637 (2004). *

• Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F, Roskams T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 28: 1370-1380 (2008). *

• Vanlemmens C, Miguet JP, Bresson-Hadni S. Liver transplantation in adults. Indications and results. Presse. Med. 25: 1952-1960 (1996).

• Varela M, Bruix J. Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. J. Hepatol. 44: 8-10 (2006). *

• Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res. 11: 8441-8448 (2005). *

• Varnholt H. The role of microRNAs in primary liver cancer. Ann. Hepatol. 7: 104-113 (2008). *

• Vassilios P, Filippou D, Manolis E, Mimidis K. Haemostasis impairment in patients with obstructive jaundice. J. Gastrointestin. Liver Dis. 16: 178-186 (2007). *

• Vauthey JN, Lauwers GY. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest? J. Hepatol. 38: 237-239 (2003). *

• Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 117: 154-160 (1999). *

• Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J. Hepatol. 40: 212-218 (2004). *

• Vazquez-Chantada M, Fernandez-Ramos D, Embade N, Martinez-Lopez N, Varela-Rey M, Woodhoo A, Luka Z, Wagner C, Anglim PP, Finnell RH, Caballería J, Laird-Offringa IA, Gorospe M, Lu SC, Mato JM, Martínez-Chantar ML. HuR/Methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation and carcinogenesis. Gastroenterology Jan 23 [Epub ahead of print] (2010). *

• Veldhuijzen IK, Toy M, Hahne SJ, de Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 138: 522-530 (2010). *

• Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47: 1856-1862 (2008). *

• Vennarecci G, Ettorre GM, Boschetto A, Carboni F, Lepiane P, Lonardo MT, Santoro R, Santoro E. Liver transplantation in primary and secondary tumors of the liver. Review of the literature and perspectives. Chir. Ital. 55: 797-810 (2003).

• Ventura-Holman T, Mamoon A, Subauste JS. Modulation of expression of RA-regulated genes by the oncoprotein v-erbA. Gene 425: 23-27 (2008). *

• Vere CC, Streba CT, Streba LM, Ionescu AG, Sima F. Psychosocial stress and liver disease status. World J. Gastroenterol. 15: 2980-2986 (2009). *

• Verhoef C, Pot RG, de Man RA, Zondervan PE, Kuipers EJ, IJzermans JN, Kusters JG. Detection of identical Helicobacter DNA in the stomach and in the non-cirrhotic liver of patients with hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 15: 1171-1174 (2003).

• Verwer BJ, Bouma G, Bloemena E, Schreuder TC, Mulder CJ, van Nieuwkerk KM. Diagnosis and treatment of autoimmune hepatitis. Ned. Tijdschr. Geneeskd. 153: A247 (2009).

• Vij K, Wang HL. Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence. Int. J. Surg. Pathol. 16: 194-198 (2008).

• Vik-Mo AO, Ferno J, Skrede S, Steen VM. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol. 9: 10 (2009). *

• Vilgrain V, Lewin M, Vons C, Denys A, Valla D, Flejou JF, Belghiti J, Menu Y. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 210: 443-450 (1999). *

• Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu. Rev. Med. 61: 317-328 (2010). *

• Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27: 55-76 (2007). *

• Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol. 20: 444-453 (2008).

• Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr. Drug Metab. 5: 273-282 (2004).

• Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134: 268-280 (2008). *

• Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J. Clin. Pathol. 60: 1378-1383 (2007).

• Vitale A, Brolese A, Zanus G, Bassanello M, Montin U, Gringeri E, D'Amico F, Ciarleglio FA, Carraro A, Cappuzzo G, Bridda A, D'Amico DF, Cillo U. Multimodal therapy before liver transplantation for hepatocellular carcinoma. Hepatol. Res. 31: 112-115 (2005).

• Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51: 165-173 (2010).

• Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann. Hepatol. 8: 89-94 (2009). *

• Voiculescu M, Winkler RE, Moscovici M, Neuman MG. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J. Gastrointestin. Liver Dis. 17: 315-322 (2008). *

• Volk ML, Lok AS. Is family history of liver cancer a risk factor for hepatocellular carcinoma? J. Hepatol. 50: 247-248 (2009).

• Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H, Galle PR. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9: 195-204 (1994).

• Waalkes MP, Liu J, Chen H, Xie Y, Achanzar WE, Zhou YS, Cheng ML, Diwan BA. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J. Natl. Cancer Inst. 96: 466-474 (2004). *

• Wagman LD, Robertson JM, O'Neil B. Chapter 15. Liver, gallbladder, and biliary tract cancers. In "Cancer Management: A Multidisciplinary Approach" (Wagman L, Venook AP, Robertson JR, O’Neil BH eds.), Fifth Edition, p. 303-321 (2001). *

• Wakai T, Shirai Y, Tsukada K, Aono T, Kurosaki I, Hatakeyama K. Hepatocellular carcinoma associated with precirrhotic primary biliary cirrhosis successfully treated by a right hepatic lobectomy: report of a case. Surg. Today 26: 723-726 (1996).

• Wall WJ. Liver transplantation for hepatic and biliary malignancy. Semin. Liver Dis. 20: 425-436 (2000). *

• Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim. Biophys. Acta 1790: 663-670 (2009). *

• Wands J. Hepatocellular carcinoma and sex. N. Engl. J. Med. 357: 1974-1976 (2007). *

• Wang B, Cheng LJ, Gao ZN, Zhang XY, Huo M, Zhang DJ, Wu J, Wei MF. Activation of liver X receptor regulates fatty acid synthase expression in diabetic liver. Zhonghua Yi Xue Za Zhi 88: 848-852 (2008).

• Wang B, Feng P, Xiao Z, Ren EC. LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J. Hepatol. 50: 528-537 (2009).

• Wang C, Zhang T, Song S, Xiu D, Jiang B. Liver transplant with portocaval hemitransposition: blood supply with only hepatic artery is possible? Transplant. Proc. 37: 2163-2165 (2005). *

• Wang CW, Lin ZY, Chuang WL, Wang LY, Yu ML, Chen SC, Hsieh MY, Tsai JF, Chang WY. Safety of fine-needle aspiration in patients with small hepatocellular carcinoma. Hepatol. Res. 31: 31-35 (2005).

• Wang H, Chen XP, Qiu FZ. Correlation of expression of multidrug resistance protein and messenger RNA with (99m)Tc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J. Gastroenterol. 10: 1281-1285 (2004). *

• Wang H, Dai J, Hou S, Qian W, Li B, Ma J, Fan X, Zhao J, Yang S, Sang H, Yang Q, Wang R, Guo Y. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy. Cancer Gene Ther. 12: 769-777 (2005).

• Wang H, Gao Y, Jin X, Xiao J. Expression of contactin associated protein-like 2 in a subset of hepatic progenitor cell compartment identified by gene expression profiling in hepatitis B virus-positive cirrhosis. Liver Int. 30: 126-138 (2010). *

• Wang J, Chan JY, Fong CC, Tzang CH, Fung KP, Yang M. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int. 29: 1338-1347 (2009). *

• Wang JH, Lu SN, Hung CH, Chen TY, Chen CH, Changchien CS, Lee CM. Small hepatic nodules (less than or = 2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int. 26: 928-934 (2006). *

• Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 8: 1679-1683 (1988).

• Wang L, Levin MS. Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma. Gastroenterology 128: 228-231 (2005). *

• Wang NY, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyltransferase. Hepatol. Res. 39: 979-987 (2009). *

• Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 50: 1392-1402 (2009).

• Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J. Hepatol. 41: 267-273 (2004). *

• Wang XQ, Miao X, Cai Q, Garcia-Barcelo MM, Fan ST. SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population. Exp. Oncol. 29: 71-73 (2007).

• Wang XW, Thorgeirsson SS. Transcriptome analysis of liver cancer: ready for the clinic? J. Hepatol. 50: 1062-1064 (2009). *

• Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum. Pathol. 37: 1435-1441 (2006).

• Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J. Chin. Med. Assoc. 66: 593-598 (2003).

• Wanless IR. The pathogenesis of focal nodular hyperplasia of the liver. J. Gastroenterol. Hepatol. 19: S342-S343 (2004). *

• Wanless IR. Pathology and nomenclature of early hepatocellular neoplasia. J. Gastroenterol. Hepatol. 19: S361-S363 (2004). *

• Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schaffler A, Krempl C, Bleyl C, Aslanidis C, Scholmerich J, Buechler C. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NFkappaB, and STAT3 signalling pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G611-G618 (2009). *

• Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ Jr, Gorelick PL, Nagashima K, Gonda MA, Gilden RV, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl. Cancer Inst. 86: 1222-1227 (1994).

• Ward SC, Deniz K, Roayaie S, Qin L. Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin. Liver Dis. 28: 123-127 (2008).

• Ward SC, Thung SN, Lim KH, Tran TT, Hong TK, Hoang PL, Jang JJ, Park YN, Abe K. Hepatic progenitor cells in liver cancers from Asian children. Liver Int. 30: 102-111 (2010). *

• Watanabe T, Aikawa K, Kanefuji T, Yamazaki K, Hirono H, Hasegawa K, Soga K, Shibasaki K, Umezu H, Nomoto M. Pelioid-type hepatocellular carcinoma with numerous eosinophilic infiltrations in a patient with primary biliary cirrhosis. Hepatol. Res. 38: 421-427 (2008). *

• Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H, Aoyagi Y. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J. Gastroenterol. 15: 231-239 (2009). *

• Watanabe Y, Mori S, Fujiyama S, Sato T, Mori M. Clinical evaluation of serum ornithine carbamoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 48: 18-26 (1995).

• Waxman DJ. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. J. Endocrinol. 150: S129-S147 (1996).

• Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, Schuchmann M, Heikenwalder M, Schulze-Bergkamen H. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Weber S, Gressner OA, Hall R, Grunhage F, Lammert F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin. Liver Dis. 12: 747-757, vii (2008).

• Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl. Immunohistochem. Mol. Morphol. 14: 266-272 (2006).

• Wee A, Ludwig J, Coffey RJ Jr, LaRusso NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum. Pathol. 16: 719-726 (1985).

• Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol. 14: 193-199 (2008). *

• Weill BJ, Menkes CJ, Cormier C, Louvel A, Dougados M, Houssin D. Hepatocellular carcinoma after danazol therapy. J. Rheumatol. 15: 1447-1449 (1988).

• Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK, Yang SF. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann. Surg. Oncol. Jan 30 [Epub ahead of print] (2010).

• Weng YQ, Qiu SJ, Tang ZY, Gao Q, Wang KF, Song LJ, Ye SL, Liu YK, Fan J. Relation between changes of dendritic cell function and down-regulation of beta-centractin in hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 87: 2050-2053 (2007).

• Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, Bergquist A, Sandberg-Gertzen A, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J. Hepatol. 50: 388-393 (2009).

• Werth M, Gebhardt R, Gaunitz F. Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors. Hepatology 44: 967-975 (2006). *

• West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br. J. Cancer 94: 1751-1758 (2006). *

• Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin. Med. 7: 119-124 (2007).

• Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 134-141 (1994).

• Wiesner RH. Patient selection in an era of donor liver shortage: current US policy. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 24-30 (2005). *

• Wiesner RH. Indications. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 109-110. October 17 - 19 (2003). *

• Wilkens L, Bredt M, Flemming A, Mengel M, Klempnauer J, Kreipe H, Flemming P. Detection of chromosomal aberrations in well-differentiated hepatocellular carcinoma by bright-field in situ hybridization. Mod. Pathol. 15: 470-475 (2002).

• Williams R. Global challenges in liver disease. Hepatology 44: 521-526 (2006). *

• Williams R, MacDougall BR, Calne RY. The indications for and results of liver transplantation. Ann. Acad. Med. Singapore 9: 274-279 (1980).

• Williams SM, Harned RK. Hepatobiliary complications of inflammatory bowel disease. Radiol. Clin. North Am. 25: 175-188 (1987).

• Willis G, Bardsley V, Fellows IW, Lonsdale R, Wimperis JZ, Jennings BA. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol. 5: 17 (2005). *

• Wilson SR, Burns PN. Liver mass evaluation with ultrasound: the impact of microbubble contrast agents and pulse inversion imaging. Semin. Liver Dis. 21: 147-159 (2001).

• Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82: 373-384 (2003).

• Wolke AM, Schaffner F, Kapelman B, Sacks HS. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am. J. Med. 76: 1075-1078 (1984).

• Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49: 1583-1594 (2009).

• Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45: 1129-1138 (2007). *

• Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am. J. Gastroenterol. 100: 2205-2211 (2005). *

• Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res. 69: 4059-4066 (2009). *

• Wortham M, He L, Gyamfi M, Copple BL, Wan YJ. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 53: 2761-2774 (2008). *

• Wrede CE, Hutzler S, Bollheimer LC, Buettner R, Hellerbrand C, Schoelmerich J, Palitzsch KD. Correlation between iron status and genetic hemochromatosis (codon C282Y) in a large German population. Isr. Med. Assoc. J. 6: 30-33 (2004). *

• Wu CS, Hu CY, Hsu PN. Anti-SSB/La antibody is negatively associated with HLA-DR2 in chronic hepatitis C infection. Clin. Rheumatol. 27: 365-368 (2008).

• Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 50: 1839-1850 (2009).

• Wu J, Maluccio M. Autotaxin expression connected with TNF-alpha-NF-kappaB axis selectively in inflammation-associated hepatocellular carcinoma. J. Surg. Res. 158: 390 (2010).

• Wu J, Zheng SS. Liver transplantation in China: problems and their solutions. Hepatobiliary Pancreat. Dis. Int. 3: 170-174 (2004). *

• Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J. Hepatol. 51: 890-897 (2009).

• Wu JC, Sun BS, Ren N, Ye QH, Qin LX. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J. Cancer Res. Clin. Oncol. Oct 16 [Epub ahead of print] (2009). *

• Wu LH, Shi BZ, Zhao LQ, Wu XZ. Fucosylated glycan inhibition of human hepatocellular carcinoma cell migration through binding to chemokine receptors. Glycobiology Nov 1 [Epub ahead of print] (2009).

• Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, Liu XC, Zhou L, Xu XB, Sun YL, Zheng SS. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin. Genet. 73: 273-278 (2008). *

• Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am. J. Pathol. 149: 1167-1175 (1996).

• Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y. FGF19 induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. Dec 15 [Epub ahead of print] (2009). *

• Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-947 (2007). *

• Xia M, Zhang JQ, Shen YQ, Xu LH, Chen AQ, Miao FQ, Xie W. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma. Tissue Antigens 70: 272-282 (2007). *

• Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q, Zhang Z. Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J. Cancer Res. Clin. Oncol. Aug 30 [Epub ahead of print] (2009).

• Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J. Gastroenterol. 10: 376-380 (2004). *

• Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS, Nam SW. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 56: 136-140 (2009).

• Xie XW, Mei MH, Liao WJ, Qian LH, Yu X, Fei R, Qin LL, Zhang HH, Peng JR, Shen DH, Wei L, Chen HS. Expression of CIITA-related MHCII molecules in tumors linked to prognosis in hepatocellular carcinoma. Int. J. Oncol. 34: 681-688 (2009).

• Xiong XD, Fang JH, Qiu FE, Zhao J, Cheng J, Yuan Y, Li SP, Zhuang SM. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutat. Res. 643: 70-74 (2008).

• Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology Oct 19 [Epub ahead of print] (2009).

• Xu L, Han C, Lim K, Wu T. Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A2alpha/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 66: 11859-11868 (2006). *

• Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, Ji Y, Wu X, Han Z, Hu G. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 61: 3176-3181 (2001). *

• Xu N, Yao HP, Sun Z, Chen Z. Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol. Sin. 29: 239-244 (2008).

• Xu R, Bu-Ghanim M, Fiel MI, Schiano T, Cohen E, Thung SN. Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease. Semin. Liver Dis. 27: 122-127 (2007). *

• Xu R, Mistry P, McKenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel MI. Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin. Liver Dis. 25: 226-229 (2005).

• Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, Yang JR, Su H, Zhuang SM. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29: 2126-2131 (2008). *

• Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G(1)/S transition of human hepatocellular carcinoma cells. Hepatology 50: 113-121 (2009).

• Xu X, Xing B, Hu M, Xu Z, Xie Y, Dai G, Gu J, Wang Y, Zhang Z. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy. Cytotherapy Nov 24 [Epub ahead of print] (2009).

• Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl. Acad. Sci. U.S.A. 98: 15089-15094 (2001). *

• Yaghi C, Sharara AI, Rassam P, Moucari R, Honein K, Boujaoude J, Slim R, Noun R, Abdul-Baki H, Khalifeh M, Ramia S, Sayegh R. Hepatocellular carcinoma in Lebanon: etiology and prognostic factors associated with short-term survival. World J. Gastroenterol. 12: 3575-3580 (2006). *

• Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin. Biochem. 40: 651-655 (2007). *

• Yam JW, Ko FC, Chan CY, Yau TO, Tung EK, Leung TH, Jin DY, Ng IO. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 44: 881-890 (2006). *

• Yamashiki N, Gaynor JJ, Kato T, Reddy KR, Sobhonslidsuk A, Levi D, Nishida S, Madariaga J, Nery J, Schiff ER, Tzakis AG. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am. J. Transplant. 4: 774-781 (2004).

• Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J, Matsui Y, Togashi J, Akahane M, Makuuchi M, Omata M, Kokudo N. Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Yamashiki N, Tateishi R, Yoshida H, Shiina S, Teratani T, Sato S, Mine N, Kondo Y, Kawabe T, Omata M. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. Liver Transpl. 11: 508-514 (2005). *

• Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 50: 100-110 (2009). *

• Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024.e4 (2009). *

• Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int. J. Mol. Med. 11: 601-605 (2003).

• Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol. 18: 1591-1598 (2005). *

• Yan HX, Wang HY, Zhang R, Chen L, Li BA, Liu SQ, Cao HF, Qiu XH, Shan YF, Yan ZH, Wu HP, Tan YX, Wu MC. Negative regulation of hepatocellular carcinoma cell growth by signal regulatory protein alpha1. Hepatology 40: 618-628 (2004). *

• Yan LN. Current status and prospect of liver transplantation for hepatocellular carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27: 427-430 (2005).

• Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 121: 2301-2306 (2007). *

• Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, Hashiguchi K, Kanbe T, Saeki T, Ichiba M, Tanabe Y, Yoshida Y, Morino S, Kurimasa A, Usuda N, Yamazaki H, Kunisada T, Ito H, Murawaki Y, Shiota G. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 40: 366-375 (2004). *

• Yang DH, Huang W, Cui J, Shu JC, Tang SH, Zhang WJ, Liang JH. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 3: 86-89 (2004). *

• Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67: 863-867 (2007). *

• Yang H, Ara AI, Magilnick N, Xia M, Ramani K, Chen H, Lee TD, Mato JM, Lu SC. Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. Gastroenterology 134: 281-291 (2008). *

• Yang H, Sadda MR, Yu V, Zeng Y, Lee TD, Ou X, Chen L, Lu SC. Induction of human methionine adenosyltransferase 2A expression by tumor necrosis factor alpha. Role of NF-kappa B and AP-1. J. Biol. Chem. 278: 50887-50896 (2003). *

• Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49: 1962-1971 (2009).

• Yang L, Diehl AM. Chapter 26. Role of immune response in nonalcoholic fatty liver disease: evidence in human and animal studies. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 337-345 (2007). *

• Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 50: 1464-1474 (2009).

• Yang Q, Ito S, Gonzalez FJ. Hepatocyte-restricted constitutive activation of PPAR-alpha induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis 28: 1171-1177 (2007). *

• Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, Wu JY, Dai Y, Yan K. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol. Res. 39: 231-240 (2009). *

• Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang SH, Tsai TF, Chen DS, Chen PJ. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology 49: 1515-1524 (2009).

• Yang XH, Liu BR, Jiang HC. The presence and the significance of CD4+CD25+ regulatory T cells in livers of patients with hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 15: 279-282 (2007).

• Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J. Hepatol. 45: 254-262 (2006). *

• Yang YQ, Wu L, Chen JX, Sun JZ, Li M, Li DM, Lu HY, Su ZH, Lin XQ, Li JC. Relationship between nm23H1 genetic instability and clinical pathological characteristics in Chinese digestive system cancer patients. World J. Gastroenterol. 14: 5549-5556 (2008). *

• Yang ZF, Lau CK, Ngai P, Lam SP, Ho DW, Poon RT, Fan ST. Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28: 622-631 (2008). *

• Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 26: 964-975 (2006). *

• Yano Y, Hayashi Y, Sano K, Nagano H, Nakaji M, Seo Y, Ninomiya T, Yoon S, Yokozaki H, Kasuga M. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-I beta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. Cancer Lett. 207: 139-147 (2004).

• Yano Y, Yoon S, Seo Y, Ninomiya T, Nagano H, Nakaji M, Hayashi Y, Kasuga M. A case of well-differentiated hepatocellular carcinoma arising in primary biliary cirrhosis. Kobe J. Med. Sci. 49: 39-43 (2003). *

• Yao FY. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation - yes. Semin. Liver Dis. 26: 239-247 (2006).

• Yao FY, Kinkhabwala M, Laberge JM, Bass NM, Brown R Jr, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am. J. Transplant. 5: 795-804 (2005). *

• Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time? Liver Transpl. 10: 919-921 (2004). *

• Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, Yan M, Ge C, Zhang Z, Chen T, Wan D, Yao M, Li J, Gu J, He X. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology Nov 30 [Epub ahead of print] (2009). *

• Yata Y, Xue F, Takahara T, Kudo H, Hirano K, Yasumura S, Minemura M, Scanga AE, Sugiyama T. Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int. 29: 10-17 (2009). *

• Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J. Gastroenterol. 14: 6437-6441 (2008). *

• Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J. Fam. Pract. 51: 135-140 (2002). *

• Yeh SH, Lin MW, Lu SF, Wu DC, Tsai SF, Tsai CY, Lai MY, Hsu HC, Chen DS, Chen PJ. Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 40: 847-854 (2004). *

• Yeh SH, Wu DC, Tsai CY, Kuo TJ, Yu WC, Chang YS, Chen CL, Chang CF, Chen DS, Chen PJ. Genetic characterization of Fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res. 12: 1097-1108 (2006). *

• Yen CH, Hung JH, Ueng YF, Liu SP, Chen SY, Liu HH, Chou TY, Tsai TF, Darbha R, Hsieh LL, Chen YM. Glycine N-methyltransferase affects the metabolism of aflatoxin B(1) and blocks its carcinogenic effect. Toxicol. Appl. Pharmacol. 235: 296-304 (2009). *

• Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG, Harrison PM, Heneghan MA. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 48: 863-870 (2008). *

• Yeoman AD, Longhi MS, Heneghan MA. Review article: autoimmune hepatitis - modern management. Aliment. Pharmacol. Ther. Jan 19 [Epub ahead of print] (2010). *

• Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am. J. Gastroenterol. 100: 1995-2004 (2005). *

• Yigit T, Yigitler C, Demiriz M, Arslan I, Tufan T. Hepatocellular carcinoma in the common bile duct "hepatocellular carcinoma". Liver Int. 27: 288-290 (2007). *

• Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challanges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther. 30: 1103-1109 (2009). *

• Yin C, Lin Y, Zhang X, Chen YX, Zeng X, Yue HY, Hou JL, Deng X, Zhang JP, Han ZG, Xie WF. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 48: 1528-1539 (2008). *

• Yin XY, Wang L, Lu MD, Li BJ, Huang JF. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line. Hepatogastroenterology 55: 155-159 (2008).

• Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 40: 609-617 (2004). *

• Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J. Gastroenterol. 37: 1028-1034 (2002). *

• Yong CC, Chen YS, Wang SH, Lin CC, Liu PP, Liu YW, Yang CH, Hung KC, Chiang YC, Lin TS, Cheng YF, Huang TL, Jawan B, Eng HL, Chen CL, Wang CC. Deceased-donor liver transplantation: 10 years' experience at Change Gung Memorial Hospital-Kaohsiung Medical Center. Chang Gung Med. J. 28: 133-141 (2005).

• Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J. Clin. Oncol. 21: 4329-4335 (2003). *

• Yoo HY, Thuluvath PJ. Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int. 25: 536-541 (2005). *

• Yoo NJ, Kim S, Lee SH. Mutational analysis of WTX gene in Wnt/ beta-catenin pathway in gastric, colorectal, and hepatocellular carcinomas. Dig. Dis. Sci. 54: 1011-1014 (2009). *

• Yoo NJ, Soung YH, Lee SH, Jeong EG, Lee SH. Mutational analysis of caspase-14 gene in common carcinomas. Pathology 39: 330-333 (2007).

• Yoon CH, Kim MJ, Park MJ, Park IC, Hwang SG, An S, Choi YH, Yoon G, Lee SJ. Claudin-1 acts through c-abl-pkcdelta signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J. Biol. Chem. 285: 226-233 (2010). *

• Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr. Treat. Options Gastroenterol. 6: 105-112 (2003).

• Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY, Han KH. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29: 1192-1196 (2008). *

• Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196: 641-653 (2002). *

• Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J. Hepatol. 41: 97-103 (2004). *

• Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol. 51: 315-321 (2009).

• Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci. 98: 1868-1874 (2007). *

• Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 39: 1215-1218 (2004). *

• Yoshizawa K, Abe H, Kubo Y, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Youk JH, Kim CS, Lee JM. Contrast-enhanced agent detection imaging: value in the characterization of focal hepatic lesions. J. Ultrasound Med. 22: 897-910 (2003).

• Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C, Malfertheiner P, Farrell GC. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43: 134-143 (2006). *

• Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Rocken C, Ebert MP, Chan AT, Sung JJ. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 48: 508-518 (2008). *

• Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S72-S78 (2004). *

• Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. 3: 561-572 (2003).

• Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 98: 482-490 (2006). *

• Yuan Q, Jonas MM. Pediatric hepatobiliary disease. Curr. Opin. Gastroenterol. 19: 276-280 (2003).

• Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, Zhi L, Zhang H, Yang H, Zhang X, Qiu W, Peng Y, Zhang X, Yu L, Xia X, He F. Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 17: 3621-3627 (2008). *

• Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 29: 1248-1251 (1999). *

• Yuge K, Takahashi T, Nagano S, Terazaki Y, Murofushi Y, Ushikoshi H, Kawai T, Khai NC, Nakamura T, Fujiwara H, Kosai K. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int. J. Oncol. 27: 77-85 (2005).

• Yun MY, Kim SB, Park S, Han CJ, Han YH, Yoon SH, Kim SH, Kim CM, Choi DW, Cho MH, Park GH, Lee KH. Mutation analysis of p31(comet) gene, a negative regulator of Mad2, in human hepatocellular carcinoma. Exp. Mol. Med. 39: 508-513 (2007). *

• Zabala M, Lasarte JJ, Perret C, Sola J, Berraondo P, Alfaro M, Larrea E, Prieto J, Kramer MG. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J. Hepatol. 47: 807-815 (2007). *

• Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS , Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C, Forti D, Pinzello G. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am. J. Gastroenterol. 100: 2708-2716 (2005). *

• Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology Jan 7 [Epub ahead of print] (2010). *

• Zhang A, London R, Schulz FM, Giguere-Simmonds PW, Delriviere L, Chandraratana H, Hardy K, Zheng S, Olynyk JK, Yeoh G.. Human liver progenitor cell lines are readily established from non-tumorous tissue adjacent to hepatocellular carcinoma. Stem Cells Dev. Oct 29 [Epub ahead of print] (2009).

• Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, Zhang BX. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52: 224-232 (2008). *

• Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J. Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol. Rep. 23: 445-455 (2010).

• Zhang HH, Fei R, Mei MH, Liao WJ, Wang XY, Cong X, Qin LL, Ji Y, Wang SX, Wei L, Chen HS. The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi 15: 266-272 (2007).

• Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50: 980-989 (2009).

• Zhang JY. Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun. Rev. 6: 143-148 (2007). *

• Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol. 46: 107-114 (2007). *

• Zhang R, Wang L, Yang AG. Is microRNA-143 really a turncoat of tumor suppressor microRNA in hepatitis B virus-related hepatocellular carcinoma? Hepatology 50: 987 (2009).

• Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 50: 490-499 (2009).

• Zhang Y, Xu P, Park K, Choi Y, Moore DD, Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48: 289-298 (2008). *

• Zhao B, Lei Q, Guan KL. Mst out and HCC in. Cancer Cell 16: 363-364 (2009). *

• Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S, Wu M, Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 135: 956-968 (2008). *

• Zhao J, Wu G, Bu F, Lu B, Liang A, Cao L, Tong X, Lu X, Wu M, Guo Y. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51: 142-153 (2010).

• Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology 44: 205-215 (2006). *

• Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, Wang KS, Zhang X, Huang J, Han ZG. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J. Hepatol. 50: 377-387 (2009).

• Zhong XG, He S, Yin W, Deng JY, Cheng B. Selective tropism of liver stem cells to hepatocellular carcinoma in vivo. World J. Gastroenterol. 13: 3886-3891 (2007). *

• Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438 (2009). *

• Zhou YC, Waxman DJ. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ. Health Perspect. 106 Suppl. 4: 983-988 (1998). *

• Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11: 790-800 (2006). *

• Zhu X, Chen MS, Tian LW, Li DP, Xu PL, Lin MC, Xie D, Kung HF. Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int. J. Cancer 125: 1352-1357 (2009). *

• Zhu Z, Luo Z, Li Y, Ni C, Li H, Zhu M. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology 49: 504-512 (2009). *

• Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Buchler MW. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564 (2001). *

• Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J. Gastroenterol. 11: 289-292 (2005). *

• Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ. A study on the association of MTHFR C677T polymorphism with genetic susceptibility to hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 14: 196-198 (2006).

• Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z, Zolotarov L, Friedman D, Alper R, Ilan Y. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 56: 82-99 (2007).

• Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl. Int. 20: 747-753 (2007).

• Zimmermann A. Pathobiology of hepatobiliary neoplasms in children. J. Gastroenterol. Hepatol. 19: S372-S376 (2004). *

• Zindy PJ, L'helgoualc'h A, Bonnier D, Le Bechec A, Bourd-Boitin K, Zhang CX, Musso O, Glaise D, Berangere Troadec M, Loreal O, Turlin B, Leger J, Clement B, Theret N. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis. Hepatology 44: 1296-1307 (2006). *

• Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res. 14: 470-477 (2008). *

• Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25: 367-379 (2005). *

• Zou C, Yuan FJ, Zhou WB, Huang L, Wang J, Zhang YS. Analysis on the expression of the stem cells related genes in hepatocellular carcinoma cell lines. Zhonghua Gan Zang Bing Za Zhi 17: 599-602 (2009).

• Zschemisch NH, Liedtke C, Dierssen U, Nevzorova YA, Wustefeld T, Borlak J, Manns MP, Trautwein C. Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes in vivo. Hepatology 44: 164-173 (2006). *

• Zseli J, Csillag J, Tulassay Z, Tarjan G, Moksony I. Gonadotropin-secreting liver cancer in ulcerative colitis. Wien. Klin. Wochenschr. 96: 5-8 (1984).

Number of references = 1870

www psc-literature.org